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 CRISPR technology has revolutionized the field of genome 
engineering. CRISPR allows for the easy and efficient manipulation of 
virtually any genetic locus through a two-component system: a CRISPR 
endonuclease and guide RNA (sgRNA). These components form a complex 
that enacts double strand breaks in target DNA. The repair of the double 
strand break is the main mechanism by which genetic editing of a locus takes 
place. While the endonuclease cleaves target DNA, it is the sgRNA that 
specifies targets through complementary binding to a target site. Determining 
the specificity of sgRNAs to their target site represented a crucial challenge to 
the genome-engineering field. To facilitate the design of CRISPR libraries, we 
developed Guidescan, a software package that allowed for the customizable 
production of sgRNA databases that were guaranteed to match user-defined 
requirements for sgRNA uniqueness.   
 Furthermore, several computational studies of leukemia are described 
in this thesis that illustrate different molecular actors and mechanisms through 
which a leukemic like disease, Myelodysplastic Syndrome, can progress 
towards leukemia, how leukemia hijacks a splicing protein to maintain its 
pathology, and finally, how a leukemia can develop resistance to a targeted 
therapy. 
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Chapter 1: Introduction 
Foundations of Genome Engineering: 
Gregor Mendel’s study, in the garden of a Czech monastery, of the 
attributes of peas established the idea that traits were heritable from one 
generation to the next1. Initially ignored, his pioneering results were 
rediscovered approximately twenty years later by Hugo de Vries, Carl 
Correns, and Erich von Tschermak who replicated his results and postulated 
that heredity was carried as discrete units across generations2–4. In 1905 
William Bateson gave the term ‘genetics’ to the field of study that investigated 
the patterns and mechanisms of inheritance5. In 1944, Oswald Avery, Colin 
MacLeod, and Maclyn McCarty of The Rockefeller University demonstrated 
that genetic information was encoded in the molecule deoxyribonucleic acid 
(DNA)6. With the identity of genetic material confirmed to be DNA, a flurry of 
studies followed which established a paradigm that phenotypes derive from 
the transcription of DNA into ribonucleic acid (RNA) and translation of RNA 
into protein7 (Figure 1).  
In reality this dogma is more nuanced with the understanding that 
phenotype can be influenced by the actions of non-coding RNA, the topology 
of chromatin superstructures, epigenetic modifications to DNA and chromatin, 
and the environment8–12. However, this understanding is a more modern 
interpretation of the central dogma, which was not appreciated until the late 
twentieth century.  
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Figure	1:	Central	dogma	of	molecular	biology 
 Throughout the development of the central dogma it was noted that 
phenotypes follow statistical distributions13. Implicit in this observation was the 
notion that within the central dogma, variance exists. This variance, from a 
nucleotide-centric standpoint, can derive from changes in DNA. These 
changes in DNA can occur in a population of individuals through a myriad of 
mechanisms including positional base changes, insertions and deletions of 
extra bases at a given locus, inversions of base sequences, and 
translocations of chromosomal arms14,15. While this variance exists naturally, 
the observation that alterations on the genetic level can yield changes on the 
phenotypic level created a paradigm in the life sciences. This paradigm stated 
that through altering the base sequence composition of DNA an investigator 
could potentially alter a phenotype. This concept would form the basis of what 
would eventually become the field of genome engineering. 
 Genome engineering can be broadly defined as the ability to precisely 
modify any arbitrary sequence, whether it be coding or non-coding, in any 
Figure	1:	Central	dogma	of	molecular	biology	as	conceptualized	by	Francis	Crick.	Solid	lines	
illustrated	established	transfers,	while	do=ed	lines	show	transfers	observed	in	special	cases	or	
systems.	(Crick	F.	1970)			
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arbitrary genome. While this definition of genome engineering fits well with 
the modern interpretation of the central dogma, the initial advances in 
genome engineering derived from a more protein centric viewpoint. The 
understanding that perturbations in genotype can deliver distinct phenotypes 
through the modification of effector proteins highlighted an early interest in the 
ability to change the base sequence of protein coding genes, which would 
thereby alter the protein itself and potentially replicate a phenotype. However, 
to achieve this modification investigators would need to discretely target and 
modify sequence-specific locations in the genome. One of the first attempts at 
sequence specific targeting and modification of a genetic locus occurred in 
the late 1950’s when investigators used oligonucleotides cross-linked with 
bleomycin or psoralen to generate site-specific modifications in yeast and 
mammalian cells16–21. While this early attempt at genome engineering 
demonstrated an important proof-of-concept, that site-specific editing of a 
genomic target was possible, it failed to produce a robust method for gene 
editing.  
In the late 1970s revolutionary experiments by Wigler and Axel 
illustrated that mammalian cells deficient in thymidine kinase (tk) could have 
their tk gene function restored by exposing these cells to a co-precipitate of 
calcium phosphate with DNA containing a herpes virus thymidine kinase 
(HSV-tk)22,23.  The experiment demonstrated that co-precipitate DNA could 
accumulate on a cell’s surface membrane and undergo endocytosis by the 
cell and correct the deficient enzymatic activity. Unfortunately, this initial 
method was rather inefficient in that the desired transformation would only 
occur in one out of a million cells exposed to the co-precipitate24. This 
efficiency problem was tackled and optimized in work done by Mario 
Capecchi and colleagues who advanced the method by microinjecting the 
HSV-tk gene, linked to viral nuclear homing sequences, directly into the 
nucleus of murine cells and observing a one million fold increase in 
transformation efficiency25. Capecchi’s work revealed a key insight into the 
mechanism by which this transformation takes place. To appreciate this 
4	
insight, however, it is necessary to understand how a cell responds to a 
double strand break in the structure of its DNA. 
Nuclear Repair Response to DNA Double Strand Breaks: 
When DNA undergoes a double strand break (DSB), the cell will 
attempt to repair the break typically through either Non-Homologous End 
Joining (NHEJ) or Homologous Recombination26,27 (Figure 2). While both 
pathways fix DSB they do so in distinct fashions. NHEJ pushes back together 
the blunt ends of the broken DNA to ligate the break28–30. This process is 
error-prone and can result in the introduction of insertions and deletions 
(indels) in the repaired DNA locus31. In contrast, homologous recombination 
mends DSB by using a sister template for homologous recombination and 
perfectly repairs the DSB with the template provided by the sister chromatid32. 
The presence of a sister template limits the stages in the cell cycle where 
homologous recombination repair can take place to the S and G2 phases, 
with greatest efficiency of repair occurring in the early S phase33,34. By 
contrast, NHEJ repair can occur at any point in the cell cycle35. If an 
engineered template is introduced into a cell by a researcher it can be treated 
as a sister template by the cell and used to enact a targeted modification via 
homologous recombination (also knows as homology directed repair 
[HDR])36.  
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Figure	2:	DNA	DSB	repair 
Genome Engineering and Homologous Recombination: 
What Capecchi and colleagues discovered in the process of 
microinjecting HSV-tk into murine nuclei was that when many copies of the 
HSK-tk plasmid were introduced into a nucleus, they integrated into genomic 
loci in a highly ordered head-to-tail fashion37. The probability of such a head-
to-tail structure occurring by chance at a single locus, x times, can be 
assessed with the following measure: 
 𝑃 𝑥 =  12! 
 
where P(x) is the probability of observing x independent copies of a plasmid 
integrating into a single genetic locus in a continuous head-to-tail orientation. 
In Capecchi and colleague’s original experiments they observed 
approximately 100 HSV-tk carrying plasmids all incorporated, in a structured 
Figure	2:	Double	strand	DNA	repair	through	imprecise	non-homologous	end	joining	(NHEJ)	
introducing	inserMons	and	deleMons	of	variable	length.	AlternaMvely,	DNA	can	repair	more	
precisely	with	homology	directed	repair	(HDR)	with	donor	template	.		(Sander	et	al.	2014)	
6	
head-to-tail fashion, into a single genetic locus which represented an event 
with the probability of occurrence of: 
 𝑃 100 =  12!"" =  7𝑒!!" 
 
Such a probability, they reasoned, was so unlikely to occur by chance that a 
basic biological mechanism had to be at play. Further studies by Capecchi’s 
group proved that such a structure was achieved through homologous 
recombination of the cell’s genome with the DNA located on the plasmid38. 
This work demonstrated, for the first time, that mammalian cells could 
undergo homologous recombination with experimentally engineered 
exogenous DNA molecules38. The importance of this discovery was not lost 
upon investigators as they quickly realized that, by harnessing the 
homologous repair machinery intrinsic to the cell, they could potentially 
modify any gene in a cell through the introduction of engineered DNA 
molecules39. Using this technology to generate transgenic mice carrying a 
desired genetic modification, researchers originally microinjected DNA into 
the nucleus of a mouse zygote. While this process was robust it was also 
tedious. In the mid-1980s the usage of mouse embryonic stems cells (mESC) 
to create germline transgenic mice began to take hold with investigators 
finding they could engineer genomic modifications through electroporating 
mESC with the desired modification DNA40,41. While this process allowed for a 
high throughput way to generate genomic alterations in a mouse, it was not 
modular nor did it easily allow for the custom targeting of genomic regions 
outside of murine system.  
Meganucleases, Zinc-Finger Nucleases, and TALE Nucleases: 
  The first hint that researchers could develop a method that would allow 
for the arbitrary editing of a genetic locus in a wide array of model organisms 
and conditions came with the discovery of meganucleases (MGNs)42. These 
endonucleases derive from a large set of organisms including bacteriophage, 
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archaea, bacteria, fungi, yeast, algae, and even some plant species42–45. 
MGNs contain DNA binding domains that are characterized by having a large 
sequence recognition site typically on the order of twelve to forty bases 
long46. The size of this recognition site, coupled with its low tolerance for 
mismatches, makes MGNs highly specific to their target regions. Once the 
MGN binds a target site the catalytic domains on the endonuclease induce a 
DSB that allows for the HDR and NHEJ pathways to be activated, which like 
previous methods, provides a mechanism to custom engineer a genetic 
locus45,47,48. MGNs represented a tool that could potentially modify any 
cognate sequence in any organism. MGNs represented the first step towards 
establishing a generalized genome-engineering system49,50. However, the 
same specificity that made MGNs attractive also limited their use. While 
hundreds of MGNs have been discovered the existence of target sites within 
a studied genome remains restrictive. In fact, to discover a MGN eighteen 
base recognition site by chance in the human genome would require the 
human genome to be approximately twenty-three times larger than it 
presently is. 
 𝑃𝑜𝑠𝑠𝑖𝑏𝑙𝑒 18𝑚𝑒𝑟𝑠𝐵𝑎𝑠𝑒𝑠 𝑖𝑛 𝐻𝑢𝑚𝑎𝑛 𝑔𝑒𝑛𝑜𝑚𝑒 =  4!"3 ∗ 10! = 22.9 
 
While efforts were made to modify MGNs sequence recognition sites so that 
they could home to desired targets within a genome, progress was slow 
coming. The problem was that the MGN sequence recognition site was not 
easily altered and thus not trivial to customize51,52. This changed with the 
introduction of zinc finger nucleases. (Figure 3a, 3b) 
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Figure	3:	Zinc	Finger	and	TALE	proteins 
Unlike MGNs zinc finger nucleases (ZFNs) were endonucleases that 
utilized modular domains to target and cut DNA53–55. The advent of ZFNs 
allowed investigators, for the first time, to robustly and accurately engineer 
site-specific modifications into a target locus by using a zinc-finger module 
that recognized a triplet of bases in the major groove of DNA56,57. These 
modules could be assembled together with a highly conserved linker 
sequences to yield a multi-modular ZFN that could recognize 9-18 continuous 
bases in length53. This modular array could then be joined to an effector 
domain, like a nuclease, and allow for site-specific modification at a locus53. 
Despite allowing for precise targeting of a sequence, ZFNs failed to gain 
widespread use. ZFNs suffered from a difficulty in design in that the linker 
sequence between zinc finger modules made their assembly difficult58. This 
design obstacle was partially overcome with the discovery of TALE proteins 
(Figure 3c,3d). 
Figure	3:	Zinc	ﬁnger	and	TALE	proteins	a.)	Zinc	ﬁnger	in	complex	with	DNA.	Zinc	ﬁngers	are	
composed	of	approximately	30	amino	acids	and	possess	DNA	contact	domains	which	recognize	
3-4	bp	of	DNA	in	the	major	groove.	b.)	Diagram	of	zinc	ﬁnger	nuclease	dimer	binding	to	a	target	
site.	The	zinc	ﬁnger	target	site	is	separated	by	a	5-7	bp	spacer	which	is	recognized	by	a	FokI	
cleaving	domain.	The	acMon	of	the	zinc-ﬁnger	dimer	binds	target	sites	while	the	cleavage	of	the	
target	site	is	achieved	by	the	ligated	FokI	domains.	c.)	TALE	protein	in	complex	with	DNA.	TALE	
proteins	consist	of	33-35	amino	acids	and	are	able	to	recognize	a	single	bp	of	DNA	through	the	
use	of	dual	hyper-variable	residues	(RVDs).	d.)	Diagram	of	TALE	nuclease	(TALEN)	binding	a	
target	site.	Like	zinc	ﬁnger	nucleases,	TALEN	target	sites	consist	of	two	binding	sites	separated	
by	a	spacer	sequence	12-20bp	in	length.	(Cathomen	et	al.	2008)		
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TALEs are bacterial derived proteins that, like MGNs and ZFNs, 
contain DNA-binding domains59,60. They are composed of a repeat sequence 
of 33-35 amino acids that form a domain that recognizes a single base 
pair61,62. Again, like ZFNs, these repeat sequence domains can be 
modularized to recognize a series of bases and joined to an effector domain, 
like a nuclease, to form TALENs63,64. Unlike ZFNs, the TALE modules do not 
require assembly with a linker sequence and the ability to recognize single 
bases as opposed to a triplet of bases required by ZFNs simultaneously 
simplified the assembly of these sequence-targeting proteins and increased 
their targeting resolution65. However, the difficulties inherent in protein design, 
synthesis, and validation, especially given the presence of repeat sequences 
in the TALE domains, limited the widespread adoption and use of TALENs58. 
This changed with the emergence of CRISPR systems.  
Basic Biology of CRISPR: 
 Clustered-regularly-interspersed-short-palindromic-repeats (CRISPR) 
were first described in 1987 when Nakata and colleagues reported a series of 
29-base repeats (termed direct repeats) interspersed by 32-base non-
repetitive sequences (termed spacers) in the E. coli iap gene66. The presence 
of direct repeats and spacers was subsequently discovered to be a broadly 
conserved characteristic present in greater than 40% of bacteria and 90% of 
archaea67,68. However, the purpose of these alternating sequences remained 
elusive until 2005 when investigators determined a bacteriophage derived 
origin for the spacer sequences69–71. Compounding this finding was 
experimental evidence demonstrating that archaea with spacer sequences 
matching sequences found in a bacteriophage’s genome, were immune to 
infection from that phage70. These findings suggested that CRISPR direct 
repeats and spacers constituted a component of the adaptive immune system 
of bacteria and archaea70,71. However, the mechanisms through which this 
immunity was established remained speculative.  
 Around the same time that the CRISPR direct repeats and spacers 
were realized to be widespread and broadly conserved across bacteria and 
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archaea, another important discovery regarding the CRISPR system came 
about: CRISPR -associated (Cas) genes72,73. CRISPR direct repeats were 
discovered to not be the only widely conserved sequences present in the 
CRISPR system with the realization that several protein coding gene clusters 
rested adjacent to the direct repeat and spacer regions. These gene clusters 
coded for a set of nuclease enzymes that facilitated the recognition and 
destruction of target nucleic acids and acquisition of new spacer sequences. 
From the diversity of these gene clusters and their products, CRISPR was 
divided into three distinct systems: Type I, Type II, and Type III74,75 (Figure 4). 
Type I and Type III systems depend on multiple Cas proteins to form 
complexes, which target and degrade target double-stranded DNA76. By 
contrast Type II systems consist of notably fewer Cas proteins, oftentimes 
achieving their double-stranded DNA nuclease activity with just one 
enzyme76.  
 
Figure	4:	CRISPR	Cas	System 
Figure	4:	Diagram	of	the	three	types	of	CRISPR	Cas	systems.	The	adaptaMon	step	is	conserved	
across	all	three	systems,	while	the	expression	and	interference	steps	in	the	systems	are	disMnct	
(Doudna	et	al.	2014)			
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Once it was understood that spacer sequences derived from viral 
origin and Cas genes were nucleases, the field moved quickly towards 
understanding the mechanisms underlying CRISPR systems. In short order, it 
was demonstrated that CRISPR spacers represented a nucleotide-based 
memory of past infections and Cas enzymes were responsible for spacer 
acquisition upon novel infection as well as neutralizing phage77,78. 
Furthermore it was shown that CRISPR arrays were transcribed and cleaved 
into constituent components (termed crRNAs) that contained individual 
spacer sequences that guided Cas enzyme nuclease activity against DNA76. 
As study intensified on the Type II system, a critical piece of the CRISPR 
puzzle was elucidated; the protospacer adjacent motif (PAM) sequence. It 
was noticed that Type I and Type II Cas proteins did not target all sequences 
in the bacterial genomes where complementarity between the crRNA and the 
genome existed (notably, Cas enzymes never targeted the CRISPR array 
itself)79. Rather it was discovered that Cas enzymes appeared to target only 
those complementary regions that had a stereotyped sequence adjacent to 
the complementarity site. These sequences were termed protospacer 
adjacent motif (PAM) sequences and are recognized directly by the Cas 
enzyme80,81. Evidence that PAM sequences were required for targeting was 
bolstered by the fact that PAM sequences are completely absent from the 
CRISPR array direct repeats79. While Cas enzymes can recognize several 
PAM sequences, it was further demonstrated that they have a hierarchy of 
preferred PAMs. Likewise these PAM sequences vary across the different 
organisms that utilize CRISPR systems. As an example, a Type II Cas 
enzyme of intense study is spCas9 (derived from Streptococcus pyogenes) 
and has a preferred PAM sequence of NGG (N is a wildcard) with lesser 
degrees of tolerance for NAG, NGA, and NTG82,83.  
CRISPR as a Model for Bacterial and Archaea Adaptive Immunity: 
 The model depicting how a CRISPR system acts as a form of adaptive 
immunity in bacteria and archaea starts with an infection by a bacteriophage. 
Upon injection of the bacteriophage’s DNA into the cell, the invading DNA is 
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recognized by two Cas enzymes, Cas1 and Cas2, which cleave the invading 
DNA into smaller components known as protospacers. These protospacers 
are brought into the CRISPR array as spacers between the first direct repeat 
in the array and the array leader sequence. A direct repeat sequence is then 
reestablished upstream of the new spacer and in this manner new spacers 
are continually prepended to the array thereby establishing nucleotide based 
memory of past viral infections. When the CRISPR array is called into action 
in the cell’s adaptive immune response, the CRISPR array and Cas genes 
are transcribed and crRNAs are created. The processing of the CRISPR 
transcript and generation of the crRNAs vary across Type I, II, and III 
CRISPR systems75,76. 
In Type I systems the direct repeats of the CRISPR transcript form 
hairpin loops and cleavage of the crRNAs occurs at the junction of the single 
stranded RNA and double stranded RNA present at the boundary of the 
hairpin loops by Cas6e and Cas6f enzymes. The resulting crRNAs are then 
loaded into a multi-Cas enzyme complex (termed CASCADE complex) where 
target DNA interference is established through simultaneous PAM site 
recognition and complementary binding between crRNA and target 
sequence76,84,85.  
In Type II systems the direct repeats also form double stranded RNA, 
but instead of forming hairpin loop structures, the direct repeats bind to a 
noncoding piece of RNA (later discovered to be the tracrRNA). The double 
stranded RNA is then used by Cas9 and RNaseIII to cleave the CRISPR 
transcript into crRNAs. The resulting crRNAs undergo 5’ trimming to form 
mature crRNAs that are then loaded into Cas9 where target DNA is cleaved 
by recognition of a PAM site by the Cas9 enzyme followed by the 
complementary binding between the target site and the crRNA84–86.  
In Type III systems the requirement for double stranded RNA is absent 
and the CRISPR transcript is cleaved by a Cas6 homolog. The resulting 
crRNAs undergo 3’ trimming to form mature crRNAs that are then loaded into 
various Cas enzymes that are used to cleave target DNA. Interestingly, Type 
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III Cas enzymes do not require the recognition of the PAM sequence in order 
to deploy their nuclease activity84.  
Consequently, when a bacteria or archaea is infected by a 
bacteriophage, the phage DNA is cleaved and remembered as the spacer 
sequences in the CRISPR array and a host immune response is enabled 
through the direct cleavage of the DNA in the cytosol or extraction of 
integrated viral DNA in the bacterial or archaea genome through the activity of 
targeting crRNAs and Cas nucleases.   
CRISPR Systems as a RNA-Guided Genome Editing Tool: 
 As the mechanisms by which CRISPR mediates bacterial and archaea 
adaptive immunity became established, the idea that CRISPR systems could 
be used as a genome editing tool started to gain traction. The understanding 
of this potential became clear when one of the key components in Type II 
crRNA biogenesis with the Cas9 enzyme was uncovered: the trans-activating 
crRNA (tracrRNA). The tracrRNA is a conserved non-coding RNA that binds 
with crRNA in the Type II system to form a crRNA-tracrRNA hybrid that is 
important in the processing of the CRISPR transcript87. The tracrRNA 
provides the secondary structure needed to allow the crRNA to be properly 
loaded into the Cas9 enzyme86,88. With the discovery that only the tracrRNA, 
crRNA, and Cas9 enzyme were needed to effect sequence target activity, 
investigators realized the potential of the CRISPR-Cas9 system to serve as a 
RNA-guided genome editing technology. This potential was further developed 
when the system was reduced from three to two components with the 
creation of a synthetic single guide RNA (sgRNA) that resulted from the 
fusion of a crRNA and tracrRNA sequences89. Researchers could now simply 
vary the approximately 20-nucleotide complementary region of the 5’ end of 
the sgRNA (crRNA component of the sgRNA) to target any region of the 
genome they desired provided a PAM sequence existed 3’ to the target site. 
The target site would undergo a double-strand break through Cas9’s 
nuclease activity and the NHEJ or HDR repair pathways would be activated90. 
The CRISPR-Cas9 system was shown to function in a myriad of cell types, 
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including mammalian cells, at which point the modern era of genome 
engineering was born91,92.    
Applications of CRISPR-Systems in Genome Engineering: 
 Site-specific sequence targeting using CRISPR-Cas9 opened up a 
vast array of previously intractable problems in genome engineering (Figure 
5a). Cas9 induced frameshift mutations in coding sequences of target genes 
allowed for the generation of gene knockout models through rapid and 
efficient means93. Furthermore, the introduction of multiple sgRNAs into a cell 
allowed investigators to simultaneously assess knockout mutations across a 
set of genes in one experiment94–96. This ability also allows CRISPR sgRNAs 
to be used in a paired way enabling large-scale positive and negative deletion 
screens in both the coding and non-coding regions of the genome93,97. 
However, the engineering of frameshift mutations represented only the 
beginning of CRISPR’s potential applications.  
The editing potential of CRISPR systems also allows for the 
recapitulation of the genetic variants present in disease. The CRISPR-Cas9 
system, coupled with an oligonucleotide carrying a potential pathogenic 
alteration, allows investigators to directly interrogate the role of a genetic 
variant in disease pathogenesis98. This represents a substantial advance in 
allowing researchers to model disease by dissecting its genetic underpinnings 
instead of relying on animal models that may only phenocopy disease traits. 
This use of CRISPR systems is especially intriguing when applied to 
understanding complex human diseases such as diabetes, cancer, and 
schizophrenia. It also offers a lens to understand the results of genome-wide 
association studies where it is often difficult to determine which of several 
genetic variants, in linkage disequilibrium with a haplotype, are causing the 
phenotype99. Additionally, CRISPR-Cas9 systems can be used to model 
pathogenic genetic lesions in their native regulatory environment; such as 
with the modeling of the EML4-ALK fusion present in a rare set of lung 
cancers100 (Figure 5b).  
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Figure	5:	Applications	of	CRISPR 
Beyond direct sequence modification, CRISPR-Cas9 systems can also 
be utilized to affect transcriptional regulation through the use of a version of 
Cas9 where the nuclease domains have been rendered inactive (dCas9)101. 
dCas9 can bind to target DNA and repress transcription by sterically inhibiting 
the activity of transcription machinery. This inhibition of transcription (termed 
CRISPRi) works well in bacteria and archaea and shows promise in 
eukaryotes102. Tethering transcriptional repressors to the dCas9 enzyme can 
augment the inhibitory activity of CRISPRi103. Conversely, tethering 
transcriptional activators to the dCas9 enzyme and directing the multiple 
dCas9s to a promoter sequence can promote transcription of a target gene103.  
Overall, CRISPR systems in general and the Cas9 system specifically, 
allow investigators to quickly and efficiently target and modify site sequence 
composition and expression. However, the uses of CRISPR-systems are not 
limited to just research.  
Figure	5:	ApplicaMons	of	CRISPR	systems.	a.)	The	potenMal	use	of	CRISPR	systems	is	broad	with	
applicaMons	being	sought	in	medicine	as	an	advance	in	gene	therapy,	opMmize	certain	
applicaMons	in	syntheMc	biology,	engineer	crops	that	are	resistant	to	pests	and	increases	global	
food	security,	assist	in	the	development	of	organic	fuels	based	on	ethanol	or	algae,	streamline	
the	producMon	of	drug	precursors	needed	for	pharmaceuMcal	development,	and	ﬁnally	in	
generaMng	animal	models	of	biology	or	disease	that	more	precisely	replicate	a	geneMc	variant	in	
its	naMve	background	environment	such	as	in	117	b.)	the	Eml4-Alk	gene	fusion	which	has	been	
observed	in	a	subset	of	lung	adenocarcinomas.	Such	modeling	expresses	the	fusion	protein	
under	its	natural	regulatory	environment.	(Wright	et	al.	2016)		
a	 b	
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Clinical Potential of CRISPR Systems: 
  Perhaps the most exciting potential application of CRISPR systems is 
their use as a therapeutic in human diseases. Genome engineering has long 
held the promise of serving as a treatment for genetic diseases. While early 
attempts at treating aliments such as cystic fibrosis made use of wild-type 
genes brought into diseased cells through adenoviruses, these approaches 
did not give sustained phenotypes because their effectors, over time, became 
diluted or inactivated104,105. With the advent of ZFN and TALENs further 
progress was made, even to the point where ZFNs were utilized in a clinical 
trail to engineer protective knockout mutation in the CCR5 receptor of human 
T-cells against the HIV virus106. However, these tools remained difficult to 
synthesis, validate, and ultimately use in many clinical settings57. The 
accessibly and versatility of CRISPR systems makes the task of engineering 
changes to a patient’s genome achievable on a clinical time scale. A well-
studied CRISPR system set to appear in upcoming clinical trails is the Cas9 
system.  
 Cas9’s ability to induce DSBs repaired by the NHEJ pathway makes it 
an exciting tool to combat diseases characterized by dominant-negative 
mutations. Illnesses such as transthyretin-related hereditary amyloidosis or 
the genetically dominant version of retinitis pigmentosum are characterized as 
having one mutant allele whose protein product makes the cell 
haploinsufficient for the gene107,108. A Cas9 sgRNA designed against the 
mutated allele can introduce frameshift mutations into the gene that could 
disrupt the protein structure thereby eliminating the pathogenic dominant 
negative action of the protein.    
 Paired-sgRNA approaches, where two sgRNAs are designed against a 
target, possess the potential to serve as a therapeutic in treating tri-nucleotide 
repeat disorders such as Huntington’s Disease, Myotonic dystrophy, and 
Friedreich’s ataxia109–111. SgRNAs can be designed flanking repeat expansion 
regions and used to delete these pathologic regions of the genome. This 
approach holds special potential for Friedreich’s ataxia, a neurodegenerative 
17	
disease that primarily affects children. The tri-nucleotide repeats in 
Friedreich’s ataxia occurs in a non-coding region, which makes frameshift 
mutations caused by the indels created by NHEJ less worrisome111 (Figure 
6). 
 
Figure	6:	Frataxin	gene 
 Cas9 induced DSBs may also be repaired through the HDR pathway, 
which allows for the precise editing of loss-of-functions genes characteristic of 
diseases such as cystic fibrosis, sickle-cell anemia, and Duchenne muscular 
dystrophy112–114. Wild-type oligonucleotide templates can be introduced with a 
Cas9 sgRNA targeted against a mutant site. The resulting DSB can undergo 
HDR and incorporate the wild-type template and in so eliminate the 
pathogenic mutation. While promising, this approach may still be several 
years down the line as the HDR repair frequency of DSB sites is low 
compared to NHEJ repair at the same site24.  
 However, the application of CRISPR systems to the clinic is not just 
theoretical. Presently, the Cas9 system is being used in clinical trials 
designed to engineer chimeric antigen receptor (CAR) T cells to re-recognize 
cancer antigens present in patient’s with prostate cancer115. Investigations are 
underway to use the Cas9 system to engineer the protective CCR5 mutation 
in human T cells to delete PCSK9 or angiopoietin to treat statin-resistant 
Figure	6:	Gene	diagram	of	frataxin	with	the	pathogenic	tri-nucleoMde	repeat	(red)	shown	to	
occur	in	the	intronic	region	of	the	gene.	This	tri-nucleoMde	repeat	is	believed,	through	a	poorly	
understood	mechanism,	to	be	involved	in	the	pathological	mechanism	underlying	Friedreich’s	
Ataxia.	(Campuzano	et	al.	1996)	
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hyperlipidemia and hypercholesterolemia99. CRISPR systems are already 
being used at the forefront of the precision medicine revolution.  
Challenges Facing CRISPR Systems as Genome Engineering Tools: 
 The promise of CRISPR systems for the field of genome engineering is 
immense, however, it is not without its challenges58. Chief among these 
concerns is the notion of off-target cutting by the CRISPR 
endonucleases58,90,99. The specificity of CRISPR systems derives from the 
complementary sequence present in the sgRNA that recognizes a target site 
in a genome116. The target site is composed of a sequence of approximately 
twenty nucleotides that is, ideally, unique in a genome for a given PAM. Yet, 
even if a sequence is uniquely occurring for a specific PAM, it does not mean 
it is immune from off-target cleavage. The sequence could have perfect 
occurrences with alternative PAM sequences. These sites would be cleaved 
with reduced, but still notable, efficiency. For example, in the Cas9 system the 
NAG alternative PAM sequence is cleaved at approximately 20-25% the 
efficiency of the NGG PAM117. The occurrence of perfect match target sites 
with alternative PAMs represents a considerable off-target effect for CRISPR 
systems. However, alternative PAM perfect match off-targets are not the only 
concern regarding CRISPR off-targets. The complementary region of the 
sgRNA is capable of withstanding mismatches116. Similar to short-hairpin 
RNA (shRNA), sgRNAs can cleave off-target sequences that differ from a 
target site by only a few bases116,118. While the rules regarding mismatch 
tolerance in sgRNAs are an area of active investigation, the literature 
supports the idea that sgRNAs with a 20-nucleotide long complementary 
region can withstand upwards of 6 positional mismatches to a target116. The 
ability to design sgRNA that target precisely in a genome is essential for both 
research and clinical applications of CRISPR systems. Consequently, the 
ability to correctly enumerate all potential off-target sites for a given sgRNA is 
critical for the development of CRISPR as a genome engineering technology.  
 The understanding that sgRNA specificity derives from genome 
specific target site similarity raises an additional concern for using CRISPR 
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systems for genome editing: designing sgRNAs from a reference genome. In 
2003 the Human Genome Project released the initial assembly of the human 
genome119,120. This assembly, along with assemblies for various other 
organisms, has been made more complete with advances in next-generation 
sequencing over the years allowing for the creation of organismal reference 
genomes121,122. Although these reference genomes are invaluable for 
bioinformatics, they cannot be used in all designs of sgRNAs. Although the 
sequence conservation among individuals in a non-clonal species is 
exquisitely high, it is never one hundred percent (excluding identical twins). 
Consequently, the genomes of cell lines derived from a specific individual will 
differ slightly from another. Furthermore, should CRISPR systems ever to be 
used in clinical medicine, sgRNAs would have to be designed with the 
knowledge that patient genomes have overlapping, but distinct, sets of target 
sites. Designing sgRNAs from a reference genome makes an incorrect 
assumption that a set of target sites is present in all individuals of a given 
species. An sgRNA that may be uniquely occurring in one individual’s 
genome but may have multiple perfect or near-perfect occurrences in another 
individual’s genome. These off-target effects could confound research 
findings or even induce disease if used clinically123. Ultimately, the use of 
CRISPR systems in research and medicine will depend on the ability to 
create individual-specific sets of sgRNAs.  
  SgRNA on-target cutting efficiency constitutes an additional major 
concern of researchers and clinicians when using CRISPR systems. An 
sgRNA’s ability to uniquely cleave a target site is made void if the cleavage 
efficiency at the site is minimal. While several groups have been made efforts 
to understand the variables contributing to sgRNA cutting efficiency, the 
general rules governing cleavage efficiency remain relatively undefined124–126. 
Furthermore, present methods of assessing an individual sgRNAs’ cleavage 
efficiency largely ignore the specificity of the sgRNA124–126. The cutting 
efficiency of sgRNAs is likely multifactorial in etiology and methods to predict 
such efficiency likely depend on a complete understanding of all these 
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factors. As a result a more complete understanding of the factors that 
contribute to sgRNA on-target cutting efficiency are needed if CRISPR 
systems are to be used more broadly.  
 Ultimately, researchers and clinicians using CRISPR systems for 
genome engineering tasks seek sgRNAs that are optimized for both target 
specificity and cutting efficiency. Various groups have developed tools that 
attempt to service this task, however, they suffer from certain limitations.  
Limitations of Current sgRNA Selection Methods: 
 Many methods exist which attempt to select sgRNAs optimized to be 
specific to a given target site as well as quantify how efficiently that target site 
will be cut126–129. Unfortunately, these tools tend to suffer from a common set 
of limitations. For one, these tools will generate sgRNAs using the reference 
genome. With the exception of the method described in the forthcoming 
chapter, none of the currently available tools allow for the construction of 
individual specific sgRNA databases. Consequently, these tools will produce 
a subset of sgRNAs that may have non-existent or even heavily expanded 
target spaces in a particular individual of a given species due to genetic 
variation among individuals.  
Secondly, most presently available sgRNA selection tools provide 
sgRNAs only for the CRISPR-Cas9 system. While this CRISPR system is one 
of the most widely used, it is not the only CRISPR system that could be used 
for genome engineering purposes. Numerous other Type II CRISPR systems 
hold the potential to serve as genome engineering systems. In particular the 
Type II CRISPR system involving the Cpf1 enzyme garners much interest 
among investigators due to its ability to induce staggered end cuts at a target 
site as opposed to the blunt end cutting induced by Cas9130. Few tools 
provide sgRNAs using non-Cas9 CRISPR systems and many methods 
appear to be specific to generating CRISPR-Cas9 sgRNA sets. As a result 
many of these tools are inflexible to advances in the CRISPR field should a 
more desirable endonuclease come about that replicates the popularity of 
Cas9.  
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Thirdly, many methods only consider sgRNAs that possess the 
canonical NGG PAM sequence for sgRNA selection. These methods will 
often consider the NAG alternative PAM in their off-target assessment, but 
few tools consider other potential alternative PAMs126,127,129,131. This 
represents a limitation given that multiple alternative PAM sites exist for the 
Cas9 CRISPR system and knowledge of all potential cutting sites will be 
essential if the technology is to ever be translated into the clinic. However, the 
limitation is not only relevant to off-target searches. Many groups are 
attempting to increase the specificity of the Cas9 CRISPR system by altering 
PAM site specificity132. This typically takes the form of expanding the PAM 
sequence that Cas9 recognizes from NGG to a stereotyped k-mer that is 
longer than NGG. The inability of many tools to easily consider expanded sets 
of alternative PAM sequences inhibits their broader utility.  
Fourthly, virtually all current methods fail to correctly identify potential 
off-targets within a defined number of mismatches. Several groups have 
noted the failure of popular sgRNA selection tools to enumerate potential off-
targets that are even one base different from the intended target site116,124. 
The inability of tools to determine the target universe for a sgRNA undermines 
the purpose of sgRNA selection tools. A correct and exhaustive enumeration 
of an sgRNA’s target universe represents an essential requirement for 
CRISPR systems if they are to be used as genome editing tools. The failure 
of present methods to precisely determine the targetable universe for a 
sgRNA within a finite set of mismatches illustrates a critical need in the 
CRISPR field. 
Lastly, all current sgRNA selection tools consider on-target cutting 
efficiency, either without considering or considering with incomplete 
knowledge, the specificity of a given sgRNA124–126.  
Overall these limitations of present sgRNA selection tools constitute a 
critical and unmet need in the CRISPR genome engineering field. The task of 
providing a potential solution to overcome these limitations is the essence of 
the following body of work.  
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Chapter 2: GuideScan 
The sgRNA Specificity Problem:  
 Targeted alterations of a genomic locus using a CRISPR system 
depends on a.) the recognition of a PAM sequence by a CRISPR 
endonuclease and b.) complementary binding between the sgRNA and the 
target site. The matching of a sgRNA to a target site is accomplished through 
hydrogen bonding between nucleobases133,134 (Figure 7a,b,c).  
 
Figure	7:	Watson-Crick	hydrogen	bonding 
As hydrogen bonding is a non-covalent interaction, the pairing between the 
CRISPR endonuclease and the target site is non-permanent. The strength of 
the interaction is influenced by the length of the complementary region, the 
GC content of the site, and the amount of mismatches between the 
complementary and target regions133.  Ultimately, whether a sgRNA will bind 
to a target region reduces to a question of thermodynamics and whether the 
sgRNA is sufficiently similar to a target site for it to be energetically favorable 
Figure	7:	Watson-Crick	base	pairing	a.)	
chemical	diagram	of	hydrogen	bonding	
between	adenine	(A)	and	thymine	(T)	occurs	
through	double	hydrogen	bonds.	b.)	chemical	
diagram	of	hydrogen	bonding	between	
guanine	(G)	and	cytosine	(C)	occurs	through	
three	hydrogen	bonds	giving	an	increased	
melBng	point	for	the	G:C	pairing	over	the	A:T	
pairing.	c.)	cartoon	diagram	summarizing	the	
hydrogen	bonding	that	occurs	between	
nucleobases	in	canonical	Watson-Crick	base	
pairings.	(Zurkin	et	al.	2005	&	Cronk.	2017)	
a.)	 b.)	
c.)	
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to bind. SgRNAs with perfect complementarity to a target site possess the 
greatest favorability of binding, but sgRNAs that differ from a target site by 
only a few nucleobases may also be able to bind. Stated plainly, sgRNAs can 
bind target sites with mismatches. 
 It is the binding of a sgRNA to a non-target loci in a genome that 
constitutes an off-target effect. Consequently, off-targets take on two forms 
a.) unknown loci in the genome that perfectly match a sgRNA and b.) known 
or unknown loci that are degenerate to the sgRNA complementary region, but 
which possess a free energy profile favorable to binding. For CRISPR 
systems these degenerate sites are distinct to a sgRNA by a finite number of 
positional mismatches116,124. An experimenter needs to know the target space 
of a sgRNA. The importance of this task derives from the fact that CRISPR 
systems induce a DSB at a target location that results in a mutation at that 
site. Furthermore, if a target site is present and the CRISPR endonuclease is 
active then theoretically the endonuclease will attempt to cut the region until 
the target site is disrupted and the endonuclease can no longer bind135 
(Figure 8a-e).  
 
Figure	8:	Cas9	repeat	target	scheme 
Figure	8:	Cas9	binding	scheme	a.)	Cas9	with	sgRNA	unbound	to	target	b.)	
Cas9	enzyme	recognizing	PAM	sequence	c.)	sgRNA	and	target	site	base	
pairing	d.)	sgRNA	pairing	and	ulBmate	cleavage	of	target	e.)	Cas9	aborts	
cleavage	if	sgRNA	and	target	site	unable	to	base	pair.	(Wu	et	al.	2014)	
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The reality that CRISPR systems effect permanent changes in a genome and 
will continuously attempt cleavage at target loci, highlights the need of 
experimenters to understand the target space of a given sgRNA to assess it’s 
fidelity to it’s target. If multiple genomic cuts occur without the experimenter’s 
knowledge then the conclusions drawn from the experiment are in doubt. 
Understanding a sgRNA’s target fidelity is the crux of the sgRNA specificity 
problem.  
Naïve Genomic Off-Target Search: 
 Essential to determining a sgRNA’s specificity is knowledge about its 
potential off-targets. Given the size of a sgRNA’s complementary region and 
the amount of bases present in various model organisms, there is a high 
likelihood that a given sgRNA will be uniquely occurring in a given genome136. 
 𝑃𝑜𝑠𝑠𝑖𝑏𝑙𝑒 20𝑚𝑒𝑟𝑠𝑆𝑖𝑧𝑒 𝑜𝑓 𝐺𝑒𝑛𝑜𝑚𝑒 =  4!"𝑆𝑖𝑧𝑒 𝑜𝑓 𝐺𝑒𝑛𝑜𝑚𝑒 (𝑏𝑝) = 𝑀𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑜𝑓 20𝑚𝑒𝑟 𝐸𝑥𝑐𝑒𝑠𝑠  
 
This likelihood is increased when the size of the genome is restricted to only 
the space of 20mers that are 3’ flanked by a Cas9 PAM sequence, which in 
this case we will define to be NGG or NAG (Table 1).   
 𝑃𝑜𝑠𝑠𝑖𝑏𝑙𝑒 20𝑚𝑒𝑟𝑠(𝑃𝐴𝑀 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒) =  4!"𝑃𝐴𝑀 𝑜𝑐𝑐𝑢𝑟𝑟𝑒𝑛𝑐𝑒 = 𝑀𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑜𝑓 𝑇𝑎𝑟𝑔𝑒𝑡 𝐸𝑥𝑐𝑒𝑠𝑠 
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Table	1:	Magnitude	of	target	excess 
Organism 
(Assembly) 
𝑷𝒐𝒔𝒔𝒊𝒃𝒍𝒆 𝟐𝟎𝒎𝒆𝒓𝒔𝑷𝑨𝑴 𝒐𝒄𝒄𝒖𝒓𝒓𝒆𝒏𝒄𝒆   𝑴𝒂𝒈𝒏𝒊𝒕𝒖𝒅𝒆 𝒐𝒇 𝑻𝒂𝒓𝒈𝒆𝒕 𝑬𝒙𝒄𝒆𝒔𝒔 
Human (hg38) 4!"744,651,681 1,476 
Mouse (mm10) 4!!666,467,906 1,649 
Zebrafish 
(danRer10) 
4!"251,921,183 4,264 
Fly (dm6) 4!"28,720,587 38,283 
C. elegan (ce11) 4!"16,867,034 65,187 
Yeast (SacCerv3) 4!"2,358,265 466,237 
 
Despite this high potential for a sgRNA to be unique, it is known that 
sequence repeats are characteristic of many genomes137–139. Therefore it 
cannot be assumed that a given sgRNA has a unique target site.  
Determining a sgRNA’s target specificity therefore becomes a matter 
of accounting for all potential cleavage sites available to the sgRNA within a 
set number of mismatches. Accomplishing this task naively requires the 
scanning of the entire genome for PAM sequences and computing the target 
sequence adjacent to each PAM. Once all target sequences are enumerated 
then the genome must be scanned again, comparing each specific target 
sequence against all other target sequences in the genome. This comparison 
would take the form of computing a Hamming distance between a specific 
target sequence and all other target sequences in the genome. In this manner 
the entire space of degenerative neighbors (henceforth called a mismatch 
neighborhood) could be determined. Unfortunately, this process is quadratic 
in complexity (Figure 9). 
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Figure	9:	Pseudo	code	of	naive	off-target	determination 
 𝑙 = 𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑔𝑒𝑛𝑜𝑚𝑒 ℎ = 𝐻𝑎𝑚𝑚𝑖𝑛𝑔 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑢𝑛𝑐𝑡𝑖𝑜𝑛 𝑧 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑃𝐴𝑀 𝑠𝑖𝑡𝑒𝑠 𝑞 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑔𝑅𝑁𝐴𝑠 𝑞𝑢𝑒𝑟𝑖𝑒𝑑 
 𝑙 ∗ 𝑧 ∗ ℎ 𝑙! +  𝑙! +⋯+  𝑙! =  𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛 
 𝑂 𝑙! = 𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛 
 
 This process is inefficient from the repeat scanning of an entire 
genome for each sgRNA. In reality, only the set of sequences adjacent to a 3’ 
PAM sequence need to be considered, which would reduce the scanning 
space. However, it is the repetitive comparison of a sgRNA complementary 
sequence against all possible target sites that makes this process 
computationally expensive. Ultimately, this naïve approach for determining 
sgRNA specificity is unfeasible for determining the off-targets of sgRNAs. A 
faster and more efficient approach is needed.  
Genome Aligners: 
A natural solution to the off-target search would be to employ genomic 
sequence aligners (henceforth referred to as simply aligner). An aligner is an 
essential tool in bioinformatics that serves to rapidly and efficiently map 
sequence data to a reference genome. The precise methods through which 
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this mapping takes place varies across tools, but a general description can be 
made using the Bowtie2 aligner as a case example140.   
 
Figure	10:	Bowtie2	workflow 
Reads need to be accurately assigned to a discrete location(s) in a 
genome, which is the principle task of an aligner. The aligner processes the 
reads as a string data-type and splits these strings into substrings that are a 
defined length for the forward and reverse complement (Figure 10a). These 
substrings are called seed sequences. Next the seed sequences are aligned, 
in an ungapped manner, to a reference genome using an index (Figure 10b). 
In Bowtie2 this index takes the form of an FM-Index that uses a Burrows-
Wheeler transformation to give a Burrows-Wheeler range (appendix). The 
resulting Burrows-Wheeler ranges are prioritized such that rows with smaller 
ranges are assigned a higher priority for mapping determination. Bowtie2 will 
select rows randomly with a probability proportional to the row’s priority 
weight and resolve the offset of the row with the reference genome using the 
FM-Index’s walk-left procedure (Figure 10c). Finally, the aligner performs 
Figure	10:	BowBe	2	workﬂow	a.)	Split	sequence	reads	as	substrings	b.)	Align	substrings	to	FM-
Index	using	Burrows-Wheeler	transformaBon	c.)	randomly	select	Burrows-Wheeler	range	and	
resolve	oﬀset	to	reference	genome	d.)	Final	resolve	of	alignment	to	reference	through	SIMD		
a.)	
b.)	
c.)	
d.)	
Langmead	et	al.	2012	
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Single Instruction Multiple Data (SIMD) accelerated dynamic programming 
alignment on the vicinity of the resolved alignments until either a.) a sufficient 
number of alignments are examined b.) all seed hits are examined or c.) 
dynamic programming effort limit is achieved (Figure 10d).  
The advantage of aligners is that they are optimized to be efficient and 
rapid in their alignment of reads to genomic loci. Additionally, they are 
capable of tolerating mismatches and/or indels between a read and an 
alignment location. Given that an sgRNA can be thought of as a twenty base 
pair read, the ability of an aligner to quickly assign a genetic coordinate(s), as 
well as determine degenerate alignment loci, makes it an appealing solution 
for determining a sgRNA’s off-targets.   
Suboptimal Behavior of Genome Aligners in Off-Target Search: 
 The intended purpose of aligners is to robustly and accurately map 
reads to a reference genome. However, to accomplish this task using the best 
alignment algorithms between two strings, requires an algorithm that is 
quadratic in complexity141.  
 Consequently, this behavior is unfeasible for alignment purposes and 
heuristics must be employed to make alignments quicker while remaining 
robust and accurate. A common heuristic used by aligners is to break reads 
into substrings and optimize alignments for those substrings. While this and 
other heuristics speed up aligner behavior, they can allow for missed potential 
alignment sites that represent false negative events141. 
 These false negative events can be empirically shown when one uses 
a standard aligner to map reads that have multiple known perfect sequence 
matches to the hg38 assembly of the Human reference genome140 (Table 2). 
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Table	2:	Aligner	empirical	error 
At least X 
perfect 
sequence 
matches 
Total Reads Captured All 
Possible Read 
Alignments 
Missed at 
Least One 
Possible 
Read 
Alignment 
Missed Read 
Alignment 
Percentage 
X = 2 100 48 52 52% 
X = 10 100 37 63 63% 
X = 100 100 5 95 95% 
X = 1000 100 5 95 95% 
X = 10000 100 0 100 100% 
X = 100000 12 0 12 100% 
 
When dealing with the CRISPR system the existence of these false 
negatives is worrisome since they indicate sites in the genome that have the 
potential of being cut and permanently altered. These false negative sites 
represent an underreporting of a sgRNA’s target space and may compromise 
the results or analysis of a CRISPR experiment.  Consequently, to determine 
the complete target space of a sgRNA and thereby determine it’s specificity, a 
different approach is needed to determine off-targets. 
Retrieval Tree:  
 To accurately determine the target space of any sgRNA requires the 
complete knowledge of all the potential target sites, within a set number of 
mismatches, in a genome. To do this assessment with recursive scanning of 
a genome is computationally unfeasible, however, with the utilization of a 
retrieval tree (henceforth referred to as trie) this determination becomes 
tractable142,143.  
 A trie is a specific type of ordered tree where each node contains a 
character value and the root node represents an empty string (Figure 11). 
Children nodes have the same prefix, which is derived from the traversal of 
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their parent and ancestor nodes. A trie is traversed using the pre-order 
procedure and thus trie traversals are linear in complexity. Additionally, to 
build a trie from a collection of strings has simple complexity.  𝑙 = 𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑤𝑜𝑟𝑑 𝑤 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑜𝑟𝑑𝑠 𝑖𝑛 𝑐𝑜𝑙𝑙𝑒𝑐𝑡𝑖𝑜𝑛 
 𝑂 𝑙𝑤 =  𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝑇𝑟𝑖𝑒 𝐶𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑖𝑜𝑛 
 
Figure	11:	Trie	data	structure 
 Furthermore, for a given traversal of a string through a trie, a mismatch 
neighborhood for the string can be computed. Stated another way a string 
and all strings in the trie that are similar to it, by at most a distance h, can be 
identified through a traversal. This distance can be either a Hamming 
distance or Levenshtein distance144,145. 
 
 
Root	Node	
A	 P	
L	
E	L	
X	
T	
E	
E	
J	 Y	
Leaf	Node	 Leaf	Node	 Leaf	Node	 Leaf	Node	
Leaf	Node	Leaf	Node	
Leaf	Node	
Strings:	
Ale	
Pet	
All	
Alex	
Alej	
Ally	
Pete	
Figure	11:	Trie	data	structure	
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Trie Based Off-Target Search: 
 Given the simple complexity of construction and traversals, coupled 
with its ability to enumerate mismatch neighborhoods for strings, a trie 
represents a tractable solution for determining off-targets, and thereby 
specificity, of sgRNAs. The utilization of a trie for this purpose would start with 
the scanning of a genome for PAM sequences. This scanning is a O(n) 
process and simply scales with the size of the genome. When a PAM 
sequence is identified, a sgRNA complementary sequence is computed by 
taking a sequence of length l that is adjacent to the PAM site. As the 
sequences are extracted from the genome they are stored in a file that 
represents the universe of sgRNAs for a given genome.  
This universe of sgRNA’s is then used for the construction of the trie, 
which is a process that is O(lw) in complexity. Since l will be constant, 
however, the process reduces to O(w), which is simply the amount of sgRNAs 
in the genome. The branches in the trie will represent sgRNA complementary 
sequences and the leaf nodes associated with each branch will record the 
amount of times the sgRNA sequence occurs in the genome. Simply by 
constructing the trie, one is able to determine which sgRNA sequences are 
uniquely occurring in the genome. The ability to determine sgRNA 
uniqueness is essential in determining sgRNA specificity. This determination 
can be made exactly and through a process that is linear in complexity. 
Furthermore, the complete mismatch neighborhood of a sgRNA can be 
enumerated through traversing a trie, which is also a process that is linear in 
complexity. SgRNAs have been shown to tolerate positional mismatches, but 
have low tolerance for insertions and deletion124. Consequently, computing 
the Hamming distance at a value h, for a given sgRNA as it traverses through 
the constituent sequences in the trie will exhaustively determine the 
degenerate sequences to which a sgRNA can potentially cleave. Trie 
construction and trie traversals, both linear complexity processes, can 
therefore determine the uniqueness and off-target space of a given sgRNA. 
The trie data structure represents a solution to the sgRNA specificity problem. 
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GuideScan Algorithm:  
 Prior to GuideScan, more methods suffered from several restrictions 
including a.) generating sgRNAs strictly from a reference genome b.) 
providing sgRNAs only for the Cas9 CRISPR system c.) accounting for 
multiple alternative PAM sites d.) incomplete identification of all potential off-
target cut sites and e.) determining both cutting efficiency and cutting 
specificity. These restrictions ultimately limit the use of CRISPR systems in 
both research and clinical settings. The GuideScan algorithm was designed 
specifically to address these limitations123 (Figure 12).  
 
Figure	12:	GuideScan	algorithm 
 GuideScan is a software package that robustly and accurately 
determines the specificity of all sgRNAs present in a genome as well as 
constructs a database of sgRNAs that conform to prescribed uniqueness 
standards detailed by a user. GuideScan requires only a single input, which is 
a FASTA file. This FASTA file can come from any organism or disease 
condition. Furthermore, GuideScan allows for the customization of output 
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through the use of twenty-three parameters all of which possess default 
values for the generation of a Cas9 database.  
GuideScan begins by reading in a FASTA file and scanning for PAM 
sequences. The user specifies the identity of canonical PAM sequences that 
represent intended targets. Additionally, the user may also specify the identity 
of alternative PAM sequences that represent potential off-target sites. The 
position of the PAM sequence, either 3’ or 5’ to the sgRNA sequence 
recognition site, can also be determined by the user (Figure 13a).  
When GuideScan detects either a canonical or alternative PAM site it 
computes the target sequence of this site by selecting a series of k 
sequences either upstream or downstream of the PAM (depends on the 
position of the PAM sequence to the sgRNA sequence recognition site). The 
value of k is also a parameter that can be specified by the user. Once these 
target site sequences are computed they are written to a file (Figure 13b).  
 
Figure	13:	GuideScan	workflow 
Figure	13:	Workﬂow	of	GuideScan	algorithm.	a.)	A	user	selects	a	genomic	sequence	ﬁle	in	the	
format	of	a	FASTA	ﬁle	as	input	for	GuideScan.	This	FASTA	ﬁle	is	arbitrary	in	nature	and	can	
represent	the	genomes	of	various	model	organisms,	genomes	reﬂecBve	of	disease	states,	or	
wild-type	genomes.	b.)	The	FASTA	ﬁle	is	scanned	for	canonical	PAM	sequences	associated	with	
desired	sgRNAs	in	addiBon	to	searching	for	alternaBve	PAM	sequences	that	represent	potenBal	
oﬀ-target	cut	sites.	The	target	sites	associated	with	each	PAM	sequence	are	extracted	from	the	
genome	and	are	stored	in	an	output	ﬁle.	The	PAM	sequence	scanning	enumerates	the	target	
space	of	the	genome.	c.)	The	target	sites	from	the	output	ﬁle	are	used	to	construct	a	trie.	If	a	
target	site	occurs	more	than	once,	the	amount	of	Bmes	it	occurs	in	the	genome	is	stored	in	the	
leaf	node	of	the	trie	along	with	the	genomic	coordinate	informaBon	associated	with	the	target	
site.	Traversing	the	trie	for	sequences	similar,	within	h	mismatches,	to	a	query	sequence	
determines	the	sequence’s	mismatch	neighborhood.				
a.)	 b.)	 c.)	
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Once all possible target sites are determined and written to a file, the 
contents of the file are used in the construction of a trie. Each branch of the 
trie represents a potential target site and has a leaf node that enumerates 
how often the sequence occurs in the genome. As mentioned earlier, the 
construction of the trie from target sequences determines the uniqueness of 
every target site in the genome (Figure 13c).  
However, the trie data structure allows for a more rigid definition of 
uniqueness. Trie traversals allow for the assessment of a Hamming distance 
between an input sequence and the constituent sequences of the trie.  These 
traversals can determine if a sequence has any mismatch neighbors within a 
distance h. This ability of a trie allows a user to enforce a higher level of 
uniqueness on the sgRNAs by enforcing the usage of only those sequences 
that have no mismatches neighbors within a given distance h. In other words, 
trie traversals allow a user to determine which subset of sgRNA sequences 
are uniquely occurring in the genome up to h mismatches. The sgRNA 
sequences that meet this enhanced level of specificity are then written to a 
file. The distance h is another parameter determined by the user.  
Once the set of sgRNAs unique up to h mismatches (Sh) is determined, 
the algorithm allows a user to enumerate the potential off-targets for each 
sgRNA in set Sh up to q mismatches (q > h). The rationale behind this is that a 
user may wish to automatically exclude those sgRNAs that have near off-
targets (≤ ℎ 𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ𝑒𝑠) , but still desires to have sufficient sgRNAs to 
broadly and precisely target a genome. However, the higher the value of h, 
the fewer sgRNAs will be available. Reducing the size of set Sh functionally 
reduces the size of the targetable genome, which reduces the resolution on 
which the genome can be edited. Rather than arbitrarily reducing the size of 
Sh by increasing the value of h, a user can choose a value of h that makes Sh 
exclude those sgRNAs most likely to represent troublesome off-targets (off-
targets with a Hamming distance of one for example). The remaining sgRNAs 
can then have their off-targets enumerated up to a distance q and this 
additional off-target information can be used in making the final sgRNA 
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selection. By construction the elements of Sh will have no off-targets at ≤ ℎ 
mismatches and can only have off-targets at p mismatches where ℎ < 𝑝 ≤ 𝑞. 
As when sgRNA uniqueness was assessed, the enumeration of off-targets up 
to q mismatches is done through taking the sgRNAs in Sh and traversing them 
through the trie, enumerating mismatch neighborhoods up to Hamming 
distance q. This process satisfies the need to have numerous precise 
sgRNAs since Sh > Sq but a user has the knowledge of a sgRNA’s target 
space up to q mismatches.  
As the sgRNA uniqueness or off-target information is computed, it is 
written out to a Sequence Alignment Map (SAM) file. This file will contain the 
standard SAM fields in addition to three additional fields. Theses added fields 
detail the off-target distance assessment (q), the maximum amount of off-
targets recorded in the file for a given sgRNA (parameter selected by the 
user), and the coordinates of potential off-target cut sites. To reduce the size 
of the SAM file, the off-target information is recorded in the SAM file as a hex-
byte array. For Cas9 databases two further fields may be recorded to each 
sgRNA in the SAM file: a cutting efficiency score and a specificity score.   
Once the SAM file is generated, GuideScan utilizes Samtools to a 
create a Binary Alignment Map (BAM) file and index file that both reduces the 
size of the file and accelerates the search of the database file by genomic 
coordinate146. The index increases the speed of database query from a linear 
process to a logarithmic process143. 
 𝑂 𝑛 =  𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝐿𝑖𝑛𝑒𝑎𝑟 𝐷𝑎𝑡𝑎𝑏𝑎𝑠𝑒 𝑆𝑒𝑎𝑟𝑐ℎ 
 𝑂(log𝑛) = 𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝐼𝑛𝑑𝑒𝑥 𝐵𝑎𝑠𝑒𝑑 𝐷𝑎𝑡𝑎𝑏𝑎𝑠𝑒 𝑆𝑒𝑎𝑟𝑐ℎ 
 
Consequently, GuideScan creates CRISPR databases and determines 
sgRNA specificity in linear time and allows for the lookup of sgRNAs by 
coordinate in logarithmic time. 
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Cas9 sgRNA Cutting Efficiency Score: 
 If a GuideScan database is generated for the Cas9 CRISPR system, 
the BAM file can be further enriched with cutting efficiency scores for each 
sgRNA in the database. GuideScan utilizes the Rule Set 2 cutting efficiency 
score, which quantifies how likely a given sgRNA is to efficiency cut it’s target 
site124. The score is developed from a learned boosted regression tree model 
that computes a cutting efficiency score from a myriad of factors including 
sequence features.  
 Rule Set 2 scores are defined only for Cas9 sgRNAs with a twenty 
base pair complementary sequence and the NGG PAM. Consequently, if a 
user desires to enrich a GuideScan database with Rule Set 2 scores, the 
algorithm must first ensure that the database contains sgRNAs that conform 
to the requirements of Rule Set 2. GuideScan achieves this by checking the 
header sequence in the GuideScan database BAM file and searches 
specifically for the values associated with canonical PAM sequence and 
length of the sgRNA’s complementary sequence. If, and only if, both values 
conform to Rule Set 2 requirements will the score be computed for each 
sgRNA in the database. 
 Specifically, for each line in the BAM file, GuideScan will inspect the 5’ 
coordinate and strand sequence present in the file and compute the 
coordinates for a thirty base sequence region (Figure 14).  
 
Figure	14:	Rule	Set	2	sequence	requirement 
Complementary	Sequence	 NGG	
4-base	upstream	extension	 3-base	downstream	extension	
5’	 3’	
Figure	14:	Rule	Set	2	on-target	cudng	eﬃciency	score	sequence	
requirement.	
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While sgRNAs in the GuideScan database have a complementary region of 
twenty bases, Rule Set 2 requires sequences of thirty bases to compute a 
cutting efficiency score, and hence why a thirty base lookup is done. Once the 
coordinates for the thirty bases are determined, querying an indexed version 
of the input FASTA file retrieves the sequence itself. The Rule Set 2 model 
then processes the sequence and the score is recorded as an additional field 
in the BAM file.  
Cas9 sgRNA Specificity Score: 
 An additional metric available to GuideScan Cas9 databases is a 
specificity score. This score quantifies how likely a sgRNA is to cut only an 
intended target site given information about it’s off-targets up to a Hamming 
distance of q. The specificity score uses the cutting frequency determination 
(CFD) mismatch matrix to compute the likelihood that a given off-target site, 
dissimilar to the sgRNA complementary sequence by ≤ q mismatches, will be 
cut124 (Figure 15).  
The CFD mismatch matrix is composed of empirically determined 
values that represent how deleterious a given mismatch, in the twenty base 
complementary region, is to sgRNA binding and cutting efficiency. Each 
position in a twenty base complementary region was assessed with every 
base sequence as a mismatch and the disruption of the mismatch to cutting 
efficiency was determined. If a degenerate target site is dissimilar to a sgRNA 
complementary sequence by one mismatch then the CFD score is the 
empirical value of the mismatch position in the matrix. If more than one 
mismatch exists, then the CFD score is the product of the values for each 
mismatch. The CFD score can thereby determine a value for any potential off-
target site with any number of mismatches between the degenerate target site 
and sgRNA complementary sequence.  
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Figure	15:	Cutting	frequency	determination	matrix 
 As with the Rule Set 2 score, the CFD mismatch matrix is defined only 
for Cas9 sgRNAs with a twenty base pair complementary sequence and the 
NGG PAM. Consequently, before specificity scores can be computed, the 
GuideScan database BAM file will be assessed to verify it meets the 
requirements. If, and only if, the database conforms to CFD scoring 
requirements will GuideScan compute a specificity score for a sgRNA. 
 The CFD score computes the off-target likelihood of cutting for a single 
degenerate target site. GuideScan computes a specificity score by looking up 
the sequence associated with each off-target determined out to q mismatches 
and determining the CFD score by comparing the off-target sequence against 
the sgRNA complementary sequence. GuideScan then takes the CFD score 
and multiplies it by the amount of times the off-target sequence occurs in the 
genome. The resulting value is then aggregated as a denominator and a 
composite specificity score for a sgRNA is determined.  
 𝑛 = 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑢𝑛𝑖𝑞𝑢𝑒 𝑡𝑎𝑟𝑔𝑒𝑡𝑎𝑏𝑙𝑒 𝑠𝑖𝑡𝑒𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 𝑢𝑝 𝑡𝑜 𝑧 𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ𝑒𝑠 𝑧! = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑡𝑖𝑚𝑒𝑠 𝑡ℎ𝑒 𝑖!! 𝑛𝑒𝑖𝑔ℎ𝑏𝑜𝑟 𝑜𝑐𝑐𝑢𝑟𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑔𝑒𝑛𝑜𝑚𝑒 𝐶𝐹𝐷! =  𝐶𝐹𝐷 𝑠𝑐𝑜𝑟𝑒 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑖!! 𝑢𝑛𝑖𝑞𝑢𝑒 𝑡𝑎𝑟𝑔𝑒𝑡𝑎𝑏𝑙𝑒 𝑠𝑖𝑡𝑒 
Figure	15:	Cudng	Frequency	DeterminaBon	(CFD)	mismatch	cudng	
acBvity	matrix.	This	matrix	quanBﬁes	how	deleterious	a	posiBonal	
mismatch	is	between	a	sgRNA	and	a	target	site.	(Doench	et	al.	2016)		
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 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 𝑆𝑐𝑜𝑟𝑒 =  1𝐶𝐹𝐷! ∗ 𝑧!!!!!  
 
 In this manner, GuideScan determines a specificity score for each 
sgRNA in the database by evaluating its entire mismatch neighborhood. The 
exhaustive enumeration of mismatch neighbors makes the specificity score 
reflective of a sgRNA’s possible target space. The specificity score for each 
sgRNA is recorded as an additional field in the GuideScan database BAM file. 
Genomic Feature Annotation: 
 When choosing sgRNAs, a researcher may be interested in selecting 
only those sgRNAs that cut within specific genomic features. For example an 
experimentalist may be using sgRNAs to disrupt the reading frame of a 
protein coding sequence in which case they would want to choose sgRNAs 
that target exons. Whether it is exons or another genomic feature, GuideScan 
allows for the annotation of sgRNAs that overlap any arbitrary feature through 
its use of interval trees (appendix).  
Interval trees are data structures that allow for the efficient storage and 
query of a set of overlapping intervals. While the details of an interval tree are 
discussed in the appendix, for the purposes of understanding their usage in 
annotation it is sufficient to state that these structures allows for the discovery 
of all overlapping intervals at a single interval (Figure 16).  Furthermore, they 
are efficient in both their construction and query147.  
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Figure	16:	Interval	tree	conceptual	diagram 
 𝑛 = 𝑛𝑜𝑑𝑒𝑠 𝑖𝑛 𝑡𝑟𝑒𝑒, 𝑘 = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙𝑠 𝑜𝑢𝑡𝑝𝑢𝑡 
 𝑂 𝑛 𝑙𝑜𝑔 𝑛 =  𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙 𝑇𝑟𝑒𝑒 𝐶𝑜𝑛𝑠𝑡𝑟𝑢𝑐𝑡𝑖𝑜𝑛 
 𝑂 log𝑛 + 𝑘 =  𝐶𝑜𝑚𝑝𝑙𝑒𝑥𝑖𝑡𝑦 𝑜𝑓 𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙 𝑇𝑟𝑒𝑒 𝑆𝑒𝑎𝑟𝑐ℎ 
  
 A practical example of the use of interval trees for annotation purposes 
is to return to the problem of selecting sgRNAs that overlap exons. Imagine a 
researcher is conducting a loss of function experiment with sgRNA’s targeting 
a given protein. This protein has several isoforms that use different exons, 
however some exons are expressed across all isoforms. Querying an interval 
tree, constructed from the coordinates of all the exons in the genome, allows 
the investigator to see which sgRNAs overlap exons expressed across all 
isoforms. In this manner, a researcher can choose a single sgRNA that will 
effectively cut, and hopefully disrupt, all isoforms of the protein leading to an 
effective loss of function result. 
Query	Interval	
Figure	16:	Overlapping	segments	within	a	query	interval.	The	query	of	a	
single	interval	[X1,X2]	will	return	all	segments	that	intersect	this	interval.	This	
basic	principle	is	the	underlying	logic	behind	interval	trees.	
X1	 X2	
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 GuideScan will automatically construct interval trees to annotate 
sgRNAs if it is delivered a Browser Extensible Data (BED) format file when a 
user queries a GuideScan database. The annotation is done at time of 
database query to allow a user the maximum flexibility in determining what 
annotations they would like to apply to a GuideScan database. The 
annotation is displayed as a field in the output that results when a GuideScan 
database is queried. 
GuideScan Database Query Output Options: 
 GuideScan allows users to extract sgRNAs from a database according 
to several selection parameters. To start, a researcher can have GuideScan 
return sgRNAs from within a target site or from the regions flanking a target 
site. The user defines the size of these flanking regions. Additionally, if the 
user requests sgRNAs flanking a target region, and a pair of flanking sgRNAs 
exist, then GuideScan automatically will generate an oligonucleotide that has 
both sgRNA complementary regions cloned in, provided they meet the 
sequence requirements described in the Vidigal & Ventura dual sgRNA 
delivery system148.  
The selected sgRNAs can be sorted according to at least two, and at 
most four, parameters (depends if database is for Cas9). The number of 
enumerated off-targets up to distance q can sort all queries. In this process 
those sgRNAs with the least total number of off-targets appear first in the 
output while those with the most appear last. Additionally, sgRNAs can be 
sorted by their proximity to a target site. For within queries, sgRNAs are 
sorted with those appearing closest to the 5’ end, as seen from the positive 
strand, appearing first and those nearest the 3’ end appearing last. For 
flanking queries GuideScan output appears in two parts: sgRNAs upstream of 
the 5’ coordinate and sgRNAs downstream of the 3’ coordinate. For a flanking 
query sorted by proximity to target site, the sgRNAs upstream of the 5’ 
coordinate are sorted with those sgRNAs closest to the 5’ coordinate listed 
first and those furthest away last. Likewise for the sgRNAs downstream of the 
3’ coordinate the sgRNAs closest to the 3’ coordinate are listed first and those 
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furthest away last. Additionally, if the database is composed of Cas9 sgRNAs, 
and cutting efficiency scores and specificity scores are included in the 
database, then sgRNAs can be sorted by either score. For both cutting 
efficiency and specificity, for either within or flanking queries, the sgRNAs are 
sorted with those sgRNAs with the highest score listed first and those with the 
lowest scores listed last. 
 Furthermore, GuideScan is capable of selecting the top m sgRNAs for 
a user, for either within or flanking queries, by using a double sort method 
utilizing two selection parameters. The user sets the value of m. As an 
example, should an investigator choose to have GuideScan select the top m 
sgRNAs prioritizing the off-target option then all the sgRNAs for a queried 
region will be sorted according to their off-targets values, after which the top 
m will be selected for a second sort. In this second sort, if a cutting efficiency 
score is present in the database then these m sgRNAs will be resorted by 
efficiency score, otherwise they will be resorted by proximity to query 
boundary. A full detailing of the double sort method for GuideScan sgRNA 
selection is detailed in the following table (Table 3). 
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Table	3:	GuideScan	double	sort	selection 
Sort Option First Sort First Sort 
(Cas9) 
Second Sort Second Sort 
(Cas9) 
Fewest Off-
targets 
Fewest Off-
targets 
NA Coordinates 
Closest to 
Query 
Boundary 
Cutting 
Efficiency 
Score 
Coordinates 
Closest to 
Query 
Boundary 
Coordinates 
Closest to 
Query 
Boundary 
NA Fewest Off-
targets 
NA 
Cutting 
Efficiency 
Score 
NA Cutting 
Efficiency 
Score 
Fewest Off-
targets 
NA 
Specificity NA Specificity Coordinates 
Closest to 
Query 
Boundary 
Cutting 
Efficiency 
Score 
 
 In addition to the various ways in which GuideScan can display its 
output, it also is capable of handling distinct input formats. GuideScan 
databases are ultimately organized and queried by genomic coordinates; 
however, the software was designed to handle four distinct forms of query, 
which serves to maximize its utility to researchers.   
 First, GuideScan supports batch queries that allow a user to specify a 
set of genomic coordinates that GuideScan reads in and extracts sgRNAs for. 
Batch query output is displayed according to user determined output 
parameters. Specifically, batch queries take files as input. These files are 
either of the Gene Transfer Format/General Feature Format (GTF/GFF), text, 
or BED formats. If the file is of the text of GTF/GFF format then arbitrary 
unique identifiers for each sgRNA will be assigned to each sgRNA. However, 
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if the file is a BED file then the fourth field potentially can serve as a unique 
identifier for output sgRNAs. If the file is a BED file GuideScan determines if 
any multiplicity exists in the fourth column and if none exists, it uses the 
values of the fourth field for creating unique identifiers. However, if even one 
instance of multiplicity exists then arbitrary labeling will be enacted.  
The second type of query GuideScan supports is the direct genomic 
coordinate query. A user can type in a genomic coordinate for their region of 
interest and set their output parameters to receive sgRNAs for their region of 
interest. These sgRNAs will have arbitrarily generated unique identifiers. 
The third type of query allowed by GuideScan is query by genomic 
feature. In this format a user provides a BED file where the fourth field is 
composed of unique feature identifiers. For example, imagine a BED file in 
which the fourth field consists of gene names and the first three fields 
compose the chromosome, start, and end coordinates of the genes. 
GuideScan will create a dictionary data structure with the elements of the 
fourth field as keys and genomic coordinate as values. The user can then 
specify, as either a direct query or a batch query, the feature name and get 
sgRNAs for that feature with GuideScan processing the request as a 
coordinate query in the background. These sgRNAs will have arbitrarily 
generated unique identifiers. 
The last query permitted by GuideScan is query by sequence. This 
query format requires a user to specify the indexed FASTA file that was used 
as input for the generation of the GuideScan database. Additionally, the user 
must give a FASTA file, composed of the sequences of interest, to 
GuideScan as query input. GuideScan will then use BLAT to locally align the 
sequences to the indexed FASTA file. If, and only if, a perfect sequence 
match is found then the output of BLAT will be converted into coordinates and 
used by GuideScan to extract sgRNAs for the determined region 149.  
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GuideScan Database sgRNA Density and Target Resolution: 
The final output of the GuideScan algorithm is a sgRNA database in a 
BAM file format. The sgRNA’s in this database are guaranteed to be unique 
up to h mismatches, which means that not all possible sgRNAs will be 
included in Sh. To ensure that the sgRNA database still has a density of 
sgRNAs that allow it to precisely edit any arbitrary genomic locus, a 
GuideScan database for the mm10 assembly of the mouse genome was 
generated with sgRNAs unique up to two mismatches. To determine sgRNA 
density, the mouse genome was binned into fifty kilobase regions and the 
quantity of sgRNAs per bin was determined using both the mm10 GuideScan 
database and the only other genome-wide database of sgRNAs available at 
the time (Hsu database)129 (Figure 17).  
 
Figure	17:	GuideScan	mm10	sgRNA	density 
Figure	17:	sgRNA	density	per	50	kilobase	region	in	the	mm10	assembly	of	the	mouse	genome.	
The	GuideScan	database	was	ﬁltered	so	sgRNAs	were	guaranteed	to	be	unique	up	to	two	
mismatches.	The	mit.edu	UCSC	tracks	were	unﬁltered	and	their	density	was	computed	using	the	
enBre	contents	of	the	track.	
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This comparison showed that the filtering of sgRNAs for a uniqueness of up 
to two mismatches did not profoundly impact the density of sgRNAs in the 
genome.  
To demonstrate that GuideScan sgRNA density translated to a better 
cutting resolution, sgRNAs were designed against non-coding features 
including all enhancers, microRNAs (miRNA), long non-coding RNAs 
(lncRNAs), and CTCF sites in the mm10 assembly of the mouse genome150–
153. Flanking sgRNAs were designed against each genomic feature and the 
distance between the nearest sgRNA and the 5’ or 3’ genomic coordinate 
defining the feature was determined. Once again the GuideScan and Hsu 
databases were used for this comparison (Figure 18).  
 
Figure	18:	Target	flanking	distance	for	non-coding	elements 
The resulting analysis showed that sgRNAs could be designed against 
enhancers, miRNAs, lncRNAs and CTCF sites with a combined flanking 
distance of 31, 24, 27, and 29 base pairs respectively with the GuideScan 
database. For the Hsu database the combined flanking distance was 783, 
Figure	18:	Combined	ﬂanking	distance	for	all	CTCF	site,	Enhancers,	miRNAs,	and	lncRNAs	in	the	
mm10	assembly	of	the	mouse	genome	were	computed	using	a	mm10	GuideScan	database	
where	all	sgRNAs	were	unique	up	to	two	mismatches	and	the	mit.edu	UCSC	tracks.	
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716, 774, and 781 base pairs respectively. Consequently, this comparison 
demonstrated that GuideScan’s more rigid definition of uniqueness not only 
does not functionally affect sgRNA density, but it also has modest effect on 
target resolution. 
To ensure that sgRNAs designed against these target sites were 
functional, one miRNA cluster and one enhancer site in the mouse genome 
were chosen at random for deletion by paired sgRNAs. Both of these sites 
had paired sgRNAs designed against them and were sequenced to verify the 
presence of the deletion (Figure 19a,b).  Overall, the requirement that 
GuideScan databases contain sgRNAs unique up to h (where h is reasonably 
low) mismatches produced databases with excellent density, resolution, and 
activity of sgRNAs. 
 
Figure	19:	Example	deletions	of	miRNA	cluster	and	enhancer	
GuideScan Database sgRNA Specificity: 
 GuideScan databases have sgRNAs filtered for a user-defined level of 
uniqueness. However, it remained to be seen whether this augmented level of 
Figure	19:	Example	deleBons	of	genomic	regions	containing	RNA	(a)	and	DNA	(b)	non-coding	
elements	using	pairs	of	sgRNAs	designed	by	GuideScan.	sgRNA	sequences,	blue	and	red;	PAM	
sequences,	bold	underlined.	The	predicted	sequence	amer	deleBon,	the	sequences	amer	three	
edited	alleles,	and	a	representaBve	chromatogram	are	shown	for	each	target	locus.	19		
a.)	 b.)	
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uniqueness translates to higher sgRNA specificity. To make this 
determination genomic coordinates of fifty random mouse (mm10) protein 
coding genes, non-coding elements, and repeat masked regions were chosen 
for sgRNA design by three widely used tools: mit.edu, CRISPRScan, and E-
CRISP in addition to GuideScan 126,127,129. All three tools required sequence 
input for sgRNA design; therefore genomic coordinates were translated into 
sequences and delivered as input to the methods. The sgRNAs outputted by 
each method were then assessed for mismatch neighbors by traversing them 
through the mm10 trie and determining the identity of mismatch neighbors up 
to a Hamming distance of two.  This assessment showed that all methods, 
except GuideScan, produced sgRNAs that either had multiple perfect 
sequence match target sites or target sites dissimilar by only one mismatch 
(Figure 20). These sites represented off-targets with extremely high cutting 
potential116.  
 
Figure	20:	Tool	comparison	with	single	and	perfect	sequence	match	target	sites 
 Multiple perfect target site matches represent a particularly 
troublesome off-target for CRISPR usage. To investigate how many times 
perfect target site matches occurred in the sgRNAs outputted by competing 
methods, a strict enumeration of the target site occurrence in the genome 
was computed for each duplicitous sgRNA. This showed that some sgRNAs 
Figure	20:	Number	of	mouse	sgRNAs	designed	against	ﬁmy	random	protein	coding	genes,	ﬁmy	
random	non-coding	elements,	and	ﬁmy	random	repeat	masked	regions.	All	tools	but	GuideScan	
delivered	sgRNAs	that	contained	mulBple	perfect	sequence	match	target	sites	and	degenerate	
target	sites	diﬀerent	from	the	intended	target	site	by	only	one.		
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delivered by these methods occurred in the genome tens of thousands of 
times (Figure 21).  
 
Figure	21:	Quantity	of	perfect	sequence	match	target	sites 
Such a magnitude of perfect target site matches in the genome makes the 
usage of such sgRNAs worrisome given that the abundance of target sites 
would likely lead to prolific DSBs and potentially compromise the survival of 
the cell. This effect could be particularly worrisome when using these sgRNAs 
as part of a negative or positive selection screen.  
 Additionally, many selection methods assign a specificity score to their 
sgRNAs that takes into account off-target information. A particularly popular 
method was the web interface tool from MIT (henceforth termed mit.edu). 
This method assigned a specificity score based on a number ranging from 
one to one hundred with one indicating highly nonspecific and one hundred 
indicating highly specific. Additionally, these values took on a color score that 
illustrated the mit.edu’s assessment for the specificity of the sgRNA. Green 
represented sgRNAs that were most specific to their target, yellow 
represented sgRNAs that were somewhat specific to their target, and red 
represented sgRNAs that were likely non-specific to their target. Ideally those 
sgRNAs with multiple perfect target site matches would be assigned a low 
Figure	21:	sgRNAs	designed	against	ﬁmy	random	protein	coding	genes,	ﬁmy	random	non-coding	
elements,	and	ﬁmy	random	repeat	masked	regions	with	mulBple	perfect	sequence	match	target	
sites.	All	tools	but	GuideScan	returned	sgRNAs	that	had	sgRNAs	that	were	not	uniquely	
occurring	in	the	mm10	assembly	of	the	mouse	genome.	
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specificity score since they possess multiple exact target sites in a genome. 
However, when the mit.edu specificity scores were compared against the 
amount of perfect match target sites no correlation was observed (Figure 22).  
 
Figure	22:	mit.edu	specificity	score 
Figure	22:	Dot	plot	showing	speciﬁcity	scores	and	number	of	perfect	sequence	match	target	
sites	for	sgRNAs	designed	by	mit.edu.	Red	dots	indicate	low	speciﬁcity,	yellow	dots	medium	
speciﬁcity,	and	green	dots	indicate	high	speciﬁcity.		
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 Furthermore, upon closer analysis of the mit.edu tool’s output it was 
noted that many sgRNAs with multiple perfect target site matches were being 
reported as uniquely occurring in the mouse genome. This result was 
worrisome because sgRNAs will target and cut perfect sequence matches 
with approximately equal efficiency (Figure 23).  
 
Figure	23:	Cleavage	assay	of	perfect	sequence	match	target	sites 
Furthermore, if a sgRNA is described as being uniquely occurring, and in 
reality is not, then multiple genetic lesions can occur unbeknownst to the 
experimenter that potentially compromises the interpretation of the 
experiment.  
 CRISPR systems induce DSB in DNA at a target site. If two DSB occur 
in a chromosome an inversion or a deletion can result. Furthermore, should 
two DSBs occur on separate chromosomes then translocations between the 
chromosomes can occur. In reality, however, when multiple DSB occur 
across or within multiple chromosomes then multiple translocations and 
inversions will occur. These alterations, if unintended, pose tremendous 
Figure	23:	T7	cleavage	assay	for	sgRNAs	having	
single	(black,	on-target)	or	mulBple	(red,	blue,	
on-target)	perfect	matches	in	genome.	PosiBon	
of	cleavage	substrates	(ﬁlled	triangles),	posiBon	
of	cleavage	product	(open	triangles).			
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difficulty in interpreting the result of a CRISPR experiment. This is especially 
true for chromosomal translocations that are known to be oncogenic in 
several well-described cases154–156 (Figure 24).   We investigated a sgRNA 
from the mit.edu tool that was termed to be highly specific and uniquely 
occurring in the genome, but which had three perfect sequence match target 
sites in the genome. When we transfected this sgRNA we observed cutting at 
all three target sites and the generation of translocations. Such a result is 
undesirable to an investigator.  
 
Figure	24:	Undesired	translocations 
 Multiple perfect sequence match target sites can also pose a problem 
even if the target sites are not located distantly from another. If CRISPR 
systems are being used to engineer a specific genomic alteration at a given 
locus with the HDR mechanism, then it is imperative that a target site be 
unique. However, if sgRNAs are designed against a region that has locally 
repetitive sequences then the genetic alteration will only occur in a minority of 
cells. Furthermore, the readout of the experiment will give non-descript bands 
that reveal the multi-cut nature of the sgRNA. Again, we investigated a 
Figure	24:	Lem,	schemaBc	representaBon	of	chromosomal	translocaBon.	Right,	PCR-
based	idenBﬁcaBon	of	chromosomal	translocaBons	between	perfect	sequence	
match	target	sites.	+	sgRNA,	–	empty	vector.	sgRNA	is	marked	as	highly	speciﬁc	by	
mit.edu	(score	=	78)		
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sgRNA from the mit.edu method that was stated to be specific and uniquely 
targeting in the genome, but in reality had several local perfect match target 
sites. In transfecting this sgRNA we observed the creation of non-descript 
bands revealing the multiple cutting tendency of the sgRNA (Figure 25).   
These repetitive local cut sites, again, can be undesirable to a researcher.  
 
Figure	25:	Undesired	local	target	sites 
 While specific examples demonstrated the unintended effects of non-
unique sgRNAs, it remained to be determined if the higher standard of 
uniqueness GuideScan enforces on its sgRNAs translated globally into 
increased sgRNA specificity. To determine if GuideScan sgRNAs as a whole 
were more specific than the sgRNAs returned by mit.edu, CRISPRScan, and 
E-CRISP, specificity scores were computed for all the sgRNAs outputted by 
the tools. The distributions of specificity scores were then assessed and the 
differences between populations were statistically evaluated using the 
Kolmogorov-Smirnov test (Figure 26). As a population GuideScan sgRNAs 
were significantly more specific to their target sites than sgRNAs from either 
Figure	25:	Lem,	schemaBc	representaBon	of	the	chromosomal	locaBons	of	
three	perfect	sequence	match	target	sites	,	all	within	chromosome	two,	of	a	
sgRNA	labeled	highly	speciﬁc	by	mit.edu	(score	=	89).	Genomic	sequence:	
target	sites,	red;	PAM	sequence,	bold.	Right,	PCR-based	idenBﬁcaBon	of	
chromosomal	deleBons	between	target	sites.	PosiBons	of	the	wild-type	
amplicon,	ﬁlled	triangle;	posiBon	of	deleBon	amplicon,	open	triangle.	+,	
sgRNA;	-,	empty	plasmid.	
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mit.edu or CRISPRScan (p < 2.2 x 10-16). The sgRNAs from E-CRISP were 
not significantly more specific than the sgRNAs from GuideScan; however, 
the amount of sgRNAs delivered by E-CRISP was an order of magnitude less 
than the amount of sgRNAs returned by GuideScan. Furthermore, output by 
E-CRISP still contained sgRNAs that had multiple perfect sequence match 
target sites as well as target sites distinct from a sgRNA complementary 
region by only one mismatch, albeit less frequently than mit.edu or 
CRISPRScan. Consequently, GuideScan was the only tool that delivered 
completely unique sgRNAs, which were significantly more specific than 
mit.edu and CRISPRScan and an order of magnitude more numerous than E-
CRISP.  
 
Figure	26:	GuideScan	specificity	score 
Competitor Methods Off-Target Search: 
 CRISPRScan, mit.edu, and E-CRISP are conceptually robust and 
ingeniously designed tools, yet they fail to relay the complete target space 
information about a given sgRNA within a set number of mismatches. As a 
Figure	26:	CumulaBve	distribuBon	plot	of	speciﬁcity	scores	for	each	of	the	sgRNAs	designed	by	
each	tool.		
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consequence, these methods will overestimate the specificity of sgRNAs and 
occasionally miss off-targets with high cutting potential. It appears the reason 
for this is that all three methods rely on genome aligners for their off-target 
search. As previously discussed, these tools are excellent for aligning high 
throughput sequencing data, but are not optimized for exhaustive alignment 
mapping. These tools utilize heuristics to determine mapping sites in an 
efficient and rapid manner. However, these heuristics are known to give false 
negatives. As a result, when genome aligners are used to determine the off-
targets of a sgRNA, only occasionally will the complete target space be 
enumerated by the aligner. Unfortunately, in a system that enacts permanent 
changes in a genome such as CRISPR, the complete knowledge of a target 
space is essential. It is the enumeration of all genomic target sites coupled 
with the exhaustive determination of sgRNA mismatch neighborhoods by the 
trie data structure that gives GuideScan it’s advantage over aligner based 
methods. 
GuideScan Command Line Tool: 
 The GuideScan algorithm was designed as a python software package 
that can be installed system-wide on a machine. The package can generate 
and query databases from the command line and creates its own output 
directory with required intermediate and final output files. The software can be 
downloaded from a public repository at 
https://bitbucket.org/arp2012/guidescan_public/overview. Furthermore, the 
package is also available as a Docker container at 
https://hub.docker.com/r/xerez/guidescan/. 
GuideScan Web Interface:  
To better facilitate the usage of GuideScan, a web interface was 
created. This interface contains pre-computed Cas9 and Cpf1 GuideScan 
databases, for the human (hg38), mouse (mm10), zebrafish (danRer10), fruit 
fly (dm6), Caenorhabditis elegans (ce11), and yeast (SacCer3) genomes. 
These genomes can be queried by coordinate, gene symbol, sequence, text 
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file, BED file, or GTF file upload for all organisms with an easy to use front 
end. The back end of the site runs completely off the GuideScan software.  
The web interface also allows for the direct download of the hosted 
GuideScan databases as well as directs a user to the software repository and 
Docker instance should an investigator want to utilize GuideScan to create 
their own custom CRISPR databases.  
Since the launch of the GuideScan web interface on March 1, 2017 
through July 11, 2017 the site has serviced 1,577 unique users with retention 
rate over fifty percent (Figure 27).  
 
Figure	27:	GuideScan	web	interface	retention 
These users have generated 3,368 unique sessions and 11,187 page-
views. User IP addresses originate from fifty-one distinct countries and 405 
different cities (Figure 28). Site usage follows a weekly cyclic pattern with 
lowest activity occurring on the weekend.   
The web interface can be found at www.guidescan.com. The site is 
constructed with the CherryPy, a python web framework. The website was co-
Figure	27:	pie	plot	diagram	showing	site	visits	by	familiar	IP	addresses	and	by	novel	IP	addresses	
to	GuideScan	web	interface.	
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developed with Sagar Chhangawala and main algorithm was co-developed 
with Yuri Pritykin. 
 
Figure	28:	GuideScan	web	interface	global	access 
  
Figure	28:	Map	of	country	usage	of	GuideScan	web	interface.	Darker	blue	indicates	greater	
usage.	
58	
Chapter 3: RBMX 
Overview of Splicing: 
 The most recent assessment by Ensembl states that there are 20,412 
genes in the human genome136. Not all of these genes encode proteins as 
their final gene product, with some genes encoding functional forms of 
RNA157,158. Consequently, only a subset of genes is needed to generate the 
92,179 proteins that constitute the known human proteome159. This 
discrepancy between the quantity of genes and their protein products is 
achieved through a fundamental genetic process known as splicing.  
Genes, in a broad sense, can be defined as segments of DNA that 
undergo transcription. Protein coding genes are those DNA sequences that, 
when transcribed, ultimately form messenger RNA (mRNA). These genes are 
composed of two distinct types of DNA sequences: those sequences that 
ultimately interact with a ribosome and those sequences that do not. The 
sections of DNA that interact with a ribosome are termed exons, while the 
non-interacting sections are called introns. When DNA is transcribed, introns 
are either concurrently or shortly thereafter removed from the resulting RNA 
transcript to form the mRNA160. The removal of introns from a RNA transcript 
is the general definition of splicing (Figure 29).  
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Figure	29:	Overview	of	splicing 
 Splicing is an evolutionarily ancient process that is functionally present 
across all domains of life. Similar splicing machinery exists in both eukaryotes 
and prokaryotes, but the utilization of splicing varies between these 
kingdoms. While eukaryotes frequently splice protein coding RNA transcripts 
and to a lesser extent non-coding RNA transcripts, prokaryotes splice less 
often and commonly focus on non-coding RNA transcripts161–163. Splicing 
occurs in archaea as well, but it appears limited to tRNA splicing164,165. 
Interestingly, though prokaryotes and eukaryotes possess similar splicing 
machinery, the splicing mechanism present in archaea most closely 
resembles the mechanism present in eukaryotes164. The machinery available 
for splicing is most numerous in eukaryotes with this domain of life 
possessing at least three established pathways: spliceosomal complex, self-
splicing introns, and tRNA splicing166–169.  
 Among all the splicing pathways, the one that is conserved across all 
domains of life is tRNA splicing as it is crucial for the generation of tRNA 
molecules170. Self-splicing introns are found in prokaryotes and eukaryotes 
Intron	 Intron	
Exon	 Exon	 Exon	
Splicing	
Figure	29:	General	diagram	of	splicing	where	all	introns	in	a	transcript	are	spliced	out	leaving	
only	exons.	While	the	cartoon	illustrates	splicing	in	isola:on	from	transcrip:on,	the	reality	is	
that	splicing	occurs	simultaneously	with,	or	shortly	a<er,	transcrip:on.	
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and used in the creation of ribozymes171,172. Eukaryotes enact most of their 
splicing through the unique molecular machinery of the spliceosome. In fact 
the presence of the spliceosome is one of the characteristics defining the 
eukaryote domain of life173,174.  
 The spliceosome is composed of five small nuclear RNAs (snRNA) 
that interact with various heterogeneous nuclear ribonucleoproteins (hnRNPs) 
that are present in the nucleus175,176 (Figure 30).  
 
Figure	30:	Spliceosome 
Exon	 Exon	Intron	
5’	 3’	
Pre-mRNA	
Exon	 Exon	
snRNPs	
Spliceosome	
5’	 3’	
5’	 3’	
mRNA	
snRNPs	from	
disassembled	
spliceosome	
Excised	Intron	in	
lariat	structure	
Figure	30:	Spliceosome	assembly,	structure,	and	disassembly	in	the	process	of	excising	an	intron	
from	a	pre-mRNA	transcript.	
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When DNA is transcribed into RNA, it exists first as heterogeneous 
nuclear RNA (hgRNA) that contains both introns and exons. The hgRNA is 
bound by hnRNPs, which assist in preventing self-binding of the transcript, 
the transport of mRNA out of the nucleus, and associating the hgRNA with 
splicing machinery. When the snRNAs and the hgRNPs come together they 
form small nuclear ribonucleo proteins (snRNPs), which constitute the main 
actors in the spliceosome175,176. The spliceosome removes introns from the 
hgRNA through a two-step biochemical reaction (Figure 31a-c).  
 
Figure	31:	Chemical	mechanism	of	splicing 
In the first step, the splicing machinery defines a nucleotide in the 
target intron to be a branchpoint nucleotide177. The hydroxyl group on this 
branchpoint nucleotide then performs a nucleophilic attack on the base at the 
5’ splice site between the intron and the 5’ exon177 (Figure 31a). This 
nucleophilic attack results in the creation of a lariat structure intermediate. In 
the second step, the hydroxyl group on the released exon engages in a 
nucleophilic attack on the base at the 3’ splice site, which releases the lariat 
Exon	 Exon	Intron	
Branchpoint	nucleoFde	
a.)	
b.)	
c.)	
Figure	31:	Diagram	of	splicing	biochemical	reac:on.	a.)	branchpoint	nucleo:de	nucleophilic	
aDack	on	5’	exon	b.)	exposed	exon	nucleophilic	aDack	on	3’	exon	c.)	spliced	exons	and	excised	
intron	in	lariat	structure.	
5’	
5’	
5’	
3’	
3’	
3’	
3’	5’	
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structure and joins the two exons177 (Figure 31b,c). When the intron is 
released it has all the snRNPs bound to it and it is this final assembly that is 
called the spliceosome. Shortly, after the intron is released the snRNPs 
detach and the process repeats. 
Alternative Splicing: 
 However, introns are not the only components of the hgRNA that can 
be spliced out. Exons are also capable of being excised as a consequence of 
splicing. This excision contributes to the diversity of protein products encoded 
by the genome178,179. Furthermore, introns do not always need to be excised 
and some persist as retained introns in the final transcript178,179. Utilizing 
splicing to express distinct versions of a processed hgRNA (termed isoforms) 
is the essence of alternative splicing180.  
 In the human genome there is an average of 8.8 exons and 7.8 introns 
per gene181. Furthermore, it is believed that at least ninety-five percent of all 
multi-exon genes undergo some form of alternative spicing182. If one assumes 
that the average gene is spliced with the average values of exons and introns, 
one sees the tremendous genetic diversity available to the human genome 
through alternative splicing.  
 𝑃𝑜𝑠𝑠𝑖𝑏𝑙𝑒 𝐼𝑠𝑜𝑓𝑜𝑟𝑚𝑠 𝑤𝑖𝑡ℎ 𝑆𝑝𝑙𝑖𝑐𝑖𝑛𝑔 𝑜𝑓 𝐸𝑥𝑜𝑛𝑠 = 2!.! ≈ 446  
 𝑃𝑜𝑠𝑠𝑖𝑏𝑙𝑒 𝐼𝑠𝑜𝑓𝑜𝑟𝑚𝑠 𝑤𝑖𝑡ℎ 𝑆𝑝𝑙𝑖𝑐𝑖𝑛𝑔 𝑜𝑓 𝐸𝑥𝑜𝑛𝑠 𝑎𝑛𝑑 𝐼𝑛𝑡𝑟𝑜𝑛𝑠 =  2!.!!!.! ≈ 99,334  
 
63	
 Adding to complexity of the splicing system is the fact that there are at 
least five forms of splicing that are known to occur in eukaryotic genomes: 
exon skipping, mutually exclusive exons, alternative 5’ splice site, alternative 
3’ splice site, and retained introns178–180 (Figure 32a-e).  
 
Figure	32:	Alternative	splicing	events 
 Exon skipping, also known as cassette exon, is when an exon is either 
spliced out or retained during the processing of a hgRNA (Figure 32a). This 
form of splicing is the most common form of splicing in the human genome178. 
Mutually exclusive exons represent splicing events where, within a set of 
exons, one and only one is retained in a final transcript (Figure 32b). In other 
words mutually exclusive exons consists of exons that are never seen 
together in the same mRNA. Alternative 5’ and 3’ splice sites effectively 
change the size of a target exon by specifying distinct splice site boundaries 
in an exon that deviate from what is normally observed (Figure 32c,d). 
Intuitively, alternative 5’ splice sites push the 5’ splice site further into the 5’ 
exon. Likewise, the alternative 3’ splice sites push the 3’ splice site further 
Exon	Skipping	
Mutually	Exclusive	Exons	
AlternaFve	5’	Splice	Site	
AlternaFve	3’	Splice	Site	
Retained	Intron	
a.)	
b.)	
c.)	
d.)	
e.)	
5’	
5’	
5’	
5’	
5’	
3’	
3’	
3’	
3’	
3’	
Figure	32:	Alterna:ve	Splicing	events	a.)	skipped	exons	b.)	mutually	exclusive	exons	c.)	
alterna:ve	5’	splice	sites	d.)	alterna:ve	3’	splice	site	e.)	retained	intron	
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into the 3’ exon. The last, and rarest, form of alternative splicing is the 
retained intron178 (Figure 32e). The retained intron is distinct from exon 
skipping in that with exon skipping the exons are flanked by intron sequences, 
while in retained introns the introns are flanked by exon sequences178–180. 
Furthermore, these retained introns must be in the same reading frame as the 
flanking exons and code for amino acids. If the retained intron is not in frame 
or does not code for the proper amino acids then the resulting polypeptide will 
be of altered, limited, or null functionality.  
 While generally not recognized as alternative splicing events, 
eukaryotic genomes are also capable of further expression diversity with the 
usage of multiple promoter or polyadenylation sites. These alternations affect 
transcriptional regulation at the 5’ and 3’ end points of a mRNA transcript 
respectively179,180.  
RBMX: 
 Previous studies investigating the role of MUSASHI2 in leukemia 
identified RBMX as a direct actor in MUSASHI2’s riboproteomic network183. 
To further evaluate its significance in leukemia it was included in a mouse in-
vivo pooled shRNA screen of 613 shRNAs against 128 genes in MLL-AF9 
cells. Four shRNAs against RBMX in the bone marrow and two shRNAs 
against RBMX in the spleen were both highly depleted. Those cells with 
RBMX depletion also showed dramatic reduction of colony formation and 
increased differentiation. These results in aggregate suggested that RBMX 
could represent a putative oncogene.  
 RBMX, also known as hnRNP G, is a hgRNP whose function remained 
largely uncharacterized for nearly a decade after it’s discovery184,185. Initial 
studies demonstrated that RBMX associated with the spliceosome and 
appeared to influence alternative splicing, which conformed to RBMX’s 
expected function as a hgRNP186. However, the specific in vivo function of 
RBMX remained unknown187. Recent studies have implicated RBMX in 
various functions pertaining to genomic stability, suggesting a potential role of 
RBMX in genome maintenance.  
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 RBMX is ubiquitously expressed across all organs in the human body 
and has been implicated in various cellular processes188,189. Such expression 
prevalence suggests a role of RBMX that may be of general importance to a 
cell. Recently, it was shown that RBMX acts as a critical regulator for sister 
chromatid cohesion during cell division. Investigators knocked down RBMX 
using small interfering RNA (siRNA) and observed that cells that underwent 
RBMX depletion had an increased accumulation of mitotic cells arrested in 
prometaphase. Additionally, researchers noticed that the RBMX depleted 
cells frequently had misaligned chromosomes on the metaphase plate. 
Pursuing this phenotype, researchers discovered that RBMX directly 
associated with chromatin in an RNA independent manner and was needed in 
the maintenance of cohesin, a protein complex that regulates the separation 
of sister chromatids during cell division187. Furthermore, they noted that 
RBMX was detected in the nucleus during the G2 and S phases of cell 
division, but was absent in the nucleus and cytoplasm in M phase187. These 
results suggested a role for RBMX in genome maintenance since misaligned 
chromosomes on the metaphase plate indicate the presence of unattached 
kinetochores. Unattached kinetochores activate the spindle checkpoint signal 
that disallows the cell to progress into anaphase 190. This checkpoint acts to 
prevent aneuploidy in daughter cells and can be viewed as a means to 
ensure genomic stability.  
 The suggestion that RBMX contributed to genome maintenance was 
given further credence when investigators demonstrated that RBMX played a 
role in the homologous recombination pathway in response to DSBs in 
DNA189. In the process of conducting a screen to identify genes involved in 
the homologous recombination pathway, researchers found that one of their 
top hits was RBMX189. They observed that, in response to DNA damage, 
RBMX localized transiently to the site of damage in a PARP dependent 
manner189. Furthermore, when RBMX was knocked down by siRNA, 
investigators noted that the rate of homologous recombination dropped to just 
seven percent of the rate observed in control cells189. Additionally, 
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researchers observed that cells that underwent RBMX depletion were more 
sensitive to DNA damaging agents189. Interestingly, homologous 
recombination efficiency was not decreased when either RBMX was depleted 
or PARP was inhibited189. This result indicated that RBMX recruitment to the 
site of DNA damage was not essential, and suggested its role in mediating 
homologous recombination may be due to splicing effects on DNA repair 
proteins. In fact researchers noted that BRCA2 levels, which were decreased 
in RBMX depletion, could be rescued by reintroducing RBMX189. 
Role of RBMX in Disease: 
 RBMX function has been noted in diseases whose pathophysiology 
depends on DNA damage. Systemic lupus erythematous (SLE) is a 
devastating autoimmune disease whose pathophysiological mechanism 
remains undetermined191. A diagnosis of SLE can be made through the 
testing of whether certain autoantibodies are present in a patient’s blood. 
Among the most specific of all SLE autoantibodies is an antibody to double 
stranded DNA (anti-dsDNA)192,193. Though the mechanism behind the 
production of antibodies against DNA remains speculative, one of the 
consequences of this immune reaction is genomic instability and ultimately 
cell death through apoptosis of a target cell194. Interestingly, RBMX has been 
implicated in playing a role in SLE184. 
Another disease whose pathology appears to be influenced by RBMX 
expression is endometrial cancer195. Specifically, RBMX function in 
endometrial cancer affected the expression of the estrogen receptor alpha 
isoform, D7, by regulating the splicing of exon seven195. This lead to 
increased levels of the isoform ERaD7 which correlated with better 
survival195. A similar role for RBMX was noted in human oral squamous cell 
carcinomas, where increased expression of RBMX reversed neoplastic 
phenotypes in mice196. RBMX also appears to be a downstream effector of 
the classic tumor suppressor protein p53, where it assists p53 in ensuring the 
fidelity of DNA end joining activity in response to DNA damage197. These 
findings suggested that RBMX can act as a tumor suppressor gene, acting to 
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ensure genomic stability through both splicing and DNA DSB repair 
mechanisms189,196,197.  
 
Figure	33:	RBMX	activity	in	AML 
While the role of RBMX has been noted in a few solid cancers, it 
remains broadly undescribed in liquid malignancies. Recently, a missense 
mutation in RBMX was reported in a patient with acute myeloid leukemia 
(AML)198 (Figure 33a). To determine the role RBMX played in AML pathology, 
RBMX levels were assessed across AML cell lines with various genetic 
backgrounds199 (Figure 33b). These results demonstrated that RBMX levels 
were significantly increased in AML cell lines compared to control cell lines, 
thus inferring a role for RBMX in AML pathology. 
RBMX Knockdown Experiment in AML and Data Pre-Processing: 
 To dissect the role of RBMX in AML, short hairpin RNAs (shRNAs) 
were designed against RBMX and transfected into MOLM13 AML leukemia 
cells and control cells for twenty-four hours. Afterwards these cells underwent 
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Figure	33:	RBMX	ac:vity	in	AML	
a.)	a	gene	schema:c	showing	a	
missense	muta:on	in	a	pa:ent	
with	AML.	b.)	log2	rela:ve	
expression	levels	of	RBMX	across	
AML	cells	lines	with	diﬀerent	
gene:c	backgrounds	including	
chromosomal	inversions	and	
transloca:ons.	The	RBMX	rela:ve	
expression	levels	are	signiﬁcantly	
higher	in	the	AML	lines,	regardless	
of	the	speciﬁc	gene:c	background,	
compared	against	the	control	
samples.	(credit	to	Camila	Prieto,	
Kharas	Lab)	
a.)	
b.)	
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puromycin selection for another twenty-four hours. Finally, after forty-eight 
hours post-transduction the cells were harvested for RNA sequencing and 
shRNA knockdown efficiency analysis (Figure 34a-b).  
 
Figure	34:	RBMX	experimental	workflow 
 The RNA sequencing protocol returned FASTA files as output. These 
FASTA files were aligned to the human genome using the STAR aligner and 
were processed to BAM files using SAMtools146,200.  Read counts were 
computed from the BAM files using the function summarizeOverlaps from the 
GenomicAlignments package201. Differential Expression analysis was done 
using the DESeq software package202. Statistically significant differential 
expression of genes between the RBMX knockdown and the control 
conditions was assessed using a pairwise negative binomial test. The 
nominal p-values that resulted from this analysis were corrected using the 
Benjamini-Hochberg procedure203. Differential splicing analysis was done 
using the rMATS software package204. Splicing events were deemed 
significant if they possessed a q-value less .05. Sashimi plots were generated 
from the MISO software package205.    
 
 
 
 
MOLM13 cells 
Virus infection control or 
Rbmx-specific shRNAs for 24 
hours 
Puromycin 
selection for 24 
hours 
48 hours post transduction: 
Western for KD efficiency 
RNA-sequencing 
 
 
ACTIN 
RBMX 
Figure	34:	Experimental	workﬂow	for	the	RBMX	knockdown	
experiment.	a.)	MOLM13	AML	cell	lines	are	virally	infected	with	
RBMX	speciﬁc	shRNAs.	A<er	24	hours	cells	with	the	shRNA	are	
selected	through	a	puromycin	selec:on	and	sent	for	RNA-
Sequencing.	b.)	Western	plot	showing	eﬃcient	knockdown	of	RBMX	
by	the	shRNAs.	(credit	to	Camila	Prieto,	Kharas	Lab)	
a.)	
b.)	
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Differential Gene Expression Analysis: 
 Differential gene expression analysis was conducted between the 
RBMX knockdown samples and control samples. The result of this analysis 
demonstrated that fifty-eight genes were significant in their differential 
expression after false discovery rate (FDR) correction (Figure 35).  
 
Figure	35:	RBMX	MA	plot 
To determine how well this set of genes discriminated RBMX knockdown 
versus control conditions two unsupervised techniques were employed. The 
counts for each gene were first normalized across samples, with each gene 
taking the value of a Z-score. The resulting matrix of Z-scores was then 
hierarchically clustered and a heatmap was generated206. This heatmap 
demonstrated that the significant genes accurately partitioned RBMX 
knockdowns from controls (Figure 36).  
 A principle components analysis (PCA) was also conducted with the 
significant differentially expressed genes207 (Figure 37). This analysis, in 
addition to illustrating the distinct clustering of RBMX depleted samples 
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Figure	35:	MA	plot	of	the	universe	of	assessed	genes	that	underwent	diﬀeren:al	expression	
analysis.	Genes	that	have	a	log2	fold	change	diﬀerence	that	is	signiﬁcantly	diﬀerent	from	the	
null	hypothesis	and	maintains	signiﬁcance	a<er	false	discovery	rate	correc:on	are	labeled	in	
red.	Genes	that	do	not	meet	these	requirements	are	labeled	black.	
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compared to controls, also demonstrated the amount of variance that was 
accounted for by separating RBMX depletion from controls. The higher the 
variance accounted for by a principle component (PC), the more indicative of 
the importance of that PC in partitioning the space. In the PCA of RBMX 
depleted samples versus controls the first PC, which primarily separated the 
knockdown condition from the controls, accounted for approximately seventy-
eight percent of the variance in the data. 
 
Figure	36:	RBMX	heatmap 
This result illustrated that the genes that were deemed to be statistically 
significant in their differential expression constituted a set of data that could 
strongly differentiate RBMX depletion from controls. It is traditional in PCA 
analysis to display PCs with the largest eigenvalues, and therefore account 
for the largest variance in the data, in sequential order. In this tradition the 
first PC accounts for the most variance while the second PC accounts for the 
second most variance. In the PCA of the experimental samples, it is 
interesting to note that the second PC only accounts for six percent of the 
Figure	36:	Genes	that	were	deemed	to	be	signiﬁcant	in	their	diﬀeren:al	expression	between	the	
RBMX	knockdown	and	control	condi:ons	had	their	read	counts	transformed	into	Z-scores,	
computed	across	samples,	and	were	hierarchically	clustered.	A	heatmap	was	created	along	with	
the	clustering	to	illustrate	rela:ve	expression	levels	for	each	gene	across	samples.	The	clustering	
places	control	samples	in	their	own	super-cluster	and	the	RBMX	knockdown	samples	in	their	
own	super-cluster	demonstra:ng	that	the	diﬀeren:al	genes	can	eﬀec:vely	par::on	the	sample	
space.	
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variance. This second PC separates control and RBMX depletion samples 
from themselves. The value of the second PC also indicates that no other 
individual PC accounts for more than six percent of variance. Consequently, 
the PCA demonstrates that separation of RBMX depletion from controls is the 
most significant partitioning factor (PC1) followed by a less pronounced intra-
class separation (where classes are RBMX depletion and control samples). 
Overall, this means that while the amount of differentially expressed genes 
are small, their ability to distinguish RBMX depletion from control conditions is 
profound.  
 However, the initial characterization of RBMX was as a splicing protein 
and consequently, its ability to affect differential expression in genes may be 
modest compared to its ability to affect differential splicing. Consequently, to 
determine the effect of RBMX depletion in AML cells a splicing analysis was 
performed.  
 
Figure	37:	RBMX	Principle	Components	Analysis 
 
Figure	37:	Principle	components	analysis	(PCA)	of	experimental	samples.	Samples	were	
par::oned	based	on	genes	that	were	deemed	to	be	signiﬁcant	in	their	diﬀeren:al	expression	
between	the	RBMX	knockdown	and	control	condi:ons.	As	with	the	heatmap	the	genes	had	their	
counts	converted	to	Z-scores	for	each	gene	across	samples.	The	PCA	of	these	samples	nicely	
separates	control	samples	from	RBMX	knockdown	samples	with	the	ﬁrst	principle	component,	
which	separates	controls	from	RBMX	knockdowns,	accoun:ng	for	77.9%	of	the	variance	present	
in	the	data.	The	second	principle	component	separates	the	elements	of	each	class	from	one	
another.	In	this	case	class	is	deﬁned	as	the	control	and	RBMX	knockdown	condi:ons.	The	
second	principle	component	accounts	for	6.0%	of	the	variance	in	the	data,	which	notably	
smaller	than	the	variance	accounted	for	by	the	ﬁrst	principle	component.	This	indicates	that	the	
data	is	nicely	and	primarily	separated	by	class	using	the	signiﬁcant	diﬀeren:ally	expressed	
genes.	
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Splicing Analysis Methods: 
 The biological benefit of splicing is immense. Splicing allows for the 
tremendous diversity of gene products from a relatively small set of genes. 
Indeed for every additional element that can be spliced out of a transcript 
there is an exponential increase in the diversity of the transcript (Table 4).  
 
Table	4:	Splicing	elements	and	possible	isoforms 
Amount of Splice Elements (n) Possible Isoforms 
2 4 
5 32 
8 256 
16 65,536 
 𝑃𝑜𝑠𝑠𝑖𝑏𝑙𝑒 𝐼𝑠𝑜𝑓𝑜𝑟𝑚𝑠 = 2! 𝑤ℎ𝑒𝑟𝑒 𝑛 𝑖𝑠 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑠𝑝𝑙𝑖𝑐𝑒 𝑒𝑙𝑒𝑚𝑒𝑛𝑡𝑠 
 
However, the downside of this enormous diversity is that the analysis 
of splicing products can be quite complicated. Added to this is the fact that the 
depth of sequencing required to robustly detect splicing events is rather 
immense and hence the cost of sequencing these splicing experiments is 
substantial. The reads present in each sample for the RBMX knockdown 
experiment are shown below to illustrate the depths to which the samples 
were sequenced to robustly detect splicing events (Table 5).  
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Table	5:	RBMX	sample	depth 
Sample Name Input Reads Uniquely Mapped 
Reads 
Rbmx73-04272016 (KD) 95,767,004 85,689,975 
Rbmx74-05192016 (KD) 98,612,191 85,779,294 
Rbmx74-04272016 (KD) 90,056,141 79,443,050 
Rbmx73-05122016 (KD) 111,792,625 100,902,413 
Rbmx74-05052016 (KD) 114,673,099 104,229,784 
Rbmx73-05192016 (KD) 120,087,552 105,241,726 
Rbmx73-05052016 (KD) 134,173,603 121,035,950 
Rbmx74-05122016 (KD) 149,553,038 136,502,430 
Scr-05052016 (Control) 109,911,802 101,450,085 
Scr-05122016 (Control) 116,990,568 107,226,586 
Scr-04272016 (Control) 114,656,786 103,434,769 
Scr-05192016 (Control) 166,471,863 146,565,920 
 
A consequence of this large read depth and cost per experiment was 
that splicing experiments were initially done without replicates. The analysis 
of non-replicate data can be non-trivial and will tend towards employing 
Bayesian methods208. As the field progressed, the cost of sequencing 
decreased and replicate data for splicing experiments became more common. 
The analysis of replicate data could be done with the non-replicate methods 
by combining replicates into a merged sample; however this diminished the 
value of replicates. Instead replicate-based tools were developed for splicing 
analysis. These tools tended towards being non-Bayesian in nature. 
Consequently, numerous splicing tools proliferated, with a sampling of 
popular methods detailed below205,209–216 (Table 6).  
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Table	6:	Differential	splicing	methods 
Method Description 
DiffSplice Low precision, poorly detect skipped exons, 
assembles transcriptome based on graph 
theory methods 
Cufflinks Performs well at medium read depths, calls 
alternative 5’ and 3’ splice sites well, 
computationally slow 
DEX-Seq Utilizes a negative binomial generalized 
linear model, with proper annotation file calls 
splicing events accurately. Incomplete 
annotations cause significant problems for 
calling splicing events. 
MATS Annotates simple splicing events well. 
Performs poorly on complex splicing events. 
Performs the best of all methods on real 
data. 
SeqGSEA Generally precise method that integrates 
differential expression with differential 
splicing. Computation time increases 
dramatically with increased permutations. 
MISO Bayesian method based calling that allows 
for the easy generation and visualization of 
plots. Computationally, scales with size of 
input files. 
DSGseq Medium precision compared to other 
methods, does not report p-values, good at 
detecting retained intron events 
SplicingCompass Medium precision compared to other 
methods, good at detecting skipped exon 
events 
rDiff-param Low precision, computationally fast 
 
While these tools made admirable efforts in tackling the splicing 
problem the results across various splicing methods depended on the type of 
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analysis performed, with no single method performing the best across all 
conditions. A recent study investigating various tools ability to call splicing 
events did demonstrate, however, that the MATS splicing method bested 
competing methods in accurately calling simple alternative splicing events216. 
In this case simple splicing events are defined as alternative splicing events 
such as exon skipping, mutually exclusive exons, alternative 5’ splice site, 
alternative 3’ splice site, and retained introns. By contrast complex splicing 
events are defined as events where multiple simple splicing events are 
combined216. At the time of this study MATS was already augmented to 
handle replicate data. This adjustment to the MATS software was formalized 
with the introduction of rMATS, which was shown to outperform competing 
methods and demonstrated the added precision of using replicate data to call 
splicing events204 (Figure 38). Consequently, given the accuracy and 
robustness of the rMATS software, it was the method chosen for the RBMX 
depletion splicing analysis.  
 
Figure	38:	rMATS	pooling	vs.	replicate	ROCs 
Figure	38:	Receiver	operator	characteris:c	curves	that	demonstrate	the	beneﬁt	of	using	
replicate	data	over	pooling	replicates	into	a	single	merged	ﬁle.	In	this	simula:on	study	true	
posi:ve	and	nega:ves	are	known	and	the	variance	in	the	dataset	can	be	deﬁned	precisely.	The	
analysis	demonstrates	that	the	use	of	replicates	bested	the	pooled	data	method	across	
increasing	levels	of	variance.	The	advantage	of	using	replicate	data	is	pronounced	when	the	data	
contains	outliers.	Overall,	the	use	of	replicate	data	appears	to	oﬀer	a	signiﬁcant	advantage	in	
precise	calling	of	events.	(Shihao	et	al.	2014)	
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rMATS: 
Briefly, the rMATS software calls significant differentially spliced events 
through utilizing a generalized linear mixed model with a novel link function 
that serves to normalize read lengths204. Specifically, the rMATS model uses 
a hierarchical framework to model inclusion events (percent spliced in: PSI) 
that simultaneously accounts for estimation uncertainty in individual replicates 
and variability among replicates204. Furthermore, rMATS employs a flexible 
hypothesis-testing framework that allows a user to define a cutoff for the null 
hypothesis in assessing statistical significance204. Typically, the null 
hypothesis is set to zero (no difference between the conditions being tested), 
but rMATS allows the null hypothesis to be accepted if a difference is less 
than a value n, which is defined by the user. This allows rMATS to be more 
stringent in calling splicing events compared to other methods. Additionally, 
rMATS normalizes the lengths of individual splice variants, which allows it to 
call all major types of alternative splicing events and use reads mapped to 
both exons and splice junctions 204. Finally, rMATS allows for the usage of 
paired replicates, which makes it attractive for numerous types of timed 
intervention studies204. 
 
Characteristics of Differential Splicing Events in RBMX Depletion 
Experiment:  
 The overwhelming majority of significant differentially spliced events in 
the RBMX depletion study were skipped exons (64.6% of all called events). 
This observation conforms with previous studies that indicated that skipped 
exons are the most common splicing event observed in mammalian 
genomes178. After skipped exons the second most commonly observed event 
was mutually exclusive exons (30.0% of all called events), followed by 
retained introns (2.7% of all called events), alternative 3’ splice site (1.7% of 
all called events) and alternative 5’ splice sites (1% of all called events) 
(Figure 39). Consequently, the knockdown of RBMX in MOLM13 cells leads 
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to differential splicing events that manifest primarily as skipped exons and 
mutually exclusive exons.  
 
Figure	39:	Pie	plot	of	significant	differentially	spliced	events 
 In addition to classifying alternative splicing events, the directionality of 
each spliced event was determined. The directionality of a spliced event is 
simply the test condition that has the higher event inclusion level. This 
definition can be illustrated most clearly by way of an example. Imagine that a 
significant differentially spliced skipped exon event exists. This skipped exon 
is significant because the level of exon inclusion is sufficiently distinct 
between the RBMX depletion condition and control condition such that the 
probability of seeing this difference by chance falls below a threshold 
probability, even after correction for multiple hypothesis testing. If the exon 
inclusion is greater in the RBMX depletion condition then the directionality of 
the event is towards the RBMX condition. Conversely, if the exon inclusion is 
greater in the control condition, then the directionality of the event is towards 
the control condition. In the RBMX depletion experiment it was observed that 
Figure	39:	Pie	plot	of	all	signiﬁcant	diﬀeren:al	splicing	events	in	the	RBMX	knockdown	
experiment.	For	an	event	to	be	included	it	must	be	diﬀeren:ally	spliced	to	a	degree	that	it	
maintains	sta:s:cal	signiﬁcance	a<er	false	discovery	rate	correc:on.	
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there was greater exon inclusion in the direction of the RBMX condition for 
skipped exons, retained introns, alternative 3’ splice sites, and alternative 5’ 
splice sites. For mutually exclusive exons there was no notable directionality 
between the RBMX depletion and control conditions (Figure 40). Therefore 
following RBMX knockdown, there appeared to be preferential exon inclusion, 
where normally there would have been exon exclusion, for the majority of 
alternative splicing events.  Overall, RBMX knockdown appeared to increase 
exon retention in AML MOLM13 cell lines.  
 
Figure	40:	Bar	plot	of	significant	alternative	splicing	events 
Gene Ontology Analysis of Significant Alternatively Spliced Genes: 
 To determine what pathways were effected by RBMX knockdown a 
gene ontology analysis, using the GOrilla software, was done on all significant 
differentially spliced genes217 (Figure 41). This analysis revealed that five 
pathways were affected by the knockdown: negative regulation of intrinsic 
apoptotic signaling pathway in response to DNA damage, regulation of 
intrinsic apoptotic signaling pathway, regulation in response to DNA damage 
Figure	40:	A	bar	plot	of	signiﬁcant	alterna:ve	splicing	events.	Events	in	red	show	greater	
inclusion	in	the	RBMX	knockdown	condi:on,	while	blue	shows	great	inclusion	in	the	control	
condi:on	
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stimulus, negative regulation in response to DNA damage stimulus, and 
intrinsic apoptotic signaling pathway in response to DNA damage. Of these 
pathways two remained significant after multiple hypothesis testing (MHT) 
correction: regulation of intrinsic apoptotic signaling pathway and the negative 
regulation of intrinsic apoptotic signaling pathway in response to DNA 
damage. The results of the gene ontology analysis supported the notion that 
RBMX plays a role in genome maintenance, since the depletion of RBMX 
primarily affects DNA damage response or apoptosis pathways. To 
understand if these gene ontology terms were the consequence of the global 
effects of RBMX knockdown or primarily the consequence of one type of 
splicing event, each alternative splicing event was individually investigated.  
 
Figure	41:	Gene	ontology	pathways	using	all	significant	alternative	splicing	events 
Skipped Exon Events: 
 The significant differentially spliced skipped exon events that followed 
RBMX knockdown included 414 events with higher inclusion levels in RBMX 
condition compared to 217 events with higher inclusion levels in the control 
regula:on	of	intrinsic	apopto:c	signaling	
pathway	in	response	to	DNA	damage	
nega:ve	regula:on	of	response	to	DNA	
damage	s:mulus	
regula:on	of	response	to	DNA	damage	
s:mulus	
regula:on	of	intrinsic	apopto:c	signaling	
pathway	
nega:ve	regula:on	of	intrinsic	apopto:c	
signaling	pathway	in	response	to	DNA	damage	
Figure	41:	Gene	ontology	plot	of	terms	that	resulted	from	a	GOrilla	analysis	of	all	signiﬁcant	
diﬀeren:ally	spliced	genes.	Only	GO:2001021	and	GO:1902229	remained	signiﬁcant	a<er	MHT	
correc:on	
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condition (Figure 42).  The skipped exon events between the RBMX and 
control conditions targeted rather independent sets of genes, with only five 
common genes between them including: SCRIB, ALG11, TBCE, SLC25A26, 
and CD44 (Figure 43). Of these common genes SCRIB and CD44 have been 
implicated in having roles in cancer218–220. Furthermore, when the genes that 
constituted these sets were further investigated it was realized that some 
genes were associated with multiple significant differential splicing events. 
Specifically, of the 414 events with higher inclusion in the RBMX condition, 
only 287 genes were affected. Likewise, of the 217 events with higher 
inclusion in the control condition only 175 genes were affected. Interestingly, 
there was little overlap between significant differentially spliced and 
expressed genes, with the intersection consisting of ALDH18A1, PABPC4, 
KLHL23, and MYL9.    
 
Figure	42:	Splay	plot	of	skipped	exon	events 
A gene ontology analysis was conducted on all genes with significant 
skipped exon events revealing four terms that remained significant after MHT 
Figure	42:	Splay	plot	of	signiﬁcant	diﬀeren:ally	splice	skipped	exon	events.	Red	indicates	
signiﬁcant	events	with	higher	inclusion	in	the	RBMX	knockdown	condi:on,	while	blue	indicates	
signiﬁcant	events	with	higher	inclusion	in	the	control	condi:on.	
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correction: regulation of intrinsic apoptotic signaling pathway, regulation of 
response to DNA damage stimulus, negative regulation of intrinsic apoptotic 
signaling pathway response to DNA damage, and negative regulation of 
response to DNA damage stimulus (Figure 44a). These terms closely 
mirrored the terms that were revealed as a result of gene ontology analysis 
done on all significant differentially spliced events. However, when the 
analysis was restricted to just skipped exons the p-values associated with the 
terms increased notably and several terms gained significance after MHT 
correction that were not significant in the global gene ontology study. These 
results prompted a second gene ontology study where the genes that had 
higher inclusion in the RBMX knockdown condition were studied alone. The 
results of this study gave identical gene ontology terms as those seen in the 
gene ontology of all skipped exons (Figure 44b). When the same analysis 
was done for those genes with higher inclusion in the control condition only 
two terms were returned: cation transport and ion transport. Consequently, 
the gene ontology terms for skipped exons come from the set of genes that 
have higher exon retention levels in the RBMX knockdown condition.  
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Figure	43:	Venn	diagram	of	significant	skipped	exons	between	RBMX	KD	and	control	conditions 
DiﬀerenFally	Spliced	
Higher	Inclusion	in	RBMX	Knockdown	 Higher	Inclusion	in	Control	
Figure	43:	Venn	diagram	of	genes	with	signiﬁcant	diﬀeren:ally	spliced	skipped	exons	between	
the	RBMX	knockdown	condi:on	and	the	control	condi:on.	The	two	sets	of	genes	are	largely	
independent	of	one	another	with	an	intersec:on	of	only	ﬁve	genes:	SCRIB,	ALG11,	TBCE,	
SLC25A26,	and	CD44.	There	are	notably	more	genes	with	skipped	exons	that	retain	an	exon	in	
response	to	RBMX	knockdown	than	lose	an	exon.	
83	
Many of the genes with higher exon retention in the RBMX knockdown 
had multiple significant skipped exon events associated with them. The gene 
with the most skipped exon events was the CD44 gene (Figure 45). This gene 
is a cell surface molecule that is involved in a myriad of functions including 
cell proliferation, cell differentiation, cell migration, angiogenesis, and cell 
survival signaling221. Furthermore, it also believed that alternative splicing of 
this gene generates tumor specific isoforms and high levels of it are needed 
to generate leukemic cells222. Additionally, splice variants of CD44 have been 
implicated in head and neck squamous carcinomas (i.e.: oral squamous cell 
carcinoma) and endometriosis, which can predispose women to uterine 
cancer223–225. Other genes that had multiple significant events associated with 
them were the DAXX and POLL genes. The DAXX gene, also known as the 
death-associated protein 6, is a protein involved in the apoptosis pathway226. 
Similarly, the POLL gene has a function in DNA double strand break 
repair227,228.  
 
Figure	44:	Gene	ontology	of	skipped	exon	events 
nega:ve	regula:on	of	response	to	DNA	
damage	s:mulus	
nega:ve	regula:on	of	response	to	DNA	
damage	s:mulus	
regula:on	of	response	to	DNA	damage	
s:mulus	
regula:on	of	response	to	DNA	damage	
s:mulus	
regula:on	of	intrinsic	apopto:c	signaling	pathway	
regula:on	of	intrinsic	apopto:c	signaling	pathway	
nega:ve	regula:on	of	intrinsic	apopto:c	
signaling	pathway	in	response	to	DNA	damage	
nega:ve	regula:on	of	intrinsic	apopto:c	
signaling	pathway	in	response	to	DNA	damage	
a.)	
b.)	
Figure	44:	Gene	ontology	plots	for	a.)	all	genes	with	signiﬁcant	skipped	exons	and	b.)	all	genes	
with	signiﬁcant	skipped	exons	with	higher	inclusion	in	the	RBMX	knockdown	condi:on	
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To better determine how these splicing events were affecting target 
genes a domain analysis was conducted using interval trees constructed with 
UniProt gene domain annotations159. Using these interval trees, domain 
annotations overlapping the coordinates of the splicing event could be 
determined. Domains were determined to be associated with skipped exons 
with higher exon retention in the RBMX knockdown, if they significantly 
associated with these skipped exons over all other non-significant splicing 
events called by rMATS using the Fisher Exact Test (Figure 46). The most 
significantly associated domains in this analysis both belonged exclusively to 
the CD44 gene: CD44-antigen and stem. Interestingly, the BRCT domain 
associated exclusively with the POLL gene. The BRCT domain is the C-
terminal domain of a breast cancer susceptibility protein and is found in those 
proteins that play a role in cell cycle checkpoint responses to DNA 
damage229,230. Consequently, in response to RBMX depletion, the identity of 
the genes involved in skipped exon events, and the domains that are spliced, 
both reinforce the idea that RBMX contributes to genome maintenance.  
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Figure	45:	Sashimi	plot	of	CD44 
Figure	45:	Sashimi	plot	showing	an	example	of	diﬀeren:al	exon	reten:on	in	the	CD44	gene.	
Speciﬁcally,	the	reten:on	is	seen	as	the	greater	amount	of	reads	spanning	the	junc:ons	of	
exon	6	and	exon	7	in	the	RBMX	knockdown	condi:on	compared	to	control	
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Finally, RBMX depletion had certain global effects on the potential 
types of gene isoforms expressed. Using interval trees constructed of gene 
transcript annotations, the lengths and number of exons were assessed for 
significant differently spliced skipped exon events. Interestingly, RBMX 
depletion significantly shifted splicing events towards the exons at the end of 
transcripts (Figure 47b). Considering just those genes with significant skipped 
exons, RBMX knockdown significantly targeted those genes with fewer exons 
(Figure 47a).  
 
Figure	46:	Bar	plot	of	domains	significantly	associated	with	skipped	exon	events 
Overall, RBMX knockdown generated a large amount of skipped exon 
events in genes that influence the apoptotic and DNA damage response 
pathways. The pathways implicated are virtually identical to the pathways 
tagged with the gene ontology analysis of all significant differentially spliced 
genes. Furthermore, it appears that only those skipped exon events with 
higher exon retention in the RBMX knockdown condition contribute to the 
generation of these gene ontology terms. Several of these genes have 
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Figure	46:	Bar	plot	showing	domain	annota:ons	that	are	signiﬁcantly	associated	with	genes	that	
have	signiﬁcant	skipped	exon	events	in	which	there	is	higher	exon	reten:on	in	the	RBMX	
knockdown	condi:on.	
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multiple significant skipped exon events and the domains these events 
overlap, reinforce the idea that RBMX splicing affects genes that are essential 
to genome maintenance.  
 
Figure	47:	CDFs	of	skipped	exon	events 
Mutually Exclusive Exons: 
 The significant differentially spliced mutually exclusive exon events that 
followed RBMX knockdown included 136 events with higher inclusion levels in 
RBMX condition compared to 157 events with higher inclusion levels in the 
control condition (Figure 48).  The mutually exclusive exon events between 
the RBMX and control conditions targeted largely independent sets of genes, 
with only ten common genes between them including: FNTA, AK2, VAPA, 
CCDC14, N4BP2L2, CNPY3, TTC13, POLL, PHF3, and KIAA1191. Of these 
genes, POLL is notable for it’s implication as a DNA damage repair protein. 
As with skipped exon events, when the genes that constituted these sets 
were further investigated it was realized that some genes had multiple 
significant differential splicing events. Specifically, of the 136 events with 
Figure	47:	Descrip:ve	global	eﬀects	
of	RBMX	knockdown.	a.)	RBMX	
knockdown	preferen:ally	aﬀected	
transcripts	with	fewer	exons.	In	this	
study	only	those	genes,	and	their	
associated	transcripts,	that	had	
signiﬁcant	skipped	exon	events	
were	considered	in	the	RBMX	KD	
condi:on.	b.)	RBMX	knockdown	
demonstrated	a	signiﬁcant	
preference	for	splicing	events	that	
occurred	towards	the	end	of	a	
transcript.	In	this	cumula:ve	
distribu:on	plot	the	rela:ve	
posi:on	of	the	exon	is	deﬁned	as	
1.0	if	the	exon	in	ques:on	is	the	last	
exon	in	the	transcript.	Conversely,	
an	exon	with	a	rela:ve	posi:on	of	
0.0	is	the	ﬁrst	exon	in	the	transcript.	
Any	values	between	0.0	and	1.0	are	
middle	exons.	The	plot	shows	those	
genes	with	signiﬁcant	skipped	exon	
events	tended	to	have	skipped	exon	
events	in	their	distal	exons.				
a.)	
b.)	
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higher inclusion in the RBMX condition, only 104 genes were affected. 
Likewise, of the 157 events with higher inclusion in the control condition only 
123 genes were affected (Figure 49a). Interestingly, there was little overlap 
between significant differentially spliced and expressed genes, with the 
intersection consisting of PABPC4. However, a gene ontology analysis of the 
genes with significant mutually exclusive exons did not yield any specific gene 
ontology terms and individual investigation of several genes showed functions 
that were largely related to basic biochemical pathways.  
 
Figure	48:	Splay	plot	of	mutually	exclusive	exon	events 
 Unlike with skipped exons, RBMX depletion did not significantly shift 
mutually exclusive splicing events towards the exons at the end of a 
transcript. However, genes with significant mutually exclusive exon events 
had fewer exons than would be expected (Figure 49b). Overall, mutually 
exclusive exons signify the second most numerous alternative splicing event 
when RBMX is depleted from MOLM13 cells. However, the genes 
experiencing significant mutually exclusive exon events do not replicate, or 
Figure	48:	Splay	plot	of	signiﬁcant	diﬀeren:ally	splice	mutually	exclusive	exon	events.	Red	
indicates	signiﬁcant	events	with	higher	inclusion	in	the	RBMX	knockdown	condi:on,	while	blue	
indicates	signiﬁcant	events	with	higher	inclusion	in	the	control	condi:on.	
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contribute to, the terms seen in the global gene ontology study. Similar to 
what was seen with skipped exon events, mutually exclusive exons that occur 
in the context of RBMX depletion, tend to be associated with transcripts that 
possess fewer exons.  
 
Figure	49:	Mutually	exclusive	exon	events	CDF	and	bar	plot 
Retained Introns: 
  The significant differentially spliced retained events that followed 
RBMX knockdown included twenty-three events with higher inclusion levels in 
RBMX condition compared to three events with higher inclusion levels in the 
control condition (Figure 50). The retained intron events between the RBMX 
and control conditions targeted independent sets of genes, with no 
intersecting genes between them. When the genes that constituted these sets 
were further investigated it was realized that only the genes with higher 
inclusion levels in the RBMX knockdown condition had any genes with 
multiple significant retained intron events. Specifically, of the twenty-three 
events with higher inclusion in the RBMX condition, only nineteen genes were 
Figure	49:	Mutually	exclusive	exon	
splicing	events	a.)	a	bar	plot	
demonstra:ng	the	amount	of	
signiﬁcant	mutually	exclusive	exon	
events	and	the	genes	they	occur	in	
for	both	the	RBMX	and	control	
condi:ons.	As	illustrated,	mutually	
exclusive	exon	events	outnumber	
genes	enumerated	indica:ng	that	
some	genes	possess	mul:ple	
signiﬁcant	mutually	exclusive	exon	
events.	b.)	RBMX	knockdown	
preferen:ally	aﬀected	transcripts	
with	fewer	exons.	In	this	study	
only	those	genes,	and	their	
associated	transcripts,	that	had	
signiﬁcant	mutually	exclusive	exon	
events	were	considered	in	the	
RBMX	KD	condi:on.		
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affected (Figure 51a). There was no overlap between significant differentially 
spliced and expressed genes. Additionally, a gene ontology analysis on 
significant differentially spliced retained introns did not yield any gene 
ontology terms, likely due to the small sample size of genes in this splicing 
category.  
 
Figure	50:	Splay	plot	of	retained	introns 
Figure	50:	Splay	plot	of	signiﬁcant	diﬀeren:ally	splice	retained	intron	events.	Red	indicates	
signiﬁcant	events	with	higher	inclusion	in	the	RBMX	knockdown	condi:on,	while	blue	indicates	
signiﬁcant	events	with	higher	inclusion	in	the	control	condi:on.	
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 The observation seen with skipped exons that during RBMX depletion 
splicing events tend to target exons towards the end of the transcript was not 
replicated with retained exons. Additionally, while the there was a significant 
difference in the amount of exons present in a transcript of a genes with 
significant retained intron events versus control, a clear pattern was not 
discernible indicating that the populations are distinct but a trend is not 
obvious (Figure 51b). Once again this is likely due to the small sample size of 
genes present in the retained intron category.  
 
Figure	51:	Retained	intron	CDF	and	bar	plot 
Alternative 3’ Splice Site: 
 The significant differentially spliced alternative 3’ splice site that 
followed RBMX knockdown included twelve events with higher inclusion 
levels in RBMX condition compared to five events with higher inclusion levels 
in the control condition (Figure 52). The alternative 3’ splice site events 
between the RBMX and control conditions targeted independent sets of 
genes, with no intersecting genes between them. When the genes that 
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Figure	51:	Retained	intron	splicing	
events	a.)	a	bar	plot	
demonstra:ng	the	amount	of	
signiﬁcant	retained	intron	events	
and	the	genes	they	occur	in	for	
both	the	RBMX	and	control	
condi:ons.	As	illustrated,	retained	
intron	events	outnumber	genes	for	
the	RBMX	knockdown	condi:on	
only.	This	indicates	that	some	
RBMX	knockdown	genes	possess	
mul:ple	signiﬁcant	retained	intron	
events.	b.)	RBMX	knockdown	
appears	to	have	an	associa:on	
with	the	number	of	exons	in	a	
transcript.	However,	the	paDern	is	
unclear	for	the	retained	intron	
case.	In	this	study	only	those	
genes,	and	their	associated	
transcripts,	that	had	signiﬁcant	
retained	intron	events	were	
considered	in	the	RBMX	KD	
condi:on.		
a.)	
b.)	
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constituted these sets were further investigated it was realized that only the 
genes with higher inclusion levels in the RBMX knockdown condition had any 
genes with multiple significant alternative 3’ splice sites events. Specifically, 
of the twelve events with higher inclusion in the RBMX condition, only nine 
genes were affected (Figure 53a). There was no overlap between significant 
differentially spliced and expressed genes. Additionally, a gene ontology 
analysis on genes with significant differentially spliced alternative 3’ splice site 
events did not yield any gene ontology terms, likely due to the small sample 
size of genes in this splicing category.  
 
Figure	52:	Splay	plot	of	alternative	3'	splice	site 
 The observation seen with skipped exons that during RBMX depletion 
splicing events tend to target exons towards the end of the transcript was 
reversed with alternative 3’ splice sites (Figure 53b). Genes with significant 
alternative 3’ splice sites had a significant shift towards having splicing occur 
at the beginning of their transcript. Furthermore, as with skipped exons and 
mutually exclusive exons, alternative 3’ splice sites that occur in the context of 
Figure	52:	Splay	plot	of	signiﬁcant	diﬀeren:ally	splice	alterna:ve	3’	splice	site	events.	Red	
indicates	signiﬁcant	events	with	higher	inclusion	in	the	RBMX	knockdown	condi:on,	while	blue	
indicates	signiﬁcant	events	with	higher	inclusion	in	the	control	condi:on.	
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RBMX depletion, tend to be associated with transcripts that possess fewer 
exons (Figure 53c).  
 
Figure	53:	Alternative	3'	splice	site	CDFs	and	bar	plot 
Alternative 5’ Splice Sites: 
The significant differentially spliced alternative 5’ splice site events that 
followed RBMX knockdown included seven events with higher inclusion levels 
in RBMX condition compared to three events with higher inclusion levels in 
the control condition (Figure 54). The alternative 5’ splice site events between 
the RBMX and control conditions targeted independent sets of genes, with no 
intersecting genes between them. When the genes that constituted these sets 
were further investigated it was realized that some genes were associated 
with multiple significant differential splicing events. Specifically, of the seven 
events with higher inclusion in the RBMX condition, only four genes were 
affected. Likewise, of the three events with higher inclusion in the control 
condition only two genes were affected. There was no overlap between 
significant differentially spliced and expressed genes. Additionally, a gene 
Figure	53:	Alterna:ve	3’	splice	site	
(A3SS)	a.)	a	bar	plot	demonstra:ng	the	
amount	of	signiﬁcant	A3SS	events	and	
the	genes	they	occur	in	for	both	the	
RBMX	and	control	condi:ons.	b.)	RBMX	
knockdown	demonstrated	a	signiﬁcant	
preference	for	splicing	events	that	
occurred	towards	the	start	of	a	
transcript.	c.)	RBMX	knockdown	
preferen:ally	aﬀected	transcripts	with	
fewer	exons.		
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ontology analysis on genes with significant differentially spliced alternative 5’ 
splice site events did not yield any gene ontology terms, likely due to the 
small sample size of genes in this splicing category.  
 The repeated observation that RBMX depletion tends to shift 
splicing events towards the end of the transcript was not replicated with 
alternative 5’ splice sites nor was the observation that RBMX depletion 
appears to cause splicing events on genes with fewer exons. However, this 
result may be due to the small sample size of the splicing events in this 
category. 
 
Figure	54:	Splay	plot	of	alternative	5'	splice	site 
Alternative Splicing Events in the Context of RBMX Depletion: 
 Gene ontology analysis of all significant differentially spliced genes 
indicated that RBMX depletion specifically affects cellular pathways 
responsible for DNA damage repair and apoptosis regulation. Investigating 
the roles each splicing event contributed to the generation of this annotation, 
it was noted that only the skipped exon events could replicate the gene 
Figure	54:	Splay	plot	of	signiﬁcant	diﬀeren:ally	splice	alterna:ve	5’	splice	site	events.	Red	
indicates	signiﬁcant	events	with	higher	inclusion	in	the	RBMX	knockdown	condi:on,	while	blue	
indicates	signiﬁcant	events	with	higher	inclusion	in	the	control	condi:on.	
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ontology result. Specifically, within skipped exons it was only those events 
where an exon was retained in response to RBMX depletion that the gene 
ontology terms could be generated. Further delving into those genes that 
retained exons in response to RBMX knockdown revealed that numerous 
genes had multiple significant skipped exons events. Among this subset of 
genes several such as DAXX and POLL supported the notion that RBMX 
plays a role in regulating the proteins involved in maintaining genomic 
stability. Interestingly, the gene with the most significant skipped exon events 
was CD44, which is a gene implicated in various cancers. Perhaps most 
interestingly CD44 is reported to be essential for creating leukemic cells in 
AML222. Additionally, the domains affected by significant differential splicing in 
response to RBMX depletion suggest targets that may contribute to cancer 
evolution. The most suggestive domain in this category is the BRCT domain 
that is the repeated target of skipped exon events in the POLL gene. Overall it 
appears that RBMX plays a role in genome maintenance through regulating 
the splicing of genomic maintenance proteins primarily through the splicing 
mechanism of skipped exons. 
Reverse Phase Protein Array Data: 
 Reverse phase protein array (RPPA) is a tool that allows investigators 
to assess the expression levels of a set of a priori selected proteins across a 
large number of samples simultaneously (appendix). The details of the 
experiment are described in the appendix, but it is sufficient to understand 
that this procedure aims to quantify protein expression in a quantitative 
manner so differential expression of proteins across samples can be 
assessed. RPPA data was collected for six RBMX depletion experiments and 
three control experiments and protein expression levels were quantified. 
Significant differential expression for a protein between the two conditions 
was determined using the Wilcoxon ranked sum test on the normLog2 values 
of the data as reported by the facility that conducted the RPPA experiment. A 
total of 304 proteins were analyzed in this experiment, of which twenty-six 
had nominally significant p-values (Table 7).  
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Table	7:	RPPA	nominally	significant	genes 
Nominally Significant Protein (gene 
name) 
53BP1 
Akt_pS473 
ATR_pS428 
b-Catenin_pT41_S45 
Caveolin-1 
cdc25C 
Chk1 
Chk2 
Cyclin-B1 
Cyclin-D3 
Glutaminase 
HES1 
INPP4b 
JNK2 
MCT4 
PAR 
PARP 
Paxillin 
PLK1 
Rb 
Rictor 
S6_pS240_S244 
XPA 
 
Unfortunately, after MHT correction all p-values became non-
significant. Furthermore, there was no intersection between the RPPA genes 
and the genes that were significantly differentially spliced.    
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H3k9me3 Observation: 
 A few studies have suggested an association between RBMX and 
H3k9me3 methylation187,231. H3k9me3 is a histone mark that is associated 
with repressed gene expression given its high correlation with constitutive 
heterochromatin232. To investigate this potential association, H3k9me3 Chip-
Seq data from k562 chronic myelogenous leukemia (CML) cell lines was 
downloaded from ENCODE150. Unfortunately, ENCODE did not have 
H3k9me3 Chip-Seq data for the MOLM13 cell line, but the two cells lines are 
sufficiently similar to allow for a preliminary, albeit not conclusive, analysis 
about the association of H3k9me3 marks in the context of RBMX knockdown. 
The 16,446 H3k9me3 peaks in the k562 file were converted into an interval 
tree and used to annotate whether significant differential splicing events 
overlapped H3k9me3 peaks. 
 Across all significant differentially spliced events only three events 
were noted to have any overlap with H3k9me3 peaks. Furthermore, these 
splicing events were all skipped exon where there was greater exon retention 
in the face of RBMX knockdown. The skipped exon events occurred in the 
genes PRKACA, ZNF792, and MBD1. ZNF792 is a zinc finger protein 
involved broadly with transcription and PRKACA is a catalytic subunit of 
protein kinase A233–235. Interestingly MBD1, also known as methyl-CpG-
binding domain protein 1, is involved in binding methylated sequences to 
influence transcription236. Specifically, the protein is known to affect chromatin 
modification through its interaction with H3K9 methyltransferase, which is the 
enzyme responsible for laying down H3k9me3 methylation marks237. 
Additionally, the location of the skipped exon corresponds to the last exon in 
every MBD1 isoform (Table 8).  
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Table	8:	MBD1	last	exon	isoforms 
MBD1 Isoform Exon Splicing 
MBD1_ENST00000382948.9_1_exon_16_of_16 
MBD1_ENST00000353909.7_1_exon_15_of_15 
MBD1_ENST00000591416.5_1_exon_16_of_16 
MBD1_ENST00000269468.9_1_exon_16_of_16 
MBD1_ENST00000347968.7_1_exon_15_of_15 
MBD1_ENST00000585595.5_1_exon_17_of_17 
MBD1_ENST00000589541.5_1_exon_7_of_7 
MBD1_ENST00000398495.6_1_exon_15_of_15 
MBD1_ENST00000457839.6_1_exon_17_of_17 
MBD1_ENST00000398493.5_1_exon_15_of_15 
MBD1_ENST00000398488.5_1_exon_13_of_13 
MBD1_ENST00000591535.5_1_exon_13_of_13 
 
 H3k9me3 methylation peaks were also overlapped with differentially 
expressed genes and a total of seventeen out of 141 genes were found to 
overlap at least one of these peaks. Overall, it was interesting to note the 
intersection of H3k9me3 methylation marks with both differentially spliced and 
expressed genes. Of particular interest is that RBMX depletion appears to 
affect the splicing of the MBD1 gene, which may play a role in regulating the 
establishment of H3k9me3 marks (Table 9).  
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Table	9:	H3k9me3	marks	overlapping	differentially	expressed	genes 
Differentially Expressed Genes Overlapping H3K9me3 Methylation 
Peaks 
JPH1 
AFAP1-AS1 
FAM46A 
SLC38A1 
SLC39A10 
CUX2 
GGTA1P 
PRKAR1B 
GALNT12 
SLAMF1 
NCS1 
SLC16A7 
NLRC3 
SIPA1L2 
IL18R1 
UBE3C 
CKAP4 
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Chapter 4: Musashi2 
MUSASHI2: 
 MUSASHI2 is an RNA-binding protein that is expressed broadly across 
human tissues238,183. It was noted to have a role in regulating tissue stem cell 
processes as well as being able to act as a translational inhibitor239. 
MUSASHI2 appears to play a general role in tissue stem cell biology. It has 
been shown to affect the development of embryonic stem cells and influences 
control over the proliferation of neuronal progenitors in the developing central 
nervous system240,241. Crucially, MUSASHI2 has also been implicated in 
regulating hematopoietic stems cells183.  
 The origin cells of the hematopoietic system consist of the long-term 
hematopoietic stem cells, the short-term hematopoietic stem cells and the 
multipotent progenitor cells242,243. These cells give rise to the myeloid and 
lymphoid linages and their controlled asymmetric differentiation is essential 
for establishing normal populations of myeloid and lymphoid cells242,243. 
Specifically, it is the stem cell self-renewal and subsequent differentiation 
processes that must be tightly regulated in ensure normal hematopoietic 
homoeostasis. MUSASHI2 appears to regulate the proliferation rate of 
hematopoietic stem cells239. In fact it was shown that if musashi2 levels are 
decreased a reduction in hematopoietic stem cell primitive progenitors cells 
follows238.  
 MUSASHI2’s role as a regulator of hematopoietic stem cell 
proliferation suggests that disruption of its activity could affect the normal 
biology of the hematopoietic cells. Indeed it has been noted that MUSASHI2 
plays a critical role in the pathologies of both acute myeloid leukemia and 
chronic myeloid leukemia183,244–246. In both diseases, MUSASHI2 
dysregulates stem cell proliferation and appears to inhibit the differentiation of 
myeloid cells thus contributing to the pathology of leukemia.  
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Myelodysplastic Syndromes: 
  Myelodysplastic syndromes (MDS) are a constellation of symptoms 
that are indicative of bone marrow failure247,248. The syndrome is generally 
accepted to be an acquired disorder. The pathology is thought to be linked to 
environmental or chemical exposures to compounds such as xylene, 
petroleum related hydrocarbons, agent orange, mercury, lead, and even 
tobacco smoke249,250. Furthermore, patients with prior exposure to 
chemotherapy, specifically alkylating chemotherapeutics, or heavy doses of 
ionizing radiation have a higher likelihood of developing MDS251. Despite 
numerous associations with various environmental toxins, the direct 
mechanism underlying MDS pathogenesis remains undetermined.  
 MDS is insidious in its onset, often developing initially without any 
symptoms. As the disease progresses a patient can acquire a pancytopenia 
resulting from bone marrow failure252,253. This pancytopenia gives a patient 
tremendous fatigue, dyspnea, acquired hemophilia, and frequent 
infection252,254. Disease staging and progression is traditionally done using the 
French-America-British (FAB) classification that classifies MDS by 
hematological characteristics255 (Table 10).  
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Table	10:	French-American-British	MDS	classifications 
FAB Classification Abbreviation Description 
Refractory anemia RA <5% myeloblasts in 
bone marrow, 
abnormalities seen in 
red cell precursors 
Refractory anemia with 
ring sideroblasts 
RARS <5% myeloblasts in 
bone marrow, >15% 
ring sideroblasts in bone 
marrow 
Refractory anemia with 
excess blasts 
RAEB 5-19% myeloblasts in 
bone marrow 
Chronic myelomonocytic 
leukemia 
CMML <20% myeloblasts in 
bone marrow, > 1x109/L 
monocytes in peripheral 
circulation 
Acute myelogenous 
leukemia 
AML >20% myeloblasts in 
bone marrow 
  
A final stage of this classification is chronic myelomonocytic leukemia 
(CMML). Furthermore, some cases of MDS progress to particularly 
aggressive forms of acute myelogenous leukemia (AML) that tends to be 
resistant to chemotherapy256,257.  
 The progression of MDS to chronic and acute forms of leukemia 
suggests that MDS represents a pre or pseudo leukemic state. Though the 
precise mechanism responsible for MDS pathology is unknown, it is thought 
to be tied to underlying genomic instability in hematopoietic stem cells258. 
Consequently, it’s possible the molecular actors implicated in leukemia 
progression are shared with MDS. Specifically, the role of MUSASHI2 in MDS 
has been a topic of general investigation259. In the study below, it was shown 
that MUSASHI2 was required for maintaining activated MDS stem cells. This 
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finding sheds light on the molecular basis of MDS pathology and potentially 
even suggests musashi2 as a therapeutic target.  
Contribution: 
 It was my privilege to contribute to the study of musashi2 in MDS 
pathology in the following ways260. Briefly, musashi2 was overexpressed in 
NHD13 background mice and hematopoietic stem/progenitor cell were 
extracted for transcriptome profiling analysis via RNA-sequencing. Using 
RNA-seq data from the laboratory of Dr. Michael Kharas along with publically 
available microarray data from MDS patients, I demonstrated that the most 
aggressive (non-leukemic) FAB MDS classification, RAEB, had significantly 
higher levels of MUSASHI2 expression than the other less aggressive FAB 
classifications261.  
Furthermore, I converted MUSASHI2 levels to a Z-score value and 
stratified the survival data in the following way: patients whose MUSASHI2 Z-
score was less than negative one were deemed to be MUSASHI2 low, 
patients with MUSASHI2 Z-scores between and including the range of 
negative one to one where deemed to be MUSASHI2 normal, and finally 
those patients with MUSASHI2 levels above one were deemed to be 
MUSASHI2 high. When the patient survival data was stratified according to 
MUSASHI2 levels, I demonstrated that there was a significant survival 
difference between those patients that had high MUSASHI2 levels and low 
MUSASHI2 levels. Additionally, while the difference in survival between 
MUSASHI2 high and MUSASHI2 normal was not significant, a survival trend 
could clearly be seen in the data. This demonstrated that just by looking at 
MUSASHI2 levels one could hypothesize patient long-term survival.  
Additionally, I performed the differential gene expression analysis of 
musashi2 overexpression in the NHD13 background. I determined the 
significant genes, accounting for the NHD13 background, by using a 
generalized linear model. Furthermore, I showed that the control condition, 
NHD13 condition, and NHD13 with musashi2 over-expression condition all 
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clustered distinctly from another. These significant genes represented a 
genetic signature of musashi2 overexpression in the NHD13 background.  
The initial gene expression analysis was conducted in a mouse 
background, and it was desired to see if the genes that were significant in 
mouse could also be used to cluster patients into distinct cohorts. Using 
human microarray data I selected human probes that corresponded to the 
human orthologues of the mouse genes deemed significant due to musashi2 
overexpression. Using these human genes I clustered the patient samples 
and showed that four primary cohorts resulted. One particular cluster was 
significantly enriched for patients with MUSASHI2 high levels. I further 
showed that this cluster had significantly worst survival compared to all other 
clusters.  
Overall, my contribution to the study was in computationally correlating 
musashi2 levels with patient survival and showing that a musashi2 specific 
genetic signature present in mouse translated to informative clustering of 
human patients into cohorts. Specifically, the cohort with the highest mean 
MUSASHI2 level had worst survival compared to all other cohorts.  
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elevated MSI2 expression correlates with poor survival in MDS. Conditional deletion of Msi2
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expression after disease initiation. Furthermore, MSI2 expression expands and maintains a
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identify a role for MSI2 in MDS representing a therapeutic target in this disease.
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The majority of haematological disorders involving themyeloid lineage are thought to be of stem cell origin,including myeloproliferative diseases, myelodysplastic
syndromes, acute myeloid leukaemia and acquired or heritable
bone marrow failure syndromes1–3. In each instance,
dysregulation of normal stem cell function is thought to
contribute to the disease phenotype. Moreover, stem cell
characteristics are modulated by a variety of developmental
pathways and regulators. Recent studies of MSI2 in normal and
malignant hematopoietic stem cell (HSC) biology suggested that
MSI2 might play a role in myelodysplastic syndromes (MDS)4–11.
It was previously reported that MSI2 expression in MDS was
reduced in patients with low-risk and high-risk MDS compared
with normal CD34 cells7. However, in this study there was a
subset of MDS patients with excess blasts with increased MSI2
(ref. 7). The functional importance of MSI2 in MDS therefore
remains unclear. We examine previously published expression
data sets and patient samples to find that MSI2 is increased in
high-risk MDS patients. Additionally, we utilize MSI2 loss and
gain of function approaches in the context of a mouse model of
MDS and find that MSI2 is required for MDS.
Results
Elevated MSI2 expression predicts poor survival in MDS. In
our examination of a previously published expression data set, we
found that MSI2 expression was increased in CD34þ population
in high-risk MDS patients (refractroy anemia with excess blasts;
RAEB) compared with healthy individuals that were not age
matched or Low-Risk MDS (Refractory Anemia; RA or refractory
anemia with ringed sideroblasts; RARS), Fig. 1a)12. Elevated MSI2
levels correlated with a poor clinical survival (Fig. 1b and
Supplementary Fig. 1a). In line with the microarray data, high-
risk MDS patients had increased intracellular MSI2 in their
CD34þCD38" cells compared with low-risk MDS
patients and healthy individuals (Fig. 1c,d). Altogether, the
MDS patient data suggests that the level of MSI2 expression
correlates with disease subtype and clinical outcome. In contrast
to the acute myelogenous leukemia (AML) patient data, where
elevated MSI2 expression correlates with FLT3-ITD/NPM1
mutations5,8,9,11, MDS patients do not typically harbour these
mutations. Due to the low number of patients with recurrent
mutations in this study, we are unable to correlate MSI2 levels
with individual mutations (Supplementary Table 1).
Msi2 is required for MDS. To test if Msi2 could be functionally
important in MDS, we utilized a murine model of MDS. The
NUP98-HOXD13 transgenic model (NHD13) recapitulates many
of the salient features of MDS, including neutropenia, lympho-
penia and hypercellular or normocellular bone marrow at 4–7
months13–16. Also, 12–17% of the marrow contains dysplastic
erythroid, myeloid and rare megakaryocytic cell types13. Similar
to patients with MDS, a significant cohort of the primary mice
can progress and develop an aggressive AML. However, if the
bone marrow of NHD13 mice is transplanted, the recipient
animals succumb to a fully penetrant but non-lethal form of MDS
that rarely progresses to AML (ref. 15). Although the NHD13
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Figure 1 | Elevated MSI2 expression predicts poor survival in MDS. (a) Microarray expression data (CD34þ population) from normal elderly individuals
(CD34þ ; n¼ 17) and MDS (n¼ 183), RARS, RA, RAEB, *Po0.05, **Po0.01, ***Po0.001 Student’s t-test mean±s.e.m12. (b) Overall survival in MDS
patients stratified by MSI2 expression (as high (Z-score41), low (Z-scoreo" 1), or normal (" 1rZ-scorer1) log-rank test. (c). Representative flow
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Student’s t-test horizontal line is the mean±s.e.m.
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transplanted bone marrow cells engraft poorly, they still retain
the clinical features of MDS (B10–20% peripheral blood
chimerism)15. Utilizing intracellular staining for MSI2, we
found a significant albeit modest increase in MSI2 levels in
the bone marrow of 44% of NHD13 pre-MDS, 50% of MDS,
and 80% of AML animals (Fig. 1e and Supplementary Fig. 1b).
The significant increase in MSI2 was also observed within the
sorted progenitors from pre-MDS animals (Supplementary
Fig. 1c,d).
In agreement with MDS patient data, we observed an increase in
the expression of MSI2 in the NHD13 mice during disease
progression. These data suggested that altering MSI2 levels in the
NHD13 model could alter the disease fate. To test this hypothesis,
Msi2 conditional knockout were crossed with the NHD13mice and
then transplanted into congenic recipients (Fig. 2a,b). The
chimerism in the peripheral blood and at the level of the
haematopoietic stem and progenitor cell (HSPC) was significantly
reduced one month after pIpC-mediated deletion (Fig. 2c,d). Msi2
deletion resulted in the loss of the NHD13-expressing cells and a
reversal of MDS-like disease that included an increase in white
blood cell (WBC) counts, red blood cells and platelets (Fig. 2e–g).
When the mice were analyzed 14 months after transplantation
there was a trend towards reduced spleen weight, normalized WBC
counts and significantly reduced chimerism in the HSPCs and in
progenitors (Supplementary Fig. 2a–c). Despite the fact that some
of the mice had detectable donor chimerism, the donor myeloid
cells were mainly absent and the few remaining donor cells
retained MSI2 expression indicating that the deleted cells were
selected against (Supplementary Fig. 2d,e). Nevertheless, these
mice did not have detectable dysplastic cells or leukaemia in their
bone marrow (Supplementary Fig. 2f).
MSI2 overexpression in MDS drives transformation. We next
assessed if forced MSI2 expression could alter the disease course
using the same model of MDS. Of note, MSI2 overexpression by
itself does not result in leukaemic transformation5. We
utilized our previously described inducible MSI2 overexpressing
mouse model that can be controlled with doxycycline
(KH2-Col1A1-tet-on-MSI2/ROSA26-rTTA) and crossed them
with the NHD13 mice5. Control (C57BL/6), NHD13 or NHD13/
MSI2 bone marrow was transplanted into congenic mice and then
allowed to engraft before MSI2 was induced (Fig. 3a). After 5
months the NHD13/MSI2 overexpression mice started to
succumb to lethal myeloid diseases while the NHD13 mice had
symptoms of a mild MDS. The NHD13/MSI2 mice had reduced
WBC (5/25) or elevated WBC counts, reduced red blood cell
counts, increased mean corpuscular volume and increased
chimerism in the blood at 5 months post-transplantation
compared with the control and the NHD13 mice (Fig. 3b–e).
We observed increased immature myeloid cells in the peripheral
blood, and all of the MSI2 overexpressing NHD13mice eventually
succumbed to various lethal myeloid diseases including
MPN/MDS or an AML/MDS with a median latency of 228
days (Fig. 3f–h and Supplementary Fig. 3a–g). At end point, we
found that the NHD13/MSI2 mice had a more severe disease
burden based on increased spleen and liver weights compared
with the control and NHD13 mice (Fig. 3i,j). The NHD13 mice
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showed signs of a MPN/MDS or MDS disease, but only 3 out 15
mice died of a characterized myeloid disease (AML/MDS n¼ 2,
MDS n¼ 1, and one mouse was found dead and another died of a
non-myeloid disease; Fig. 3i,j). Serial transplantation of the
NHD13/MSI2 demonstrated reduced latency further supporting
the idea that MSI2 overexpression resulted in a clonal myeloid
disease (Fig. 3k and Supplementary Fig. 3h). We secondarily
transplanted the NHD13 AMLs and then compared the disease
burden to the secondary transplants from the NHD13/MSI2 mice.
Despite the fact that both groups had myeloid disease, the
NHD13/MSI2 group retained their more aggressive phenotype
compared with the NHD13 AMLs indicated by the increased
spleen and liver weights (Supplementary Fig. 3i,j).
MSI2 maintains activated MDS stem and progenitor cells. We
then determined if MSI2 overexpression was required to maintain
the disease. Thus, we transplanted NHD13/MSI2 overexpressing
mice into secondary recipients with or without doxycycline feed.
Mice that were maintained on doxycycline and expressed MSI2
rapidly formed a lethal myeloid disease, while the majority of
mice that were no longer being induced survived significantly
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two independent transplants *Po0.05, **Po0.01, ***Po0.001, b–e, g,i and j are Student’s t-test and horizontal line is the mean±s.e.m and h,k,m and p,
P values assessed by log-rank.
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longer (median, 96 versus 303 days; Fig. 3l,m and Supplementary
Fig. 3k–t). Moreover, in mice that were no longer induced and
died at the same time as the mice in the induced group, we were
still able to detect high levels of intracellular MSI2 suggesting
selection for constitutive activation in vivo (Fig. 3n). Similarly, a
mouse that died later also demonstrated leaky MSI2 expression
albeit at lower levels compared with the mouse that died earlier.
Overall, in all the mice that died of leukaemia, MSI2-positive cells
were detectable. However, mice killed at the experimental end
point that remained disease free, we found that the chimerism
was either low or undetectable (Fig. 3o). To further examine if
transient withdrawal of MSI2 expression could also delay the
leukaemia, we transplanted NHD13/MSI2 cells and waited 2
weeks to induce MSI2 expression (Fig. 3p). We observed a delay
in the myeloid leukaemia (312 days compared with 96 days) in
the control, and these leukaemias relapsed with MSI2 positivity,
providing evidence that MSI2 overexpression must be sustained
to maintain disease.
NHD13 haematopoietic cells have a block in their differentia-
tion at the HSC to multipotent progenitors (MPP) stage and have
dramatically reduced numbers of HSPCs (ref. 16; Fig. 4a,b). MSI2
induction for 5 days resulted in an increase in the percentage of
phenotypic LSKs (Lin-Sca1þKitþ cells) and a decrease in the
phenotypic HSCs, but no difference in the frequency of the
myeloid or erythroid progenitors (Fig. 4a–c and Supplementary
Fig. 4a). Interestingly, if the 5-day-induced NHD13/MSI2 cells
were then transplanted in the absence of doxycycline to turn off
MSI2, we observed reduced chimerism at 1 month (Fig. 4d).
Alternatively, when non-induced bone marrow was engrafted and
then activated for MSI2, the LSK compartment was expanded at 1
month (Supplementary Fig. 4b), and in the diseased NHD13/
MSI2 mice LSKs and myeloid progenitors (granulocyte-monocyte
progenitor (GMP) and common myeloid progenitor (CMP))
were increased compared with the NHD13 mice (Fig. 4e and
Supplementary Fig. 4c). Similarly to the 5-day induction the
chimerism of the phenotypic HSCs (LSKþCD150þ ;CD48) was
reduced in the diseased NHD13/MSI2 compared with the NHD13
and the control animals. We then profiled the cell cycle status of
the HSPCs using Brdu incorporation and Hoechst staining and
found reduced cell death (sub-G1) and increased percentage of
cells in G1, which suggests the accumulation of more activated
HSPCs (Fig. 4f,g). Taken together with the previous data, MSI2
expression maintains a more aggressive myeloid disease and a
more activated HSPC.
To further characterize how MSI2 alters the NHD13 MDS
programme in the dysregulated stem cell compartment, we
performed transcriptome profiling in the HSPCs (LSK) from
transplanted mice after 3 months of doxycycline administration
and before the mice demonstrate any disease phenotype.
To elucidate the NHD13/MSI2 expression programme, we
utilized a generalized linear model that identified 891 significant
genes (q-value o0.01, generalized linear model), of which 137
genes were upregulated (log2 fold change 40) and 754 genes
were downregulated (log2 fold changer0). We then matched the
gene signature to human homologues (690 genes; Supplementary
Data 1) and created a heatmap after unsupervised hierarchical
clustering, which separated the samples into their respective
groups (Fig. 4h).
To functionally annotate our RNA-sequencing, we performed
gene set enrichment analysis17 on all curated gene sets in the
molecular signatures database (http://www.broadinstitute.org/
msigdb; 3,256 gene sets) combined with an additional set of
relevant gene sets (92 gene sets from our experimentally derived or
published haematopoietic self-renewal and differentiation
signatures4,17; rank list; Supplementary Data 2). We found 14
gene sets that were enriched for genes that were upregulated and
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29 gene sets enriched for downregulated genes (Supplementary
Tables 2 and 3). The top ranked gene sets included enrichment in
an NRAS activated signature18, a reduced quiescent phenotype19
and a more progenitor-like cell (Fig. 4i–k). Taken together with
our phenotypic analysis of the HSPC compartment, MSI2
induction increases the cells that are in G1, switching them to a
less quiescent and more progenitor-like gene expression signature.
To determine if the MSI2 signature from the murine model of
MDS corresponds to patients with MDS, we overlapped the
NHD13/MSI2 RNA-seq (690 genes) with microarray data from
control (n¼ 17) and MDS patients (n¼ 183) (refs 12,20). After
unsupervised clustering of the human microarray data, we
obtained four distinct clusters (Fig. 4l). Patients with elevated
MSI2 expression were mainly found in Cluster-2, which predicted
a poor survival compared with the other clusters (Fig. 4m,n). Our
study demonstrates an important functional role of MSI2 in MDS
(Supplementary Fig. 4d).
Discussion
In summary, we found that elevated MSI2 expression predicts
poor prognosis in MDS and is required for maintaining the
diseased MDS stem cell. Cooperativity with NHD13 has been
associated with various factors including FLT3, MEIS1, P16 and
TP53 (refs 16,21–23). MSI2 overexpression can act as a
cooperating oncogene and drive transformation, accelerate
leukaemia and increase disease burden in the context of a MDS
mouse model. Additionally, we found reduced apoptosis and a
more activated stem cell, suggesting that the altered HSPC may
contribute to disease progression. Gene expression profiling of
HSPCs from the NHD13/MSI2 mice generated a signature that
overlapped with human MDS and could predict patient outcome.
Our lab previously found that MSI2 directly binds to the mRNA
of mixed-lineage leukaemia target genes including Hoxa9, Myc
and Ikzf2, and regulates the translation of these targets in a
mixed-lineage leukaemia-AF9 leukaemia model9. Additionally, a
recent report showed that Msi2 may regulate the development
and propagation of AML through Tetraspanin 3 (refs 24). Future
studies will determine how MSI2 alter stem cells in MDS or
whether it uses similar mechanisms as in AML.
Several studies have demonstrated that Msi2 is required for
HSPC engraftment4,10. It is unclear if in the context of suppressed
hematopoiesis where few normal HSCs remain, targeting could
result in additional toxicity. However, we found that the HSPC
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population demonstrated a selective advantage and remained
addicted to the forced MSI2 expression, as removal of MSI2
overexpression greatly reduced chimerism and reversed the
myeloid disease. We propose that the increased expression of
MSI2 in the HSPCs in high-risk MDS patients might allow for a
therapeutic index in these patients. Our mouse model might
provide a context to test how targeting MSI2 might alter the
disease. Overall, our study suggests that targeting MSI2 could
provide a therapeutic benefit in MDS.
Methods
Transgenic mice. KH2-Col1A1-tet-on-MSI2/ROSA26-rTTA transgenic mice5,
backcrossed 10 times to C57BL/6 strain or Msi2 conditional knockout4 were
crossed with Vav-Tg-NUP98-HOXD13 mice. The primary donors that were used
for transplants were either male or female of 3–4-month-old animals14. All animal
procedures were approved by the Institutional Animal Care and Use Committee at
Memorial Sloan Kettering Cancer Center.
Non-competitive transplants. Transplants were performed with 2–3! 106 bone
marrow cells from 12–16-week-old C57BL/6 donor mice mixed with 0.2! 106
CD45.1þ helper cells injected into the retro-orbital of lethally irradiated
B6.SJL-Ptprca Pepcb/BoyJ recipient mice. Secondary transplants were performed
by injecting 1! 106 bone marrow or spleen cells into sublethally irradiated
B6.SJL-Ptprca Pepcb/BoyJ mice.
Peripheral blood analysis. Peripheral blood was collected from the facial vein
using a lancet or retro-orbital cavity using a heparinized glass capillary tube.
A compete peripheral blood count was collected using a Hemavet 950 (Drew
Scientific).
Flow cytometry. Flow cytometry experiments were carried out using BD Fortessa,
LSRII, or LSRFortessa instruments. Bone marrow and spleen cells collected from
mice were subjected to red blood cell lysis before staining. Peripheral blood and
leukaemic bone marrow and spleen were immunophenotyped with the following
antibodies: CD45.2, CD45.1, Mac1, Gr1, c-Kit, CD71, Ter119 and B220. For stem
cell analyses, bone marrow cells were stained with the following antibodies: lineage
(Gr1, B220, CD3a, CD4, CD8 and Ter119), Sca1, c-Kit, CD150, CD48, CD16/32
and CD34. MSI2 staining was performed using a rabbit anti-mouse/human MSI2
antibody (Abcam) with a goat anti-rabbit Alexa647 conjugated secondary (Life
Technologies). Anti-mouse antibodies were used at 1:200 and secondary antibodies
were used at 1:400. Data analyses were performed using the FlowJo software.
Statistical analyses. To compute P values for bar graphs, an unpaired 2-tailed
Student’s t-test was used except where stated otherwise. Error bars reflect the s.e.m.,
except where stated otherwise. In survival curves, significance was calculated using
log-rank analysis. Graph Pad Prism 4.0 and the R statistical environment were used
to carry out all statistical analyses.
NHD13 RNA-seq analysis. NHD13 mouse RNA-seq raw data were deposited to
Gene Expression Omnibus (GEO) GSE76840. Differential analysis of RNA-seq
samples utilized the DESeq package for gene expression analysis25. False discovery
rate correction of P values used for all bioinformatics analyses of this study utilized
the Benjamini–Hochberg procedure. Mapping between entrez IDs between mouse
and human genes was done using the biomaRt R packages26. Heatmap clustering
and production was done using the heatmap function found within the NMF
package in R (ref. 27).
Human data analysis and RNA-seq analysis. The clinical microarray samples
consist of 183 and 17 healthy controls from anonymized donors that were not age
matched, but included elderly patients who underwent hip replacement. MDS
patients and 17 controls samples were publically available on GEO with the
reference series tag: GSE19429 (ref. 12). The MDS patient samples were collected
from several centres: Oxford and Bournemouth (UK), Duisburg (Germany),
Stockholm (Sweden) and Pavia (Italy). This study was approved by the ethics
committees (Oxford C00.196, Bournemouth 9991/03/E, Duisburg 2283/03,
Stockholm 410/03, Pavia 26264/2002) and informed consent was obtained12.
The microarray data were downloaded and had gene identifiers in the form of
AffyID probes. For MSI2 we mapped the probes and found that only 4 out of the 9
probes were correctly matched to MSI2. We utilized the Spearman correlation
coefficient to assess the correlation with the remaining probes and the three probes,
which showed a good correlation (1552364_s_at, 243010_at and 243579_at), were
then averaged together. These AffyID probes were converted to human and mouse
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Entrez IDs, which was done using the biomaRt tool in R. The AffyIDs that had
human and mouse Entrez IDs were kept as it indicated that the AffyID
corresponded to a human gene that had an orthologue in mouse. In the case that
several AffyIDs mapped to a single human Entrez ID the corresponding AffyID
rows were combined and a mean of their values were taken. This gave one row of
mean expression of all Affy probes that corresponded to a human Entrez gene.
Kaplan–Meier curves were generated to gauge survival probability between the
samples that had high, low and normal MSI2 expression. A heatmap was generated
using the statistically significant genes derived from the general linearized model. The
rows in this expression matrix were log10 transformed and then a Z-score was
computed for every element in the row. A heatmap was generated using this matrix
of Z-scores. This heatmap allowed for row and column clustering. The 200 samples
which composed this matrix were labelled according to whether the sample was
derived from an MDS patient or a control. Additionally, the samples were labelled
according to their French–American–British MDS clinical classification. The samples
could take 1 of 4 possible classifications: healthy, RA, RA with excess blasts (RAEB)
and RARS. Lastly, the samples were also classified according to theirMSI2 expression
levels, which could be classed as high MSI2 expression, low MSI2 expression or
normalMSI2 expression.MSI2 expression was classified as high if the Z-score for the
MSI2 in a sample was 41. MSI2 expression was classified as low if the Z-score for
the musashi2 gene in a sample waso! 1. MSI2 expression was classified as normal
if the Z-score for the musashi2 gene in a sample was ! 1r"r1.
Age-matched normal individuals and primary MDS patient samples. Normal
bone marrows from elderly individuals were obtained from hip replacements and
MDS patient samples (PBMCs, low risk; RA n¼ 3, RARS n¼ 2 and high risk;
RAEB-1 n¼ 4, RAEB-2 n¼ 6) were obtained from the Memorial Hospital Tumor
Bank under the protocol IRB Waiver Number: WA0260-12 and HBUC:
HBS2012060.
Cell Cycle analysis. Before 24 h analysis, mice received an intraperitoneal injection
of 1mg kg! 1 of BRDU. Mice were killed and Lin-Sca1þ c-Kitþ cells were sorted,
fixed with 1.6% paraformaldehyde for 15min, and permeablized with ice-cold
methanol. To prevent cell loss, LSKs were mixed with B220þ splenocytes and
subsequently stained with CD34 and Hoechst for cell cycle, and then analysed by
flow cytometry.
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Chapter 5: Ibrutinib 
Chronic Lymphocytic Leukemia: 
 Chronic lymphocytic leukemia (CLL) is a typically indolent liquid 
malignancy characterized by the uncontrolled expansion and accumulation of 
B-cell lymphocytes in the bone marrow, blood, and lymph nodes262.  The 
aggressive proliferation of B-cells overwhelms the normal constituents cells of 
the hematopoietic system and thus gives the pathology263. Despite the 
uncontrolled expansion of B-cell lymphocytes, CLL is typically diagnosed 
through a routine blood test, prior to a patient experiencing any of the 
symptoms typical of leukemic malignancies such as fatigue, dyspnea, or 
pancytopenia264. Patients with CLL tend to be older and their prognosis varies 
according to their clinical subtype265. However, CLL median survival has a 
broad range with some patients dying within a couple years to others 
surviving for decades with the disease266,267.  
 While CLL is generally seen as a smoldering leukemia, its prevalence 
is profound. CLL accounts for twenty-five to thirty percent of all leukemias in 
the Western world268. The median age of CLL diagnosis is seventy, but the 
medical literature has reports of teenage CLL patients, indicating the disease 
can affect all age ranges265,269. Disease genesis is believed to result from 
genetic abnormalities in B-cell lymphocytes, but the complete underlying 
disease mechanism remains poorly understood. Treatments for CLL include 
cytotoxic chemotherapies along with targeted approaches270–272. These 
targeted drugs primarily go after B-cell surface markers, but a few drugs 
target molecular pathways critical to cancer cell survival such as the PI3 
kinase or Bcl-2 pathways273–275. One particular targeted therapy used in the 
treatment of relapsed and refractory CLL is the drug ibrutinib276.  
Ibrutinib and its Resistance Mechanism: 
  Ibrutinib is a small molecule inhibitor that covalently binds to Bruton’s 
tyrosine kinase (BTK)277. BTK activity is essential for B-cell lymphocyte 
development and disrupting its activity has clinical benefit for patients 
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suffering from CLL278,279. Specifically, ibrutinib covalently binds the C481 
sulfhydryl group of BTK’s active site279. This irreversible inhibition of the 
enzyme’s active site nullifies BTK’s activity and disrupts the production of B-
cell lymphocytes. Ibrutinib can force CLL into remission, but 5.3% of all 
patients on ibrutinib will have disease progression279. A mechanism behind 
this progression was unknown until the present study279.  
 In the study a forty-nine year old woman with refractory CLL was 
placed on ibrutinib and observed to have a positive response to treatment. 
However, her disease relapsed after twenty-one months despite ibrutinib 
dose escalation. Two patient blood samples before relapse and after relapse 
were sent for RNA-sequencing and mutation calling was performed. This 
analysis demonstrated that a thymidine to adenine mutation in C481 amino 
acid changed the active site of BTK such that ibrutinib no longer permanently 
inhibited the binding pocket. With ibrutinib no longer able to inhibit BTK the 
CLL progressed. This was the first report of a genetic mechanism yielding 
resistance to ibrutinib279.  
Contribution: 
 It was my privilege to contribute to the discovery of a genetic 
resistance mechanism to ibrutinib in the following ways. Initially, when the 
patient’s data was delivered to the laboratory of Dr. Christina Leslie, a 
targeted search of a pre-selected set of genes was investigated to see if any 
mutation was present. This initial survey of genes included BTK and the 
C481S mutation was described. However, to ensure that no other mutations 
could possibly account for the resistance phenotype, I performed a genome-
wide mutation analysis. In this analysis I compared the patient’s pre-relapsed 
samples against her post-relapsed samples and called mutations between the 
two conditions. The analysis was done on a genome-wide scale with the final 
result being that no notable genetic changes were observed between the pre 
and post relapse conditions aside from the C481S mutation. Consequently, 
the patient’s resistance to ibrutinib was determined to be caused by the 
identified C481S mutation.   
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portant questions both about the nature of the 
evidence and about its sufficiency, a topic that has 
been the subject of inquiry and discussion in the 
patient-safety community for well over a decade.1 
As noted in the editorial, replications have con-
firmed substantial effects regarding the use of a 
surgical checklist, but rigorous randomized trials 
have not been carried out and are unlikely to be. 
In contrast to the relatively simple act of provid-
ing a new drug or procedure, implementing the 
surgical checklist calls for performance of a di-
verse array of 20 or more actions, which can, and 
should, vary from one institution to another.
An even more important barrier to performing 
a randomized trial is that implementation of the 
checklist almost always requires major culture 
change. Although culture can (and should) be 
measured, because of its unique nature in a given 
operating suite (even among individual rooms), 
the more relevant comparison after implementa-
tion of a checklist is with the prior condition, a 
before-versus-after study, not with other organi-
zations with very different cultures. The key cul-
ture change facilitated by the surgical checklist 
is the development of highly functioning teams, 
the value of which is well supported by evidence 
from many venues in and out of health care.
Weiser and Krummel reemphasize the key 
learnings from all checklist replication studies: 
success requires great effort directed toward the 
implementation process and strong leadership, a 
point also made by Haynes et al., who in addition 
note that the 9% reduction in mortality that 
Urbach et al. report could be a significant trend 
if mortality was followed for a longer time period.
Robblee notes a potential benefit from imple-
menting the surgical checklist that has been un-
derappreciated in the literature: the identification 
of near misses, which are defined as errors or 
malfunctions that might well have caused harm 
if they had not been intercepted. If these events 
are analyzed, the underlying process failures (so-
called latent failures) can often be identified and 
the process redesigned to prevent the errors from 
recurring. Indeed, if and when performance of 
the surgical checklist is fully institutionalized as 
an integral part of a culture of everyday teamwork 
in the operating room, it may turn out that one of 
its major benefits will be identifying opportuni-
ties for process improvement.
Lucian L. Leape, M.D.
Harvard School of Public Health 
Boston, MA
Since publication of his article, the author reports no further 
potential conflict of interest.
1. Leape LL, Berwick DM, Bates DW. What practices will most 
improve safety? Evidence-based medicine meets patient safety. 
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Ibrutinib Resistance in Chronic Lymphocytic Leukemia
To the Editor: Ibrutinib, an inhibitor that binds 
covalently to C481 of Bruton’s tyrosine kinase 
(BTK), has produced remarkable responses in pa-
tients with relapsed and refractory chronic lym-
phocytic leukemia (CLL).1-4 However, 5.3% of 
patients have disease progression, and the mech-
anism of resistance is largely unknown. Herein 
we describe the mechanism of resistance in such 
a case.
A 49-year-old woman had a diagnosis of CLL 
established in 2000. After the failure of multiple 
treatments, she began receiving ibrutinib at a 
dose of 560 mg daily in 2010 as part of a phase 1, 
dose-escalation study of ibrutinib in B-cell can-
cers.1 By month 11, a partial response was 
achieved with an absolute lymphocyte count of 
4530 cells per cubic millimeter. Computed to-
mography at month 18 showed a marked but 
incomplete reduction of lymphadenopathy. At 
month 21, a rapidly rising lymphocyte count and 
progressive lymphadenopathy were noted. De-
spite a dose escalation to 840 mg daily, CLL pro-
gressed during the next 4 weeks (for details, see 
the Supplementary Appendix, available with the 
full text of this letter at NEJM.org). Peripheral-
blood samples were collected before ibrutinib 
administration (day −52), while the patient was 
having a response to the drug (day 472), when 
progressive disease was first noted (day 589), 
and before dose escalation (day 616). Figure S1 
in the Supplementary Appendix shows the dates 
of sample collection in relation to the patient’s 
absolute lymphocyte count over the treatment 
course.
RNA sequencing revealed a thymidine-to-ade-
nine mutation at nucleotide 1634 of the BTK 
complementary DNA (cDNA) (GenBank accession 
number, NM_000061.2), leading to a substitution 
of serine for cysteine at residue 481 (C481S). The 
mutation was detected in the samples collected 
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when progressive disease was first noted (88% 
of reads) and before dose escalation (92% of 
reads) but not in those collected before ibruti-
nib administration or while the patient was 
having a response (Fig. S2A in the Supplemen-
tary Appendix). No other genetic changes were 
identified that correlated with the patient’s 
clinical course in the same manner as the BTK 
mutation. Sanger sequencing of cDNA verified 
that the mutation was detected only in the 
samples collected during relapse (Fig. S2B in 
the Supplementary Appendix). A more sensi-
tive, allele-specific polymerase-chain-reaction 
assay (1% analytic sensitivity) detected the mu-
tation in the genomic DNA of samples collected 
during relapse but not in those collected before 
ibrutinib administration or while the patient 
was having a response (Fig. S3 in the Supple-
mentary Appendix).
Ibrutinib binds covalently to the sulfhydryl 
group of C481 of BTK in the active site, resulting 
in irreversible inhibition of its kinase activity.5
Structural modeling suggested that the C481S 
mutation would disrupt this covalent binding, 
changing irreversible binding to reversible bind-
ing (Fig. 1A). Fluorescently tagged ibrutinib la-
beled the nonmutant BTK, and the covalent 
binding that was formed withstood electropho-
resis, whereas reversible binding to the C481S or 
C481A mutant of BTK did not. This showed 
biochemically the critical role of cysteine in co-
valent-bond formation (Fig. S4 in the Supple-
mentary Appendix).
Phosphorylation of BTK (pY223) reflects BTK 
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Figure 1. Effect of C481S Mutation of Bruton’s Tyrosine Kinase (BTK) on Ibrutinib Binding and the Ability of Ibrutinib to Inhibit BTK 
Phosphorylation.
Panel A shows structural modeling of nonmutant and mutant BTK with ibrutinib. The red arrows indicate the covalent bond between 
ibrutinib (purple and blue) and BTK (green and yellow) before and after the mutation. Panel B shows the inhibition of nonmutant BTK 
or C481S BTK phosphorylation by ibrutinib in HEK 293 cells. The half-maximal inhibitory concentration (IC50) of ibrutinib for inhibition 
of BTK phosphorylation was analyzed and plotted with GraphPad Prism. GFP denotes green fluorescent protein. 
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kinase activity. Introduction of the recombinant 
nonmutant and C481S BTK constructs into HEK 
293 cells showed that phosphorylation of C481S 
BTK at Y223 became significantly less sensitive 
to ibrutinib inhibition than the nonmutant BTK 
did (half-maximal inhibitory concentration, 
1006 nM vs. 2.2 nM) (Fig. 1B).
Taken together, our data indicate that the 
C481S mutation disrupts the covalent binding be-
tween BTK and ibrutinib. The impaired binding 
leads to a loss of inhibition of BTK enzymatic 
activity that ultimately results in ibrutinib resis-
tance in the patient. Consistent with the findings 
reported in the Journal by Woyach et al.,6 our stud-
ies confirm that BTK is a relevant pharmacologic 
target of ibrutinib from a genetic perspective.
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Case 12-2014: A 59-Year-Old Man with Fatigue, Abdominal 
Pain, Anemia, and Abnormal Liver Function (April 17, 2014; 
370:1542-50). In Table 2 (page 1547), the mode of inheritance 
for erythropoietic protoporphyria should have been “Autoso-
mal recessive or X-linked,” rather than “Autosomal dominant.” 
The article is correct at NEJM.org.
Case 11-2014: A Man with Traumatic Injuries after a Bomb 
Explosion at the Boston Marathon (April 10, 2014;370:1441-51). 
In the legend for Figure 1 (page 1443), the phrase “taken on 
admission,” should be added after “Plain radiographs of the 
chest (Panel A) and pelvis (Panel B) . . . ,” and the phrase 
“taken after the surgical amputation” should be added after 
“. . . contrast-enhanced multidetector CT (MDCT) with vol-
ume rendering . . . .” The article is correct at NEJM.org.
The Renormalization of Smoking? E-Cigarettes and the To-
bacco “Endgame” (January 23, 2014;370:293-5). In Figure 2 
(page 294), the bars for use of cigarettes and use of electronic 
cigarettes should have been shown side by side, rather than 
stacked, since some students may have been included in both 
categories. The article is correct at NEJM.org.
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Chapter 6: Discussion: 
GuideScan 
 The field of genome engineering has revolutionized the way 
researchers conduct science. A critical actor in this revolution is CRISPR 
technology. CRISPR systems allow investigators to efficiently change virtually 
any genetic locus quickly and easily90. Since CRISPR’s advent the technology 
has been applied to numerous fields of biology from neuroscience to cancer 
science100,280,281. It easily allows for the generation of genetic knockouts with 
sgRNAs targeted against the coding genome. A single advantage of these 
rapid knockouts is that the augmented pace of genetic screens focused on 
revealing the genetic actors involved in cellular pathways97,282,283. Such 
screens can now be done through knockout, as opposed to knockdown, 
studies of target genes. Furthermore, CRISPR gives researchers the ability to 
dissect the non-coding genome, allowing them to excise or modify long non-
coding RNA, enhancer sites, microRNA clusters or single nucleotide 
polymorphisms with ease123. The ability to efficiently and rapidly modify the 
estimated ninety-eight percent of the genome that does not code for protein is 
profound284. While the overwhelming majority of the human genome is non-
coding in nature, a large segment of it undergoes transcription, with some 
estimates saying as high as over seventy percent285. The nature of this 
transcription and the role it plays in regulating global genetic expression is 
poorly understood. The ability to understand this element of the genome is 
greatly advanced by the ability to directly modify it with CRISPR technology.  
 However CRISPR’s potential is not only limited to the research setting. 
A myriad of diseases from inborn errors of metabolism to cancer have their 
basis in human genetics. Medicine’s ability to combat these aliments is 
modest, absent a way to treat the underlying genetic condition. CRISPR 
technologies potentially offer a solution with its ability to target a genetic locus 
and alter its base sequence. Indeed this potential has already been realized 
as clinical trials involving CRISPR are already underway in the People’s 
Republic of China and the United States is just about to start their 
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own115,286,287. The ability to manipulate a genome has never been easier. Yet, 
the power of CRISPR technologies rests on a fundamental assumption: the 
sgRNA precisely cuts its target. 
 While previous literature noted several popular sgRNA selection tools 
failed to return certain worrisome sgRNA off-target sites (such as sites with 
only one mismatch), the amount of the false negative cut sites returned by 
these tools was underappreciated116,124. The GuideScan software package 
and web interface illustrated the magnitude of the specificity problem that 
accompanied these method’s returned sgRNAs. The magnitude of 
underreporting a sgRNA’s target space is potentially of particular importance 
for CRISPR genome-wide screens. Underreporting a target space of a 
sgRNA can increase the amounts of false positives and false negatives in a 
screen. For example a sgRNA, thought to be unique, but with multiple perfect 
target sites could potentially represent a false positive in a negative selection 
screen. The multiple target sites mean multiple cut sites that could 
compromise the viability of the cell. The resulting genomic instability would 
disadvantage the cell and it would appear as a positive result in a negative 
selection screen. Conversely, this same sgRNA could be a false negative in a 
positive selection screen for the exact same reason. Consequently, 
understanding the target space of a given sgRNA is essential for determining 
sgRNA specificity and therefore the fidelity of the sgRNA to an experimental 
target. GuideScan provides a solution to this specificity problem in addition to 
the added flexibility intrinsic to creating custom sgRNA databases.  
 By construction GuideScan allows for the creation of custom sgRNA 
database, unique up to a user-defined Hamming distance h, for any arbitrary 
genome. GuideScan was developed as a general CRISPR database 
construction tool to facilitate the greater use of CRISPR technologies in the 
life sciences. While CRISPR has been applied to many model organisms it 
has not been extended to all. Furthermore, individuals within species are 
diverse and this diversity exists in everything from cell lines to patients. For 
CRISPR systems to be applied effectively, the sgRNAs that are used should 
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be unique to a target genome that varies across individuals. GuideScan 
provides a solution for this problem in allowing for the generation of custom 
sgRNA databases for any organism.  
 GuideScan is a general CRISPR sgRNA database construction 
software. While it has default parameters that will create a database for the 
Cas9 enzyme, GuideScan can generate sgRNA databases for any CRISPR 
system. GuideScan allows a user to specify the location and identity of both 
canonical and alternative PAM sequences. These PAM sequences can be of 
any length and there is no limit to the amount of PAM sequences that can be 
specified. An example of this utility was demonstrated with GuideScan’s 
creation of Cpf1 databases for six model organisms that are hosted on the 
GuideScan web interface. Regardless of the advances that may come about 
in the CRISPR field, GuideScan is a generalized software method that is 
capable of producing sgRNAs to match the advance.  
 Additionally, the specification of alternative PAM sequences allows 
investigators to continually develop their CRISPR databases based on new 
knowledge of existing CRISPR systems. It is known that CRISPR 
endonucleases tend to recognize an array of PAM sequences with differing 
efficiencies of binding117. For the Cas9 endonuclease the canonical PAM 
sequence takes the form NGG, but it is also capable of recognizing other 
PAM sequences, albeit with lower efficiency. In contrast, while the Cpf1 
endonuclease has a well-described canonical PAM sequence, its potential 
alternative PAM sequences are not well described 130. Additionally, new PAM 
sequences offering greater target specificity are continually being reported for 
many CRISPR systems117. The ability to regenerate sgRNA databases using 
new knowledge about existing CRISPR systems is a key advantage that a 
flexible software package such as GuideScan allows.  
 Critically, GuideScan exhaustively enumerates the mismatch 
neighborhoods of all database sgRNAs up to a user defined Hamming 
distance. The results of this are two fold. First GuideScan produces 
databases where constituent sgRNAs are guaranteed to be unique up to a 
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user defined Hamming distance h. Second GuideScan determines the 
complete set of off-targets for a sgRNA in the database by enumerating off-
targets out to a second Hamming distance q (where q > h). This allows a 
researcher to know the complete target space of a given sgRNA and allows 
the investigator to design experiments with the confidence that their sgRNAs 
are uniquely targeting their target site. This complete off-target determination 
was virtually absent in all other methods and the ability to design sgRNAs 
databases unique up to a user defined Hamming distance is unique to 
GuideScan. 
 The complete determination of off-targets, and the filtering of sgRNAs 
meeting a user-defined uniqueness standard, makes GuideScan sgRNAs 
more specific than sgRNAs returned by competing methods. For Cas9 
sgRNAs, GuideScan is able to compute target site specificity scores for each 
sgRNA. This score essentially represents the probability that a given sgRNA 
will cleave only its target site given information about potential off-target cut 
sites. This score takes into account the full target space, up to a Hamming 
distance q, and it is the only score that represents specificity with a full 
accounting of a sgRNAs’ potential target space. GuideScan Cas9 sgRNAs 
are more specific and more numerous that other competing methods. The 
fact that GuideScan sgRNAs are more specific than competing tools may also 
suggest that they are more efficient in cutting their target sites. This added 
efficiency has nothing to do with the sequence characteristics of the cutting 
site. Simply, the efficiency may be enhanced because the target space is 
smaller than for unfiltered sgRNAs. Consequently, the probability of the 
CRISPR endonuclease binding to a specific target site increases. If cutting 
efficiency is seen as the probability that a particular target site is cut, then 
more specific sgRNAs will increase cutting efficiency.  
Overall, GuideScan provides a solution to the sgRNA specificity 
problem in addition to allowing the generation of customizable unique sgRNA 
databases for any CRISPR system in any organism. It is a generalized 
sgRNA database construction tool equipped to handle changes in the every 
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advancing field of CRISPR. Already multiple labs have utilized the software 
and the web interface receives queries from across the globe. The fact that 
GuideScan allows for rapid batch queries of unique sgRNA databases 
represents a substantial advance over other methods, and positions 
GuideScan as a useful tool to the broader genome engineering community.  
RBMX 
 RBMX is an hnRNP implicated in playing a role regulating the splicing 
of proteins involved in genome maintenance184,185,187,189. Several studies have 
investigated RBMX’s association with various pathologies and it appears to 
be tied to diseases whose mechanism relies on genomic damage or 
instability195–197. However, the manner through which RBMX influences these 
diseases remains broadly unknown. The work reported in this thesis sheds 
some light on the possible means through which RBMX could work in AML.  
 The knockdown of RBMX globally affects alternative splicing in 
MOLM13 AML cells. When a gene ontology study was done on all significant 
differentially spliced genes, the pathways that were highlighted fell into the 
DNA damage and apoptosis response categories. These pathways were in 
line with earlier reports that RBMX has a role in maintaining genomic 
integrity195–197. Looking specifically at the alternative splicing events affected 
by RBMX knockdown it was clear that skipped exon events formed the 
majority of all significant alternative splicing events. Investigating the genes 
with significant skipped exons suggested that the pathways affected were 
again the DNA damage response and apoptosis regulation pathways. Upon 
deeper investigation it was shown that only those genes that have skipped 
exon events where the exon was retained in response to RBMX knockdown 
were the genes capable of producing this pathway result. No other form of 
alternative splicing event was able to reproduce these pathways, which 
indicated that the global gene ontology terms were deriving from the 
significant skipped exon events where exons were being retained in response 
to RBMX knockdown.  
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 The identities of these genes were interesting as some of them had 
multiple significant skipped exon events. The gene with the greatest number 
of significant skipped exon events was CD44, which interestingly has been 
shown to be crucial for AML pathology222. Other interesting genes included 
POLL and DAXX which both have critical function in DNA repair and 
apoptosis respectively226–228. When a domain analysis was conducted on the 
significant skipped exon events several of the significantly associated 
domains illuminated the potential activity the gene was involved with. 
Specifically, in response to RBMX knockdown the POLL gene undergoes 
differential splicing at its BRCT domain; a domain implicated in breast cancer 
pathology229,230.   
 RBMX knockdown also affects differential splicing of the MBD1 gene 
always at its last exon. This gene interacts with H3K9 methyltransferase to lay 
down H3K9me3 marks in the genome237. These marks have a repressive 
effect on expression232. Interestingly, when H3K9me3 marks in k562 cells 
were overlaid on the significant differential splicing events only three splicing 
events intersected these marks. All three events were skipped exons where 
there was increased exon retention in response to RBMX knockdown, and all 
three marks overlapped distinct genes. One of these genes was MBD1. This 
suggests that MBD1 may be involved in some form of self-regulation using 
H3K9me3 marks to repress its own activity as a repressive actor in the 
genome.  
 As noted earlier, RBMX levels are elevated in human AML samples. 
While the exact mechanism by which RBMX is elevated in this malignancy 
remains to be determined, it is known that RBMX knockdown sensitizes cells 
to DNA damage189. It is possible that RBMX contributes to some form of DNA 
repair in AML, but its elevation suggests an interesting possibility. Given that 
RBMX depletion increases a cell’s susceptibility to DNA damage, it is 
reasonable to think that targeting RBMX for knockdown or knockout, either 
with shRNAs or sgRNAs respectively, in AML cells may sensitize them to 
chemotherapeutics. This would make the potency of chemotherapy much 
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greater and could either increase tumor lysis in a patient or reduce the 
amount of cytotoxic therapy needed to achieve therapeutic effect. AML is an 
aggressive malignancy, but it may have an Achilles heel in RBMX. A 
therapeutic pathway may exist with the sequential depletion of RBMX and 
administration of DNA-damaging chemotherapy. 
Musashi2 
 MUSASHI2 elevation has been noted in various forms of leukemia, but 
its role in Myelodysplastic Syndrome (MDS) remained largely undefined183,244–
246. MDS is a disease characterized by bone marrow failure and can result in 
both chronic and acute forms of leukemia247,248. Understanding MDS 
pathology is critical for prolonging patient survival and safeguarding patients 
from having their MDS undergo transformation to leukemia. Showing that 
MUSASHI2 levels correlated with disease survival and that a musashi2 
signature from mouse accurately clustered human patient samples into 
disease cohorts that were significantly different in their MUSASHI2 
expression, suggested a role for MUSASHI2 as a potential therapeutic target.   
 Elevated MUSASHI2 levels correlated with worst survival in patients 
with MDS. As with RBMX, it may be that the targeted knockdown or knockout, 
with shRNAs or sgRNAs respectively, of MUSASHI2 has a clinical benefit for 
MDS patients. It is clear that musashi2 affects MDS pathology and its 
elevation may therefore be a mechanism through which the disease can be 
treated. Alternatively, because MUSASHI2 levels correlated with survival, 
MUSASHI2 can potentially serve as a biomarker for the disease that informs 
clinical treatment. The idea here would be that those patients with higher 
MUSASHI2 levels would warrant more aggressive treatment, while those with 
lower levels may warrant more conservative treatment. Overall the role of 
MUSASHI2 appears critical not only for the pathology of leukemia, but for 
MDS as well. 
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Ibrutinib 
 Ibrutinib is a targeted therapy used in refractory and aggressive cases 
of CLL276. It has a high patient response rate, but resistance to the drug does 
occur at a minute, albeit notable frequency279. Understanding one such 
resistance mechanism, through mutating the active site of BTK to which 
ibrutinib binds, informs both CLL and ibrutinib biology. Furthermore, by 
understanding the exact BTK resistance mutation, structural modeling can be 
used to inform the design of better small molecule inhibitors. Ultimately, being 
one of the first groups to describe the C481S resistance mutation, paved the 
way for clinicians, researchers, and drug developers to better understand 
ibrutinib treatment and its potential resistance. 
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Appendix: 
  
Burrows Wheeler Transformation and FM-Index: 
 The Burrows Wheeler transformation (BWT) is a method to convert a 
string into a permutation of itself in an efficient and reversible manner288. The 
main purpose of the BWT is to allow strings to be compressed and amenable 
to indexing. These attributes are critical for the use of strings in an FM-index. 
To best understand BWT it is useful to walk through an example of the 
process. 
 The set of possible characters shall be restricted to A,C,G,T, which are 
the symbols for the DNA nucleotides adenine, cytosine, guanine, and thymine 
respectively. Furthermore, within this set a lexicographical ordering will be 
imposed such that:  
 
A < C < G < T 
 
Additionally, one other character, $, will precede all the other characters. This 
character shall be called the terminator character and will be found naturally 
at the end of every string. 
 
$ < A < C < G < T 
 
Now imagine we have a string, S, such that S = AGTC$. Taking the final 
character of the string and pre-appending it to the front of the string will give a 
single rotation of the string S. Computing all rotations of S will give a matrix of 
rotations.  
 
$AGTC 
C$AGT 
TC$AG 
GTC$A 
127	
AGTC$ 
 
Sorting this rotation matrix lexicographically yields a shorted rotation matrix.  
 
$AGTC 
AGTC$ 
C$AGT 
GTC$A 
TC$AG 
 
Extracting the final column of this rotation matrix yields the BWT of string S 
 
S = AGTC$ 
BWT(S) = C$TAG 
 
 
When the BWT is applied to a set of strings, those strings will all be 
sorted lexicographically and these strings can be compressed using run-
length encoding procedure. Compression of data is only useful if it can be 
reversibly decompressed without loss of information. The BWT is reversible 
through the construction of the rotation matrix. To best understand this 
reversibility it is important to return to an example string. Imagine there is a 
string Q such that Q = AATGGC$. Construct a rotation matrix of Q, but before 
doing this add subscripts to each character enumerating its occurrence in the 
original string. Consequently, Q = A0A1T0G0G1C0$. The subscripts do not 
affect ranking: lexicographically A0 = A1 in terms of ranking order. The 
terminator character will not have a subscript since it can only occur once per 
string.  
 
$A0A1T0G0G1C0 
C0$A0A1T0G0G1 
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G1C0$A0A1T0G0 
G0G1C0$A0A1T0 
T0G0G1C0$A0A1 
A1T0G0G1C0$A0 
A0A1T0G0G1C0$ 
 
After sorting the resulting rotation matrix 
 
$A0A1T0G0G1C0 
A0A1T0G0G1C0$ 
A1T0G0G1C0$A0 
C0$A0A1T0G0G1 
G1C0$A0A1T0G0 
G0G1C0$A0A1T0 
T0G0G1C0$A0A1 
 
Inspecting the last column of the sorted rotation matrix and breaking up the 
elements by characters the following order is observed: 
 
A: A0, A1 | C: C0 | G: G1, G0  | T: T0 
 
Doing the same for the first column of the sorted rotation matrix results in:  
 
A: A0, A1 | C: C0 | G: G1, G0  | T: T0 
 
The orderings are identical. This property is characteristic of BWT matrices 
and is known as LF-Mapping. This ultimately allows the BWT to be reversible. 
Extract the last column of the BWT(Q) rotation matrix to get: 
 
C0$A0G1G0T0A1 
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Now re-rank the string according to character occurrence in BWT(Q) [B-rank] 
 
C0$A0G0G1T0A1 
 
Look at the sorted BWT rotation matrix once more and, for each row, identify 
the first and last character. Additionally, add the B-rank that corresponds to 
each character in the last column of the sorted BWT rotation matrix (Table 
11). 
 
Sorted BWT Rotation Matrix 
 
$A0A1T0G0G1C0 
A0A1T0G0G1C0$ 
A1T0G0G1C0$A0 
C0$A0A1T0G0G1 
G1C0$A0A1T0G0 
G0G1C0$A0A1T0 
T0G0G1C0$A0A1 
 
Table	11:	Burrows	Wheeler	Transform	Reversal 
First Character in BWT 
Rotation Matrix Row 
Last Character in BWT 
Rotation Matrix Row 
B-Rank 
$ C0 0 
A0 $ 0 
A1 A0 0 
C0 G1 0 
G1 G0 1 
G0 T0 0 
T0 A1 1 
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From this matrix one can reconstruct the original string by looking at the first 
row. Recall rotations position show those characters occurring to the left (last 
character column) of a queried character (first character in column). Looking 
at the first column it is noted that C occurs to the left of $. We see that the B-
rank for this C is 0 indicating that it is the first C seen in the string. To 
determine which character is leftward of C we go to the row in the above 
matrix that begins with C and find that G occurs to the left. The B-rank for this 
G is 0 so we once again go to the first row in the matrix that starts with G and 
repeat the process. In this manner the string is reconstructed as follows:  
 
C0$ 
G1C0$ 
G0G1C0$ 
T0G0G1C0$ 
A1T0G0G1C0$ 
A0A1T0G0G1C0$ 
 
Recall Q = A0A1T0G0G1C0$ and it is evident that the BWT is reversible. 
Ultimately, the BWT can be utilized to create an efficient data structure that 
allows for the compression of strings, the indexing of these strings, and the 
compression of the index itself, which allows for a space efficient and search 
efficient string data. This efficient data structure is termed the FM-index and 
can be seen as an extension of the BWT (after the creators: Paolo Ferragina 
and Giovanni Manzini).  
 
Tree Traversals: 
 
In-Order289 
 In-order traversal begins by starting at the leaf node of the leftmost 
branch of a tree (Figure 55). Once it visits the leftmost leaf the traversal 
advances upward one node. If the resulting node has no unvisited children it 
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is processed. However, if the resulting node has unvisited children the 
traversal will go to the leaf node of the leftmost unvisited branch and traverse 
upward. The traversal visits branches from left to right and advances from the 
leaf nodes to the root node. The traversal continues until all nodes in the tree 
are visited.  
 
Figure	55:	In-order	traversal	procedure 
Pre-Order289 
Pre-order traversal begins by starting at the root node and transiting 
down the leftmost branch until the traversal encounters a leaf node (Figure 
56). When a leaf node is encountered the traversal backtracks to the nearest 
parent node with more than one child node and transits down the leftmost 
branch once more. This procedure is done recursively until all nodes in the 
tree are visited.  
Root	Node	
A	
Figure	59:	In-order	traversal	
procedure	
B	 C	
D	 E	 F	 G	
Traversal	Order:	D,	B,	E,	A,	F,	C,	G	
Figure	55:	In-order	traversal	
procedure	
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Figure	56:	Pre-order	traversal	procedure 
Post-Order289 
Post-order traversal begins by starting at the leftmost leaf node and 
transiting upward until a parent node with multiple children nodes are 
encountered (Figure 57). When such a parent node is encountered the 
traversal repositions itself at the leftmost unvisited leaf node of the parent 
node and repeats the process. The procedure will repeat itself recursively 
until all nodes in the tree are visited.  
Root	Node	
A	
Figure	60:	Pre-order	traversal	
procedure	
B	 C	
D	 E	 F	 G	
Traversal	Order:	A,	B,	D,	E,	C,	F,	G	
Figure	56:	Pre-order	traversal	
procedure	
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Figure	57:	Post-order	traversal	procedure 
Interval Tree: 
 An interval search tree takes a set of intervals and transforms them 
into nodes in a search tree (Figure 58)290. If an interval has the coordinates 
[a,b] where a < b then the keys for each node take the value a, even though 
each node has the information [a,b] stored in it. Additionally, each node stores 
the maximum value in its subtree and can store additional metadata as well. 
By construction the left children nodes of a parent have values of a that are 
less than the parent’s value of a. Conversely, the right children nodes of a 
parent have values of a that are greater than the parent’s value of a.  
When queries are processed through an interval tree the root node 
determines if an interval overlaps the root node. If no intersection exists then 
it takes the query value of a, which shall be called aq, and determines if aq is 
less than the maximum value present in the first node of the left subtree. If aq 
is less than the maximum value in the left subtree then the interval moves to 
the first node in the left subtree and determines if overlap exists. It progresses 
Root	Node	
A	
Figure	61:	Post-order	traversal	
procedure	
B	 C	
D	 E	 F	 G	
Traversal	Order:	D,	E,	B,	F,	G,	C,	A	
Figure	57:	Post-order	traversal	
procedure	
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down the tree diverting down left and right subtree according the aq 
relationship to the subtree’s maximum value. This search is done until all 
overlapping intervals are identified.  
 
Figure	58:	Interval	tree	diagram 
Reverse Phase Protein Array: 
 Briefly, reverse phase protein array (RPPA) is performed by isolating 
cell lysate or bodily fluid and placing it on individual segments of a 
microarray291. The set of proteins that are to be quantified is determined a 
priori and antibodies against these proteins are secured. Across all samples a 
single antibody is deployed on the microarray291. Antibody labeling and 
quantification can be accomplished through multiple avenues, but all involve 
the emission of light as an output. This light emission is quantified and is how 
RPPA’s quantitative nature is derived291. This procedure is repeated for every 
protein of interest.   
12,30	
		40	
Figure	62:	Interval	tree	
10,34	
		34	
8,15	
			15	
11,20	
			20	
15,37	
			40	
14,30	
			30	
18,40	
			40	
Query	=	[38,45]	 [38,45]	does	not	intersect	[12,30]	
38	>	34,	do	not	search	
lei	subtree	 38	<	40,	search	right	
subtree	
38	>	30,	do	not	search	
lei	subtree	
IntersecBon	found	
Figure	58:	Interval	tree	
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